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Tight control of post-translational modifications such as ubiquitination is important for cell 
homeostasis and dysregulation of this process is a common feature in many diseases. Itch 
encodes an E3 ubiquitin ligase that conjugates ubiquitin to a variety of substrates such as Jun 
B, PKC-q, PLC- γ1, LATS, TXNIP and p73. In this study both transient and stable 
knockdown techniques (siRNA and CRISPR respectively) were utilised to explore the role of 
Itch in both cancer progression and bone remodelling. Transient siRNA-mediated knockdown 
of Itch inhibited cell viability of MiaPaCa-2 and Capan-2 cell lines by ~50% and ~60% 
respectively compared to both scrambled and untreated controls as determined by SRB. 
Although siRNA did not increase cell line sensitivity to g-radiation, doxorubicin, and 
gemcitabine, it did have an additive effect on resultant survivability. CRISPR-Cas9 mediated 
stable Itch knockdowns in the same cell lines in contrast showed increased sensitivity to the 
aforementioned treatment regimens however resultant data obtained from cell survival and 
clonogenicity assays suggested that the CRISPR+ MiaPaCa-2 cells divide faster than both 
scrambled and parental controls. SWATH-DIA analysis was performed to look for 
differences in proteome between CRISPR+ and parental MiaPaCa-2 cells. Preliminary data 
based on isogenic clones suggests potential differences, but additional repeats and further 
validation is required. Transient Itch knockdown in peripheral blood monocytes increased 
their capacity to differentiate into fully matured osteoclasts ex-vivo: compared to untreated 
controls, si-Itch treated wells showed higher mean numbers of large TRAP+ cells (mean = 63 
and 54 for si-Itch and untreated wells respectively) and multinucleate cells (mean = 25 and 17 
for si-Itch and untreated wells respectively) in a 96-well format. Meanwhile CRISPR-
mediated knockdown induced a large degree of cellular toxicity in PBMCs. This contrast 
between stable and transient Itch knockdown prompted discussion of the strengths and 
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Ubiquitination is a post-translational process that is crucial for cell homeostasis. It involves 
the “tagging” of proteins with the molecule ubiquitin (Ub) to dictate the fate of the protein, be 
it activating a protein to take part in pathway signalling or targeting the protein for 
degradation by the proteasome. Ubiquitination itself involves an enzyme cascade starting 
with ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), then ubiquitin 
ligases (E3) before Ub can be covalently tagged onto the target protein (Figure 1) (Berndsen 
& Wolberger, 2014; Sluimer & Distel, 2018; Zheng & Shabek, 2017). The consequence of 
ubiquitin tagging is determined by the number of and the pattern in which Ub molecules are 
conjugated. In addition to either being mono-ubiquitinated or multi-monoubiquitinated 
(multiple tagging sites on a single protein), proteins can also be polyubiquitinated with linear 
or branched Ub chains. Ub molecules can form covalent bonds with each other via their 
seven lysine (Lys) residues and amino N-terminus (Bernassola et al., 2008; Berndsen & 
Wolberger, 2014; Sluimer & Distel, 2018). Whichever Lys residue is polyubiquitinated is 
also an important factor in determining the substrate’s fate, for example Lys48 polyubiquitin 
chains typically signal for degradation via the 26s proteasome. Other consequences of 
polyubiquitination include changes in intracellular localisation and activation/inhibition of 
downstream signalling in cellular pathways.  
 
E3 ligases in particular are mainly attributed with target specificity as they are the endpoint of 
the enzyme cascade: they have been one of the main areas of study. This also makes them 
attractive candidates for drug discovery, as regulation of E3 ligases is highly implicated in 
disease (Nalepa, Rolfe, & Harper, 2006; Petroski, 2008). There are three main families of E3 
ligases: Homologous to E6AP C terminus (HECT), really interesting new gene (RINGs), and 
RING between RINGs (RBRs) (Zheng & Shabek, 2017). E3s are responsible for the 
recruitment of an E2~Ub complex and the target substrate mediating then transferring Ub 
from E2 to substrate. HECT and RBR E3 ligases perform this function as a two-step 
transthioesterification mechanism where Ub is transferred from the cysteine active site of the 
E2 enzyme to a cysteine in the HECT domain before transfer of Ub to the substrate 
(Berndsen & Wolberger, 2014; Sluimer & Distel, 2018). This is in contrast to RING E3s, 







Figure 1: Ubiquitination summary:  
(1.) E1 activating enzyme uses ATP to recruit Ub to its active cysteine residue (S). (2.) Ub is transferred 
from E1 to an E2-conjugating enzyme.(3.) E3 ubiquitin ligases catalyse transfer of Ub from E2 to the 
substrate. This is done either via a two-step transthioesterification process (HECTs/RBRs) where Ub is 
first transferred to a cysteine residue on the E3 ligase before being transferred to the substrate, or in the 
case of RING E3s, is transferred directly to the substrate. Original figure. 
Itch – a HECT domain E3 ubiquitin ligase: 
The Itch gene was first discovered by Perry in non-agouti-lethal 18H mice. These mice had a 
chromosomal inversion of the Itch gene which resulted in the mice displaying various 
autoimmune characteristics such as chronic interstitial inflammation, alveolar proteinosis, 
and inflammation of glandular stomach and skin (Perry et al., 1998). The inflamed skin 
phenotype was what attributed the gene its name as the mice displayed a large degree of 
scarring due to excessive itching (Fang et al., 2002). Itch itself encodes a HECT-domain E3 
ubiquitin ligase that belongs to the Nedd4 subfamily (neural precursor cell expressed 
developmentally downregulated protein 4), one of the more well-studied subgroups of E3-
ligases. The Nedd4 subfamily is structurally categorised by a number of WW domains and a 
single C2 domain positioned more N-terminally to the HECT domain located at the C-
terminus (Bernassola et al., 2008; Sluimer & Distel, 2018). Itch in particular has 4 tryptophan 












Figure 2: Homologous domain structure of the Itch protein:  
The Itch gene encodes a HECT E3 ubiquitin ligase that contains the catalytically active HECT domain at 
the C-terminus, 4 WW domains to facilitate and diversify substrate binding, and a C2 calcium-regulatory 
domain at the N-terminus. Original figure. 
The HECT domain catalyses the transfer of Ub from an E2 conjugating enzyme to the target 
substrate. C2 domains are usually described as Ca2+ and phospholipid binding domains 
(Rizo & Südhof, 1998) but can also direct E3 ligases to their substrates as is the case with 
Smad ubiquitination regulating factor 1 (Smurf1), another Nedd4 family member (Tian et al., 
2011). However, whether or not this is the case with Itch is unknown. The four WW domains 
allow Itch to interact with proline-rich motifs (such as PPxY) on its target substrates. 
Furthermore, they also play an important role in regulating Itch’s enzymatic activity. Itch 
naturally exists in an autoinhibited closed state (Figure 3-A.) where the central WW domains 
(notably WW2) bind to the proline-rich motifs in the HECT domain (Gallagher et al., 2006; 
Riling et al., 2015; Zhu et al., 2017). In this state Itch can associate with an E2 conjugating 
enzyme but cannot undergo transthioesterification to move Ub to the active site cysteine on 
the HECT domain. This autoinhibition can be relieved either through the binding of an 
adaptor protein such as Nedd4 family interacting protein 1 (Ndfip 1) (Figure 3-A.) or by 














Figure 3: Active and inactive forms of Itch E3 ligase: 
Internal WW domains of the Itch protein bind to the HECT domain to keep the E3 ligase in a catalytically 
inactive state. This prevents the transfer of Ub from E2 to the substrate via the HECT domain. Itch 
autoinhibition can be relieved either through associating with an adaptor protein e.g. Ndfip 1 (A.) or 
through JNK1-mediated phosphorylation near the N-terminus (B.). These interactions allow the WW 
domains to bind to potential substrates and “frees-up” the active site cysteine residue on the HECT domain 
to allow Ub to bind to it. Original diagram based on data from: Riling et al., 2015; C. Yang et al., 2006; 
Zhu et al., 2017. 





As previously mentioned, Itch was first identified as a key regulator of the immune response: 
mice lacking the gene display a severe autoimmune phenotype. This is also mirrored in 
humans: A study by Lohr’s group followed a small, closed group of children of Old-Amish 
heritage. These children displayed various autoimmune characteristics such as immune 
infiltrates in lungs, liver and gut as well as showing developmental delay, failure to thrive and 
dysmorphic features (Lohr et al., 2010). Through autozygosity mapping they discovered that 
the children had a mutation in the Itch gene which resulted in a truncated version of the E3 
ligase that lacked the catalytically active HECT domain and WW binding domains. This 
mutated form of Itch would therefore be unable to bind either an E2 or any of Itch’s 
numerous substrates or adaptor proteins. These phenotypes in mice and humans clarify that 
Itch is a clinically relevant gene worthy of investigation as there does not seem to be any 
method of redundancy by other HECT E3 ligases in the absence of functioning Itch protein. 
The first and most obvious topic to address is Itch’s role in regulating the immune response 
and how the autoimmune phenotype could develop in the case of a knockout. Itch exerts its 
influence over the immune system through various means including regulating lymphocyte 
activation, differentiation of lymphocytes, and self-tolerance. 
 
Itch in immunity:  
 
T-Cell receptor activation and T-cell anergy: 
To generate an immune response a T-lymphocyte or T-cell requires stimulation of the T-cell 
receptor (TCR) with an antigen from an antigen-presenting cell (APC). This triggers a 
signalling cascade that leads to clonal expansion of T-cells and an immune response against 
the antigen. TCR stimulation activates protein kinase C-q (PKC-q) and phospholipase C-γ1 
(PLC- γ1). PKC-q activates nuclear factor of activated T-cells (NFAT), which can lead to 
increased levels of Itch (Figure 4) as discussed below, whilst PLC- γ1 stimulates nuclear 
factor k-B (NF-kB) and activator protein-1 (AP-1) (Aki, Zhang, & Liu, 2015; Heissmeyer et 
al., 2004; Melino et al., 2008; Pardoll, 2012). For T-cell expansion to occur there needs to be 







Figure 4: Itch regulation of TCR signalling: 
Schematic showing the various ways that Itch (orange) regulates TCR signaling upon interaction with an 
APC. TCR stimulation causes both NFAT-mediated upregulation of Itch expression and JNK1-mediated 
phosphorylation of Itch protein to activate its E3 ligase activity. Itch then ubiquitinates its substrates (red), 
for example PLC-g1 and PKC-q, to inhibit further TCR signaling and promote anergy of T-cells. Diagram 
from Aki et al., 2015. 
With the surplus peripheral T-cells that circulate in our bodies and such a broad spectrum of 
antigen targets, how is it that they avoid inadvertently reacting with self-proteins, leading to 
autoimmunity? Encouragement of T-cell tolerance to self begins with their development in 
the thymus from haematopoeitic stem cells in a process known as central deletion (Walker & 
Abbas, 2002). But once they exit this initial screening step, further molecular mechanisms, 
known as peripheral tolerance mechanisms (Aki et al., 2015; Walker & Abbas, 2002), are 
required to prevent potential autoimmunity. One of these is known as anergy or “T-cell 
anergy”: the process of rendering a lymphocyte functionally inactive but still alive after 
interaction with a specific antigen and cell-surface receptors. Itch facilitates T-cell anergy by 
monoubiquitinating PKC-q and PLC- γ1 (Figure 4), targeting them for degradation by the 
proteasome (Heissmeyer et al., 2004). To initiate T-cell clonal expansion and an immune 
response after formation of the immune synapse and activation of the TCR, there needs to be 
co-stimulation and activation of NFAT and AP-1. However in the absence of co-stimulation 
of AP-1, that is when only NFAT is activated, NFAT causes transcriptional upregulation of 




localises to the immune synapse to downregulate PLC- γ1 and PKC-q signalling (and thus 
prevent persistent NF-kB signalling also), which shortens the duration of the immune 
synapse and promoting anergy. 
 
T-helper type 2 cells: 
JunB is a transcription factor that is important for the development of T-helper type 2 cells 
(TH2) from activated T-cells. It is also a substrate for polyubiquitination by Itch: upon TCR 
stimulation, Itch is recruited and phosphorylated by JNK1 to increase its E3 ligase activity 
and  ubiquitinate JunB for degradation by the proteasome (Fang et al., 2002). In Itch-/- mice 
there is a polarization of CD4+ naïve T-cells to differentiated TH2 cells as shown by increased 
levels of cytokines interleukin 4 and 5 (IL-4, IL5). Lack of degradation of JunB by Itch 
causes increased protein stability of JunB in activated T-cells, thus increasing its 
transcriptional influence on IL-4 and IL-5 promoters which in-turn encourages more naïve T-
cells to develop into TH2 cells (Li et al., 2014). This polarization of naïve T-cells may in part 
explain the autoimmune phenotype as TH2 are known to play a main role in the allergic 
response (Aki et al., 2015; Li et al., 2014) and switching of antibody classes to IgG1, IgA and 
IgE (Figure 5, Fang et al., 2002) which have been implicated in various inflammatory 
diseases (Grewe et al., 1998; Williams, Tjota, & Sperling, 2012). Accumulation of JunB in T-
cells and polarised TH2 development is also apparent in Ndfip 1-/- knockout mice which 
showed a similar phenotype to Itch-/- mice (Oliver et al., 2006). Ndfip 1 being an adaptor 
protein is important for changing the conformation of Itch from its inactive to active state by 
making the WW binding domains and HECT domain available (Riling et al., 2015). Lack of 
functioning Ndfip 1 means that Itch is kept in its “closed” conformation and therefore cannot 
ubiquitinate JunB and inhibit TH2 differentiation. A more recent study has also shown that 
Itch cooperates with another Nedd 4 family member WWP2 to limit TH2 differentiation by 











Figure 5: Increased IgA, IgG1 and IgE in Itchy mice: 
Serum samples from 10 6-week to 6-month old mice were tested for specific immunoglobulins. 
Comparison of Itch-/- mice with wild-type revealed a significant increase in classes IgGA (1st column), 
IgG1 (2nd column), and IgE (6th column). Data from Fang et al., 2002. 
T-follicular helper cells and other aspects of immune regulation: 
Further evidence of Itch being functionally important in regard to the immune system is in its 
role in the differentiation of follicular helper T-cells (TFH). Itch -/- T-cells were found to be 
unable to differentiate into TFH cells (Xiao et al., 2014), this prevents the  assisted activation 
of naïve B-cells and the maintenance of germinal centres (Crotty, 2011; Victora & 
Nussenzweig, 2012) which are key events in the adaptive immune response. A recent study 
also showed that Itch -/- mice have increased protein kinase p38α (MAPK) activity 
(Theivanthiran et al., 2015), a key inflammatory mediator, due to lack of regulation of Tab1 
(TGF-β-activated  kinase 1-binding protein 1). This causes p38α autophosphorylation and 








Figure 6: The multifaceted role of Itch in regulating immunity:  
Itch E3 ligase activity impacts many pathways linked to regulating the immune system and preventing 
autoimmunity. Transfer of Ub to proteins associated with specific pathways either upregulates (anergy and 
Treg differentiation – discussed later) or inhibits them (TFH/TH2 differentiation and TCR signalling). 
Original figure. 
A wider role for Itch in human pathology? 
These are a few examples of the multi-modal way in which Itch modulates the immune 
response to prevent autoimmunity as seen in the knockout mouse model and humans lacking 
functional Itch protein (summarised in Figure 6). One of the aspects of cancer cell and 
tumour survival in a living organism is avoidance of immune surveillance; indeed, 
immunotherapy i.e. the concept of manipulating the host’s immune system to recognise and 
target tumour tissue is currently one of the most well-researched and promising avenues of 
cancer research in the modern era (Conroy et al., 2012; Pardoll, 2012). It may be possible that 
cancer cells utilise E3 ubiquitin ligases such as Itch to manipulate their “visibility” to the 
immune system and that they may be attractive targets for anti-cancer therapy. However, Itch 
has several potential substrates that are not limited to immune system regulation. This is in 
large part due to its ability to interact with several co-factors to promote its E3 ligase activity 
on specific proteins. Furthermore, the fact that the children described in Lohr’s study also 
showed signs of developmental delay and dysmorphic features heavily implies that Itch plays 






The role of Itch in cancer: 
 
In addition to Itch’s importance in immune homeostasis, the E3 ligase has been shown to 
regulate several pathways linked to apoptosis, cell growth, and cell survival (Bernassola et 
al., 2008; Melino et al., 2008). For this reason, researchers have investigated tumourigenic 
pathways with Itch substrates that could be impacted by changes in its enzymatic activity. It 
is now emerging that manipulating Itch activity may be a potent therapeutic strategy for 
treating cancer in various tissues that show high Itch expression or aberrant signalling of 
pathways associated with Itch e.g. hippo signalling, p73, and TGF-b (Figure 7). Some labs 
have already begun to investigate the therapeutic potential of Itch inhibition: the traditionally 
used anti-depressant clomipramine (CMI) was tested to see if it could increase the sensitivity 
of lung CSCs (cancer stem cells) to DNA damaging agents including gemcitabine, paclitaxel, 
and cisplatin (Bongiorno-Borbone et al., 2015). They found that desmethylclomipramine 
(DCMI - the active metabolite of CMI) did indeed amplify the cytotoxic effect of DNA 
damaging drugs on lung CSCs when used in combination. In the same investigation they also 
found similar results through shRNA silencing of Itch in combination with the 
aforementioned chemotherapeutics. This was done after Rossi’s group performed a high 
throughput drug screen looking for compounds which inhibited Itch function with high 
specificity compared to other HECT domain E3 ligases. This screen identified CMI to be one 
of the most specific with significant inhibition of Itch activity (Rossi et al., 2014). CMI 
Inhibits Itch activity through association with the HECT domain; irreversibly blocking 
transthiolation of Ub from E2 to E3. However it was noted that in a previous study performed 
by the same group that CMI/DCMI also blocks autophagic flux which makes cancer cells 
more susceptible to cytotoxic agents (Rossi et al., 2009). Furthermore, they observed that 
whilst CMI did not inhibit any of the tested RING E3 ligases it did inhibit E3 activity of 
E6AP, another HECT domain E3 ligase. Therefore, it is unclear if the results for the 
cytotoxicity assays seen in the papers investigating CMI/DCMI’s effect on Itch levels is 
indeed due the reduction of Itch activity, inhibition of autophagy, or a combination of both in 
addition to the degree of specificity to degree of specificity to Itch. They did assess analogous 







Figure 7: human Itch predicted and known protein interaction network.  
Network generated in STRING (search tool for the retrieval of interacting genes/proteins, (Szklarczyk et 
al., 2015)) showing a confidence view. Each node donates a protein with Itch (red) at the centre and 
associations as lines between nodes: thicker lines indicate stronger associations. Confidence score 
restricted to highest (90%) and no more than 50 interactions shown. Proteins listed in order of highest 
confidence score, proteins in bold are discussed in more detail in the text: UBC: ubiquitin C; UBE2L3: 
ubiquitin-conjugating enzyme E2L3; CXCR4: chemokine (C-X-C motif) receptor 4; NOTCH1: notch 1; 
DTX1: deltex homologue 1 (Drosophila); CFLAR: CASP8 and FADD-like apoptosis regulator; NUMB: 
numb homologue (Drosophila); RNF11: ring finger protein 11; HGS: hepatocyte growth factor-regulated 
tyrosine kinase substrate; UBB: ubiquitin B; SPG20: spastic paraplegia 20; JUN: jun proto-oncogene; 
TP63: tumour protein 63; SMAD7: SMAD family member 7; LATS1: large tumour suppressor 
homologue (Drosophila); ERBB4: v-erb-a erythroblastic leukemia viral oncogene; MAVS: mitochondrial 
antiviral signalling protein; ARRDC1: arrestin domain containing 1; PCBP2: poly(rC) binding protein 2; 
UBA52: ubiquitin A-52 residue ribosomal protein fusion product 1; MAPK8: mitogen-activated protein 
kinase 8; NDFIP2: Nedd4 family interacting protein 2; RIPK2: receptor-interacting serine-threonine 
kinase 2; RPS27A: ribosomal protein S27a; AMOT: angiomotin; TP73: tumour protein 73; CXCL12 
chemokine (C-X-C motif) ligand 12; TAB3: TGF-b activated kinase 1; MAP3K7: mitogen activated 
protein kinase kinase kinase 7; TAB1 TGF-b activated kinase 1; TAB1: TGF-beta activated kinase 1; 
TNFAIP3: tumour necrosis factor, alpha induced protein 1; TAB2: TGF-beta activated kinase 1; WWP1: 




Tumour protein 73 (Tp73/p73): 
The transcription factor p73, along with Tp63 (p63), was first identified by Kaghad’s group 
and was found to have strong homology with the tumour-suppressor p53 (Kaghad et al., 
1997). It was found to be functionally similar to p53 (which is commonly mutated in 
cancers), being able to upregulate numerous targets of p53 and is thus a regulator of 
apoptosis and cell cycle progression. Tp73 and p63 have many splice isoforms (Kaghad et al., 
1997; Levrero et al., 2000) which allow variance in function and output. Whether or not p73 
specifically acts as a tumour suppressor or an oncogene seems to depend on cellular context 
and the levels of different isoforms. Splice isoforms that affect the C-terminal, i.e. the TAp73 
splice variants, are tumour suppressive, promoting apoptosis and cell cycle arrest signalling 
cascades whilst the N-terminal splice isoforms, i.e. ΔNp73 are oncogenic as they inhibit 
apoptosis (Yang et al., 2002). In general p73 is not mutated in cancer: mice that are 
heterozygous for p73 and p63 show a predisposition to developing tumours in their lifetimes; 
incidence of lung adenoma was 10% in wild-type, 25% in p63+/-, and 40% in p73+/-, n=40) 
(Flores et al., 2005). This was especially the case in mice that were also p53 null where the 
incidence of tumour develop was additive compared to just p73/63 heterozygosity. 
Additionally p73 null mice seem to show severe developmental neural defects such as 
hippocampal dysgenesis (Yang et al., 2000) along with immune defects. Developmental 
defects in a p73 null system would make sense in regards to its role in regulation of 
apoptosis: apoptosis plays a major role in the development of an organism for example by 
governing tissue morphology with respect to anatomical axis. Furthermore, several 
experiments have shown that inhibition of p73 regulators promotes apoptosis, described in 
more detail below. On the other hand it has been observed that p73 is mutated in 
neuroblastoma (Kaghad et al., 1997). Additionally in the case of glioblastoma cell lines, 
knockdown of TAp73 in-vitro reduces chemo resistance and metastasis (Landré et al., 2016) 
through inhibition of periostin (POSTN) which is a mediator of a variety of cancers such as 
ovarian and breast (Field et al., 2016; Sung et al., 2016). 
 
Tp73 also differs from p53 in the way that it is degraded. MDM2  has inherent E3 activity; 
this allows it to degrade p53 (Honda, Tanaka, & Yasuda, 1997; Kubo et al., 2010). Although 
it can interact with p73 and forced overexpression of MDM2 results in inhibition of p73 
function, it does not actually target it for degradation by the proteasome. It is now apparent 
that MDM2 promotes degradation of p73 through interaction with Itch (Kubo et al., 2010; 
Wu & Leng, 2015). Pull-down phage displays have shown that Itch is able to interact with 
the PPxY motif on p73 via its WW binding domains and target it for degradation (Rossi et 
al., 2005); p53, by contrast lacks the PPxY motif and so cannot interact with Itch. The fact 
that Itch is a specific inhibitor of p73 (and not p53) function, and p73 upregulating many of 
the same genes as p53, has made it an attractive candidate among some scientists as a 
therapeutic target for increasing chemo sensitivity of cancer cell lines (Hansen et al., 2007) 
since p53 is commonly mutated in disease whilst p73 remains largely unaffected. Hansen and 
his group reported that MEFs (mouse embryonic fibroblasts) mutant for Itch showed 
increased cell death by measuring the percentage of hypodiploid cells, annexin expression 
and changes in membrane potential. They also reported that genetic knockdown of Itch in 
HeLa cells causes them to have increased sensitivity to doxorubicin treatment (a drug that 
causes cell-cycle arrest) and that reintroduction of Itch into MEFs with an Itch null mutation 
promoted resistance to treatment (Hansen et al., 2007).  This work was consolidated in-vivo 
by de la Fuente’s group (Figure 8: A.): MiaPaCa-2 cells (a pancreatic cell line) were 
transfected with Itch-targeting shRNA and grafted onto xenograft mice and found that this 




any difference in toxicity to the mice (measured by looking at changes in body weight over 
time, Figure 8: B. & C.). However, in their experiment the combination of shRNA-scrambled 
and gemcitabine treatment also caused a significant decrease in tumour growth. This is due to 
the transfection reagent, DAB-Am16, which has been shown to inhibit cell growth (Dufès et 
al., 2005). Despite being aware of this, no alternative transfection reagent/method of 
transfection was used as a comparison. Furthermore, neither of these two papers prove that 
exclusively p73 upregulation (or more specifically, one of its isoforms) is what causes the 
beneficial result or whether it was the Itch knockdown having a much broader effect on 

















Figure 8: Itch-targeting nanoparticle strategy for increasing the sensitivity of pancreatic cancer to 
gemcitabine: 
A. A nanoparticle vector (DAB-Am16) was developed and used to shuttle Itch sh/siRNA into target cells 
(first and second panel). Itch polyubiquitinates p73, a protein important for regulating the cell cycle and 
apoptosis and targets it for degradation by the proteasome (third panel). Downregulation of Itch by RNAi-
containing nanoparticles increased MiaPaCa-2 xenografted mice to sub-IC50 doses of gemcitabine (last 
panel). B. & C. primary data of MiaPaCa-2 xenograft mice; tumour volume and percentage body weight 
were monitored in mice over a 28 day time-course. Mice treated with DAB-AM16/shItch + Gemcitabine 
inhibited tumour growth for 17 days (B. bottom line) with no statistically significant difference in toxicity 
to the treated mice (using %-age body weight as a surrogate of mouse health). Diagram and data from De 







Oxidative stress is a caused by a loss of balance between production of reactive 
oxygen/nitrogen species (ROS/RNS) and disposal of species by antioxidants (Visconti & 
Grieco, 2009). ROS are generated during aerobic respiration by the electron transport chain 
and consist of hydrogen peroxide (H2O2), the hydroxyl ion (OH•) and the superoxide ion (O2-
; Fridovich, 1978). Accumulation of ROS without sufficient disposal allows the free radicals 
to disrupt the structure and function of lipids, proteins and DNA, potentially leading to 
chronic inflammation and cancer (Reuter et al., 2010). Although generation of ROS is 
initially tumorigenic, as it can inflict DNA damage and potentially cause mutations, cancer 
cells still have a tolerance threshold of ROS and need to clear them to prevent apoptosis and 
encourage tumour growth. Thioredoxin-interacting protein (TXNIP), or vitamin-D 
upregulated protein (VDUP)/thioredoxin binding protein-2 (TBP-2), inhibits the antioxidant 
thioredoxin (Trx) by directly associating to the redox protein’s active site (Junn et al., 2000; 
Nishiyama et al., 1999). Inhibition of Trx by TXNIP causes increased oxidative stress and 
leads to the activation of apoptotic signalling cascades by promoting phosphorylation of 
apoptosis signal-regulating kinase-1 (ASK-1) (Saxena, Chen, & Shalev, 2010). For this 
reason TXNIP is described as a tumour suppressor and has been observed to be inhibited in 
various cancers (Butler et al., 2002; Kwon et al., 2010; Nishizawa et al., 2011). TXNIP itself 
is regulated by Itch as it has 2 PPxY motifs, which allows Itch to bind and polyubiquitinate it 
for degradation by the proteasome. (Liu et al., 2016; Otaki et al., 2016; Zhang et al., 2010).  
In particular Zhang’s group have already showed that overexpression of Itch causes 
inhibition of TXNIP expression and conversely that genetic knockdown of Itch using siRNA 
causes increase in levels of TXNIP (Zhang et al., 2010). Furthermore TXNIP inhibition has 
also been shown to promote metastasis in melanoma (Goldberg et al., 2003). TXNIP in this 
case upregulates KISS1 which inhibits metastasis in melanoma cell lines. TXNIP could 
therefore acts to regulate cancer progression in both early and late stage disease.  
 
Itch and the LATS /Hippo pathway: 
The Hippo pathway was first discovered in Drosophila melanogaster where flies that were 
mutant (homozygous loss) for the gene warts (wts) were observed to have overgrown somatic 
cells (Justice et al., 1995). Later on many more studies showed that mutations in various 
other genes including Salvador (sav), Hippo (hpo) and Mob as tumour suppressor (mats) 
produced the same phenotype (Harvey, Pfleger, & Hariharan, 2003; Lai et al., 2005; Tapon et 
al., 2002) indicating that these genes might all be involved in the same pathway. The hippo 
pathway is responsible for regulating apoptosis and organ size in the developing and adult 
organism and is highly conserved in mammals: knockout of Mst1/2 (an upstream component 
of the hippo pathway) causes YAP-1/TAZ (discussed below) activation in hepatocytes and 
thus liver overgrowth, indicating that the hippo pathway is also important for tissue 
regeneration in normal systems (Avruch et al., 2011). Because of this, regulation of the hippo 
pathway is important in regards to tumour progression. The upstream components of the 
Hippo pathway act by negatively regulating the oncogenic effectors of the pathway yes 
associated protein 1 (YAP-1) and transcriptional coactivator with PDZ-binding motif (TAZ), 
the mammalian homologs of yorki (yki) (J. Huang, Wu, Barrera, Matthews, & Pan, 2005), 
causing their phosphorylation and subcellular localization to the cytoplasm rather than the 
nucleus (Meng, Moroishi, & Guan, 2016). If not regulated, YAP and TAZ translocate to the 
nucleus where it can activate the co-transcription factor TEA domain family member 1-4 
(TEAD1-4) as YAP-1/TAZ cannot directly interact with DNA due to lack of DNA binding 
domains (DBDs; Zhao et al., 2008). As the hippo pathway is involved in the control of organ 




localizes to the nucleus at low cell densities to promote cell division whilst at higher cell 
densities contact inhibition localizes YAP to the cytoplasm to prevent further growth of 
tissue. YAP-1 has also been shown to be inhibited on loss of contact with the extracellular 
matrix (ECM; Zhao et al., 2012) which would then promote anoikis (a form of cell death 
caused by detachment from the ECM). 
 
Itch regulates the hippo pathway via inhibiting the serine/threonine kinase large tumour 
suppressor homolog 1 (LATS1 - the mammalian homologue of wts) (Salah, Melino, & 
Aqeilan, 2011) by targeting it for degradation by the proteasome. LATS1 phosphorylates 
YAP/TAZ, preventing their localisation to the nucleus and promoting transcription of genes 
linked to cell growth and survival (Figure 9). The LATS1 protein has two PPxY motifs that 
Itch can interact with; mutations in both of these motifs prevents Itch-mediated degradation 
of LATS1 however a mutation in just one of these sites still allows Itch to associate (Salah et 
al., 2011). Ho et. al. show that Itch acts on LATS1 protein levels in a dose-dependent manner 
and that treating with a proteasome inhibitor (MG132) blocks this degradation (Ho et al., 
2011). To prove the link between Itch, the hippo pathway and cancer, Salah et. al.  performed 
a series of experiments investigating the effect of Itch on the tumour progression of breast 
cancer cells (Salah, Itzhaki, & Aqeilan, 2014). They showed that Itch is able to enhance the 
tumour phenotype displayed by MCF10A cells both in-vitro and in-vivo (in-vivo Itch 
overexpression alone was not enough to induce tumorigenesis but it did amplify the 
phenotype in H-Ras transformed cells). Itch knockdown inhibits the tumour progression and 
metastatic ability of these cells: to demonstrate the role of the hippo pathway, and how it 
interacts with different expression levels of Itch, the levels of LATS1, and YAP-1/TAZ-
affected genes were monitored. The results showed a decrease in LATS1 expression and p-
YAP (phosphorylated YAP), accompanied by an increase in expression of YAP-1 and YAP-
induced genes. Lastly they demonstrated that YAP-1 knockdown rescues the Itch-mediated 
tumorigenic phenotype (Salah et al., 2014). Conversely a recent study has shown that Itch can 
interact and ubiquitinate YAP-1 via the a-arrestins ARRDC1/3 acting as adaptor molecules 
(J. Xiao et al., 2018). Silencing of ARRDC1/ARRDC3 increased the stability of YAP in clear 
cell renal carcinoma and promoted the tumourigenic phenotype. Thus via different points of 







































Figure 9: Itch inhibits hippo signalling through ubiquitinating LATS1: 
First panel: MST1/2 phosphorylates LATS1/2 which in turn phosphorylates YAP/TAZ. Phosphorylation 
prevents nuclear localization of YAP/TAZ and prevents their transcriptional activity. YAP/TAZ is instead 
either degraded or retained in the cytoplasm by 14-3-3. Second panel: Itch ubiquitinates LATS1/2 which 
targets it for degradation by the proteasome. This limits YAP/TAZ phosphorylation; allowing them to 
translocate to the nucleus, associate with co-transcription factor TEAD1-4, and upregulating genes linked 
to cell survival and growth. 
Transforming growth factor-b: 
Itch is a positive regulator of the transforming growth factor-β (TGF-β) signalling pathway 
(Park et al., 2015) by targeting Smad7 for ubiquitination. Smad7 is an inhibitory Smad, or i-
Smad, that inhibits the signalling activity of the Smad2/Smad4 complex and thus blocks 
TGF-β signalling: Itch therefore relieves this inhibition of the Smad2/Smad4 complex and 
promotes TGF-β signalling. Whilst with the other pathways discussed, inhibiting Itch should, 
in theory, upregulate tumour suppressive molecular mechanisms it is unsure as to what its 
effect would be in regard to the TGF-β pathway as TGF-β has a broad range of effectors. The 
role of TGF-β in cancer development seems to be paradoxical: normally TGF-β signalling 
regulates cell proliferation, differentiation, cell survival and microenvironment (Massagué, 
2008) and so is usually a pathway that cancer cells try to downregulate to promote 
tumourigenesis. Indeed, in many cancers, activators of the pathway are usually inactivated 
such as Smad4 and TGF-β receptor 2 (TGFBR2; Ikushima & Miyazono, 2010). However 
TGF-β signalling can also be exploited by cancer cells to promote invasion, metastasis and 
evasion of the immune system i.e. more late-stage pathological aspects of tumour progression 
(Fabregat et al., 2014; Massagué, 2008). It would seem, therefore, that there is some form of 
context-specific selection of outputs from the TGF-β signalling pathway that promotes 
tumour progression: knocking down tumour suppressive aspects whilst upregulating 
oncogenic ones. It would be difficult to predict the effect of an Itch knockdown in relation to 
TGF-β due to its paradoxical role in tumour progression. TGF-β upregulation may be a good 
preventative measure and may prevent the growth of an early tumour, e.g. cancer stem cells 
or tumour initiating cells (Iwasaki & Suda, 2009), due to downregulation of pro-survival 




effects of TGF-β are already inhibited, upregulation of the signal may increase the likelihood 
of tissue invasion and metastasis.  
 
Another interesting point, linking cancer to immunity, is that the TGF-β pathway facilitates 
the activities of regulatory T-cells (Tregs). In the human body there are two types of Treg 
cells; natural Treg cells (nTregs) which are derived from the thymus, and induced or adaptive 
TReg cells (iTregs) which are induced from naïve CD4+ T-cells via TGF-β signaling and IL-
2 (Adeegbe & Nishikawa, 2013; Curotto de Lafaille & Lafaille, 2009). The main role of Treg 
cells is to suppress the function of normal T-cells, thus preventing autoimmunity and 
inflammation, especially in areas of increased chemical stress such as the gut. However it has 
been noted that there is an increased prevalence of Treg cells in the tumour 
microenvironment and vasculature (Adeegbe & Nishikawa, 2013; Beyer & Schultze, 2009). 
This is considered one of the barriers of using immunotherapy against cancer cells. TGF-β is 
required to both induce and maintain Treg cells (Curotto de Lafaille & Lafaille, 2009). The 
question here is that if Itch normally acts as a positive regulator of the TGF-β pathway, could 
knockdown/interference of Itch in primary cancer tissue samples decrease the amount of Treg 
cells present in the microenvironment and by extension be able to increase a tumour’s 
sensitivity to immunotherapy? Indeed it has already been shown that silencing TGF-β1 in 
vitro causes a reduction in Treg cells and reduces tumour volume (Conroy et al., 2012). 
Furthermore Itch -/- naïve T-cells are resistant to Treg suppression and prevents development 
of iTregs (Venuprasad et al., 2008), however it remains to be seen if these effects can be 
mirrored by a genetic knockdown of Itch explicitly. 
 
 
Itch in bone remodelling: 
 
Dysregulation of the bone remodelling process can result in debilitating diseases that severely 
impact patient quality-of-life such as osteoporosis, osteopetrosis, Paget’s disease of bone, and 
rheumatoid arthritis. Bone remodelling entails a delicate balance of bone formation and bone 
resorption which shifts depending on context for example in the incidence of a bone fracture 
(formation) or digit formation (resorption). Formation and resorption is governed by 
osteoblast and osteoclasts respectively therefore study of the molecular mechanisms in which 
these cells differentiate and perform their respective functions is key to better understand the 
aforementioned pathologies. Recently Itch has been shown to regulate the activity of both 
osteoclasts and osteoblasts as discussed below. 
 
Itch and osteoblasts: 
Osteoblasts are mononuclear cells differentiated from mesenchymal stem cells typically 
found in bone marrow through bone morphogenic protein (BMP) signalling (Pittenger et al., 
1999; Yamashita, Takahashi, & Udagawa, 2012). They are the cells responsible for 
synthesising and distributing bone matrix in both endochondral and intramembranous 
ossification. One-month-old Itch-/- mice have been shown to have both increased osteoblast 
numbers and bone formation rate (BFR) leading to increased bone mass (Zhang & Xing, 
2013) hinting to a role of Itch in the terminal differentiation of osteoblasts. Isolation and 
culture of mesenchymal stem cells from Itch-/- displayed increased numbers of osteoblast 
markers such as alkaline phosphatase (ALP) and thus had increased differentiation potential 
for osteoblast formation. Furthermore they looked at the number of adipocytes formed: 




relationship with osteoblast numbers (Zhang et al., 2010). The study found that Itch-/- mice 
had fewer adipocytes being formed than wild-type (wt) mice when exposed to adipocyte-
inducing media (mean adipocyte formation from bone marrow progenitor cells: 390/well for 
Itch-/- vs 1005/well for wt). Itch-/- cells had increased Ub-tagged JunB whilst having similar 
total JunB protein levels to wt (Zhang & Xing, 2013). Previous literature has confirmed that 
JunB is an essential transcription factor for the differentiation of osteoblasts from 
mesenchymal stem cells (L. Zhao et al., 2010). When discussing Itch’s role in immune 
regulation and differentiation of TH2 cells, Itch ubiquitinates and targets JunB for degradation 
via the proteasome after JNK1-mediated phosphorylation.  
 
A later study also explored the relation of Itch and osteoblasts in bone fracture repair. 
Interestingly one initial observation was increased and sustained mRNA expression of several 
Nedd4 family E3 ligases including Itch after an induced tibial fracture in mice (J. Liu et al., 
2017). Itch-/- mice showed increased expression of osteoblast-related genes after induced 
fracture such as runt-related transcription factor 2 (Runx2) and ALP. They also observed 
mRNA levels of receptor activated NF-kB (RANK) ligand (RANKL) and osteoprotegrin 
(OPG), which are required for bone remodelling as they regulate osteoclastogenesis (Katagiri 
& Takahashi, 2002; Yamashita et al., 2012). 
 
 
Itch and osteoclasts: 
Osteoclasts are large multinucleated cells that are responsible for the resorption of bone 
matrix in the remodelling process. They are derived from monocytes, a type of leukocyte, 
when exposed to RANKL and macrophage colony stimulating factor (M-CSF; Figure 10: A.) 
which are secreted by osteoblasts and stromal cells in-vivo (Kim & Kim, 2016; Nijweide, 
Burger, & Feyen, 1986; Yamashita et al., 2012). Osteoblasts also produce OPG, which 
inhibits osteoclast formation by acting as a competitive inhibitor to RANK on osteoclast 
precursors (monocyte that is already exposed to M-CSF signalling). In-vivo a context-
dependent balance of OPG and RANKL secretion from osteoblasts determines the rate at 
which osteogenesis and resorption take place at the bone surface. Osteoclast differentiation is 
dependent on RANKL-induced NF-kB signalling in the presence of M-CSF to trigger 
transcription of genes for osteoclastogenesis. RANK/RANKL binding triggers a signalling 
cascade that induces TNF receptor-associated factor 6 (TRAF6), a RING E3 Ub ligase. 
TRAF6 then auto-ubiquitinates with Lys63 polyubiquitin chains, which promotes NF-kB 
signalling and osteoclastogenesis (Jin et al., 2008; Lamothe et al., 2007; H. Zhang et al., 

































Figure 10: Simplified diagram of RANKL-induced osteoclastogenesis and how it is inhibited: 
(A). RANKL secreted by osteoblasts interacts with RANK on the surface of osteoclast precursors. 
Intracellular signalling from RANK stimulates autoubiquitination of TRAF6 which allows it to promote 
NF-kB-mediated transcription of genes associated with mature osteoclast differentiation. B. 
osteoclastogenesis signalling pathway can be inhibited extracellularly through OPG binding to RANK and 
blocking the receptor. NF-kB also promotes transcription of Itch which can associate with the DUB 
CYLD. This enzyme complex removes Ub from TRAF6 and prevents further upregulation of NF-kB 
signalling. Original figure. 
Studies looking at Itch-/- mice showed increased numbers of osteoclasts compared to wt in 
response to RANKL signalling (Zhang et al., 2013) and increased levels of bone resorption. 
Similarly mice treated with CMI to inhibit Itch activity in wt mice also showed increased 
osteoclastogenesis and bone resorption (Li et al., 2017). Itch-/- mice treated with CMI 
showed no change in osteoclast formation, confirming that the changes in osteoclast numbers 
in wt mice was strictly due to chemical inhibition of Itch E3 activity. It was thus hypothesised 
that Itch enzymatic activity negatively regulates osteoclast formation in response to RANKL 
signalling. NF-kB signalling also induces the upregulation of Itch expression thus initiating a 
negative feedback mechanism to inhibit osteoclastogenesis. However, the thought that Itch 
would directly act on TRAF6 would seem contrary to Itch’s function as an E3 ligase as 
activated TRAF6 already exists in a self-ubiquitinated state. Instead, Itch associates with the 
deubiquitinating enzyme (DUB) cylindromatosis (CYLD) (Zhang et al., 2013) to inhibit 
TRAF6 signalling. As the name implies, DUBs act to remove Ub from target substrates: 
CYLD deubiquitinates TRAF6 and thus prevents further NF-kB signalling (Figure 10: B.). 
CYLD -/- mice are hypersensitive to RANKL signalling, show persistent NF-kB signalling, 
and have severe osteoporosis (Jin et al., 2008). TRAF6 is also deubiquitinated by A-20 
however, when only A-20 is present (or if Itch is absent, preventing the CYLD complex) the 
process is much slower meaning prolonged NF-kB signalling. 
 
Although Itch-/- mice have increased numbers of both osteoblasts and osteoclasts, i.e. cells 





osteoporotic or osteopetrotic) seems to correlate with the age of the organism: young Itch-/- 
mice appear to have greater bone density whilst older mice have lower bone density (Zhang 
et al., 2013; Zhang & Xing, 2013). Furthermore despite these differences in phenotype it was 
observed that the ratios of the two cell types in young and old Itch-/-mice is unchanged: One 
could potentially hypothesise that the differing phenotype is due to changes in developmental 
priorities i.e. in younger mice there is more emphasis for an organism to grow and thus 
produce more bone matrix whilst at an older age this is not the case.   
 
These findings in mouse models have founded a strong basis ubiquitination and Itch E3 
ligase activity are important regulatory factors in bone remodelling, however the question 
remains as to whether or not this is translatable to humans. As already noted, the children in 
Lohr’s study that are mutant for Itch show stunted growth and dysmorphic features (Lohr et 
al., 2010) which implies defective bone remodelling machinery. Furthermore, the basis for 
the study of the effect of CMI on osteoclastogenesis by Li et.al. was after reports of patients 
being treated with CMI for depression showed a higher incidence of osteoporosis and bone 
fractures (Vestergaard, Rejnmark, & Mosekilde, 2008) and the small molecular screen by 
Rossi’s group identifying CMI as a specific inhibitor of Itch E3 ligase activity (M Rossi et 




CRISPR-Cas9 gene editing – an introduction:  
 
CRISPR (Clustered Regularly-Interspaced Short Palindromic Repeats) is an adaptive immune 
system employed by various bacteria and archaea that protects against foreign genetic 
material such as virions. It works by taking a section of the foreign DNA that is directly 
adjacent to a PAM sequence (protospacer adjacent motif) and incorporating it as a spacer 
region in the CRISPR locus. Cas (CRISPR-associated protein) proteins are then synthesised 
along with crRNA (CRISPR-RNA - derived from the incorporated spacer sequences) to 
recognise and degrade foreign genetic material (Rath et al., 2015; Terns & Terns, 2011). 
Degradation of foreign nucleic acids is done by the Cas protein introducing breaks in the 
foreign DNA at sites that are complimentary to the mature crRNA (Jinek et al., 2012).  
 
Since its discovery, the CRISPR-Cas system has been adapted to perform many forms of 
genetic engineering such as RNAi (RNA interference) by irreversibly knocking down the 
expression of a gene or inserting genetic material at specific sites in the host genome. One 
can even perform several genetic edits by using multiple guide-RNA/single guide-RNA 
(gRNA/sgRNA: a combination of crRNA and tracrRNA) sequences in the same CRISPR 
array (Cong et al., 2013). Type II CRISPR system uses Cas9 to introduce double stranded 
breaks at the target site, which are then repaired either by error-prone non-homologous end 
joining (NHEJ) or homology directed repair (HDR) (Rath et al., 2015). One form of DNA 
repair can be favoured over the other depending on the design/type of CRISPR-Cas9 system 
used. Cas9 is conjugated to gRNA to recognise a sequence of 20 base pairs adjacent to a 
PAM (Mojica et al., 2009). In the case of Cas9, this PAM sequence is “NGG,” where N is 
any base. DNA repair through NHEJ generates insertions or deletions in the host DNA, 
known as indels: NHEJ machinery either “trims back” or adds bases at either side of the DSB 
to create blunt-ended DNA ends that are then ligated together (Davis & Chen, 2013). This 
results in frameshift mutations where the optimal outcome is effective silencing of a gene due 




genes-of-interest provided template DNA for HDR machinery to act on is included with the 
Cas9 and sgRNA. However since HDR is inefficient (Pardo et al., 2009), some DSBs will 
end up being repaired by NHEJ (which is highly efficient), meaning further analysis is 
required for identification and enrichment of cells which carry the precise edit. 
 
With regard to the RNAi applications of CRISPR this technology does have several 
advantages over using siRNA or shRNA: it is much more efficient in the knockdown of gene 
function and is highly specific. The knockdown is also irreversible (which may actually be a 
disadvantage depending on the context of use) as CRISPR edits host chromosomal DNA 
which is consequentially inherited by daughter cells. Meanwhile with siRNA the knockdown 
only persists until the resultant material (i.e. the siRNA) is used up/degraded, or the effect is 
diluted through cell division (Bartlett & Davis, 2006). For shRNA-mediated knockdown, 
whilst the silencing effect may persist for an individual cell, the plasmid is not usually passed 
on to daughter cells upon cell division. Meaning the effect is eventually diluted to the point of 
non-significance (Rao et al., 2009). shRNA can be stably expressed if the plasmid used has 
lentiviral or retroviral components which allow it to integrate into host DNA. However, 
shRNA still only exerts its silencing activity at the mRNA level meaning that not necessarily 
all transcripts of a gene are affected (which may be an advantage depending on experimental 
context). Furthermore use of viral constructs for in-vivo application carries risks (Thomas, 
Ehrhardt, & Kay, 2003), additionally direct transfection of plasmids (and other large nucleic 
acid constructs) in-vivo can generate a host immune response and localised inflammation 
(Rao et al., 2009). Meanwhile CRISPR can circumvent the issue of plasmid/viral use through 
direct injection of a Cas9-sgRNA ribonucleoprotein to mediate gene silencing in-vivo 
(Fogarty et al., 2017; Ma et al., 2017). It also has advantages over other stable-cell generating 
techniques such as those which use transcription activator-like endonucleases (TALENs) and 
zinc-finger endonucleases (ZFNs) in regards to simplicity, cost, and convenience. Cas9 is 
constant in all CRISPR-related applications and the only variable factor is the short sgRNA 
which can be easily customisable. Meanwhile TALENs and ZFNs, while powerful and 
accurate, need to have their DNA-binding proteins/domains specifically designed for a 
particular gene which is more laborious (Carroll, 2011; Gaj et al., 2013; Joung & Sander, 


































Figure 11: Simple diagram of the Cas9-sgRNA complex:  
Cas9 is one example of an endonuclease used in CRISPR applications to create DSBs adjacent to a PAM 
sequence (NGG in the case of Cas9) in genomic DNA. Cas9 is guided to its targets by sgRNA which is 













































































Figure 12: Cas9 induces DSBs in host genomic DNA to create knockouts:  
A. Cas9 associates with DNA that is complementary to the guide sequence of the sgRNA and induces a 
DSB 3/4nts downstream of the PAM sequence. B. DSBs created by Cas9 endonuclease activity are 
repaired either through the efficient but error-prone NHEJ pathway or by the less efficient but more 
accurate HDR which can be exploited to create precise mutations. (i) loose ends of genomic DNA are 
stabilised by Ku70/80 which then recruits NHEJ machinery to either trim-back the DNA or polymerise 
additional bases to either end of the DSB to regain end compatibility for ligation. This creates random 
insertions or deletions (termed indels) in the DNA which are different from cell to cell. Indels cause 
frameshift mutations in genomic DNA. (ii) Homology directed repair machinery can be exploited by 
introducing donor template DNA which is homologous to genomic DNA with the exception of either a 
small gene edit or potentially larger gene insertions. The result is incorporation of the edit in host DNA 
that can cause point or frameshift mutations depending on the size of the insert sequence. Original figure. 
Traditional CRISPR is not without its limitations however: gRNA typically being 20 bp’s 
long means that there can be a degree of  “wobble” base pairing, leading to potential 
mismatches (extra bases in gRNA or DNA) and off-target mutagenesis (Cornu, Mussolino, & 
Cathomen, 2017; Cradick et al., 2014; Fu et al., 2013; Hendel et al., 2015). Good gRNA 
design should, of course, limit the amount of off-target activity but there can be cases where 
it is unavoidable. One might assume that increasing the length of the gRNA may decrease off 
target activity however, as discovered by Ran’s group, extension of the gRNA, regardless of 
whether the additional bases matched or mismatched, showed no significant difference in off-
target activity than the standard 20bp gRNA (Ran et al., 2013). They did find that off-target 
activity can be reduced by using a modified CRISPR system that uses dual Cas9n (Cas9 
nickase) proteins and two separate gRNAs (Ran et al., 2013). Cas9n is a mutated version of 
the Cas9 protein that causes a single stranded “nick,” rather than DSBs in the target DNA. 
The dual Cas9n proteins each have their own individual gRNAs targeted at forward and 
reverse strands of DNA at slight offset of up to 20bp. The offset in nickase activity creates 
overhangs on each strand of DAN that promotes HDR over NHEJ meaning less-random 
mutagenesis. This achieves a knockdown that has increased on-target activity due to the 
requirement of more criteria being fulfilled at the cost of some transfection efficiency 
compared to traditional CRISPR. Another limitation of CRISPR is the need of a PAM 
sequence for Cas9 to able to induce DSB in the target gene whilst TALENs and ZFNs are not 
restricted as to where along the gene their endonuclease activity can take place (Gaj et al., 
2013). This is especially the case for Cas variants which require longer PAM sequences 











Brief summary of project aims: 
 
This project aims to explore the role of Itch in both cancer sensitivity and bone remodelling 
through means of generating transient and stable Itch knockdowns in-vitro through use of 
siRNA and CRISPR respectively; analysing and interpreting the outcome for each model 
system. The project also goes on to compare and contrast the methods of genetic knockdown 
used in experiments. The strength of using a particular gene editing technique is dependent 
on several factors: Including the pathways being explored and the 
physiological/morphological consequences of altering them, the time-frame of the 
experiment and/or project and the nature of the model system being used be it in-vitro or in-
vivo. 
 
Based on results from previous studies we hypothesise that genetic knockdown of Itch using 
both transient and stable knockdown strategies will sensitise pancreatic cell lines to current 
FDA-approved therapeutics. The reason why pancreatic cell lines were chosen was because 
of the poor survival rate associated with the disease (discussed later) and the lack of effective 
forms of treatment. Therefore, any additional methods that can supplement and potentiate 
existing therapeutic approaches to pancreatic cancer are highly researched. An increase in 
sensitivity may be characterised by an increase in total cytotoxicity or lower dose 
requirements for the same inhibitory outcome. In a clinical setting a reduction in observable 
side-effects is also a desirable outcome when testing new forms of treatment however, this is 
not necessarily an increase in sensitivity and is also difficult to characterise in-vitro.  
 
In the context of Itch’s effect on bone remodelling, utilising an ex-vivo approach, we 
hypothesise that knockdown of Itch in monocytes derived from whole blood will increase 
osteoclastogenesis and thus facilitate osteoclast function in resorbing a bone-like matrix. 
Once again, both transient and stable approaches will be used before inducing osteoclast 
development. As previous literature has already confirmed that mice lacking functional Itch 
protein have differing numbers of osteoclasts compared to wild-type, we wish to assess if this 

















Media and supplements:  
DMEM Glutamax (Cat.No. 31966047), McCoy’s 5A modified media (Cat.No. 26600080), 
and a-MEM (Cat.No. 22571020) - all purchased from ThermoFisher and produced by 
GibCo. Media was supplemented with FBS (Biowest, Cat.No. S1900-500) to a final 
concentration of 10% and penicillin/streptomycin (GibCo, Cat.No. 25030-024) to a final 
concentration of 1%. OPTImem was also purchased from ThermoFisher (Cat.No. 31985062). 
 
Mammalian Cell Culture: 
MiaPaCa-2 cells were obtained from frozen stocks and cultured in DMEM. Capan-2 cells 
were obtained from ATCC and were grown in McCoy’s 5A modified media. Cells were 
incubated at 37°C with 5% CO2, grown in either T75 or T175 flasks until a confluence of 80-
90% was reached. All cell lines used were also tested for the presence of mycoplasma by the 
Lab Manager. To passage cells, cells were treated with trypsin (GibCo, Cat.No. 25300062) 
 to cause cell detachment from the flask surface, the trypsin was neutralised, then cells were 
centrifuged at 281 ´g for 5 minutes. The supernatant was discarded and the pellet re-
suspended. Cells were then either used for analysis or re-suspended at an appropriate dilution 
in a new flask. Cells were passaged 10 times before either being disposed of or frozen down 
and stored in liquid nitrogen; at which point a new batch was thawed. 
 
Isolation of PBMCs from whole blood: 
Whole blood (10-20 ml) was taken from a healthy volunteer on 3 occasions (ethics: 
Appendix 1). The blood was immediately mixed with 10% EDTA solution to prevent blood 
coagulation (10μl of 10% EDTA solution per 1ml of whole blood). Whole blood was then 
diluted 1:1 with cold, sterile phosphate-buffered saline (PBS - made from tablets dissolved in 
dH2O and autoclaved, ThermoFisher, Cat.No. BR0014G) which was then layered on top of 
10 ml of Histopaque-1077 (Sigma Aldrich, Cat.No. 10771) and centrifuged at 800 ´g for 30 
minutes (no brake). After the spin the blood separated out into 4 distinct layers (Figure 12). 
Using a sterile Pasteur pipette, the whitish-pink buffy coat layer containing PBMCs was 
removed.  
 
PBMCs were then re-suspended in 10 ml cold PBS and centrifuged at 300 g for 10 minutes as 
an initial wash step, which was then repeated 2-3 times. Cells were then counted and pelleted 
again before being re-suspended in a-MEM containing 20 ng/ml M-CSF (R&D Systems, 
Cat.No. 216-MC, carrier-free) to achieve a final cell density of 106 cells per ml. PBMC 
containing media was then dispensed on 6-well plates (1 ml/well) and was topped-up to 3 ml 
with a-MEM at a final concentration 20 ng/ml m-CSF. Alternatively, PBMCs were 
resuspended in m-CSF containing medium and aliquoted onto either a plain 96-well plate or a 
96-well Osteo Assay Surface plate (Corning, Cat.No. 3988) with an initial cell density of 























Figure 13: Separation of whole blood by centrifugation using Histopaque: 
Upon dilution of whole blood with cold PBS, blood solution is dispensed onto Histopaque in a 50ml tube. 
The blood is then separated by centrifugation at 800 ´g for 30 minutes. After centrifugation the different 
components of blood can be seen including Erythrocytes (red blood cells), Leukocytes (PBMCs, T-cells, 
and B-cells), and blood plasma. Original figure. 
 
Cell Culture of PBMCs: 
Once isolated, PBMCs were incubated at 37°C with 5% CO2 in a humidified incubator. 
Media was replaced every 3 days with fresh a-MEM containing 20 ng/ml m-CSF. After 7 
days of cell culture, media was supplemented with 50ng/ml recombinant RANKL (R&D 
Systems, Cat.No. 6499-TEC, carrier-free) to encourage differentiation of monocytes into 
osteoclasts. Media was then replaced every 2 days including fresh cytokines. 
  
Transient Itch knockdown using siRNA: 
 
siRNA design: 
Anti-Itch siRNA duplex sequence data was kindly provided by Dr Simon Newman, 
Nanogenics Ltd and oligonucleotides synthesised by Eurogentec (Table 1). 
 
 


















As a negative control a commercial scrambled control from Eurogentec was used. Duplexes 
were re-suspended in dH2O to achieve a concentration of 20 µM. Specificity of siRNA was 
determined through Blast search of the forward and reverse oligonucleotides. 
 
siRNA duplex preparation: 
Tubes labelled A and B were, made for each siRNA duplex (4 total for si-Itch and Negative 
control). 
• Tube A: 800 μl OPTImem + 16 μl Lipofectamine RNAiMAX (ThermoFisher, 
Cat.No. 13778030) 
• Tube B: 800 μl OPTImem + 10 ul of 20 μM siRNA duplexes 
Each pair of tubes was incubated separately for 5 minutes before the contents from tubes A 
and B were mixed and incubated for a further 20 minutes at room temperature. This results in 
125 nM of siRNA in 1.6 ml. This reaction was scaled up or down depending on the final 
concentration of siRNA required for particular experiments (some cell lines required a larger 
final concentration of siRNA for successful knockdown). 
 
siRNA transfection - dish/plate format: 
To first verify that the siRNA duplexes could knock-down Itch expression we performed 
forward transfection of siRNA duplexes in cells. Forward transfection involves seeding cells 
prior to transfection whilst reverse transfection involves seeding cells on top of duplex 
solution. For western blot verification, firstly 1.5x106 cells were seeded in 10 cm diameter 
dishes in 10 ml of media. After one day of cell attachment, siRNA duplexes were prepared as 
above, and the resultant solution was added to the plates drop-by-drop and incubated 
overnight. After 24 hours transfection, cell lysates were made and protein expression was 
verified and measured by Western blot. For qPCR verification 5x105 cells were seeded in 6-
well plates and before siRNA solution was applied. 
 
Cell-death and functional assays requiring a 96-well plate employed reverse rather than 
forward transfection. siRNA duplexes were prepared as previously described, 16μl of duplex 
solution was aliquoted into each well of a 96-well plate (separate plates were used for 
negative and untreated controls). 100 µl of cell solution with appropriate supplements was 
then added to each well containing siRNA duplex media (initial cell density dependent on 
cell line used). After 24 hours of incubation the media was replaced and downstream assays 
were performed. In experiments where there were supplementary doses of siRNA for a 
persistent knockdown, siRNA was re-applied at the same concentration 24 and 72 hours after 
the addition of doxorubicin/gemcitabine or 48 hours after g-irradiation. 
 
In the case of monocytes already seeded on a 96 well plate (Osteo Assay Surface or 
otherwise) forward transfection was used and 16 μl of siRNA solution was added to each 
well already containing supplemented media (a-MEM containing 20 ng/ml m-CSF). After 24 
hrs the media was replaced and further supplemented with 50 ng/ml RANKL to see the 
effects of Itch knockdown on osteoclast differentiation. Freshly prepared siRNA solution was 
re-applied to the cells at day 3 of RANKL treatment to maintain the knockdown over a 7-day 






Stable Itch Knockdown using CRISPR-Cas9: 
 
sgRNA design: 
Forward crRNA design templates were made using 20 base nucleotide sequences from the 
GeCKOv2 library (Sanjana, Shalem, & Zhang, 2014) and from these the reverse oligos were 
generated along with additional primer sequences (Table 2). Oligonucleotides were ordered 
at 50 nmol yield, 5’ phosphorylated and unsalted (ThermoFisher). 
 







Itch4F  CACCGGGTGCTTCTCAGAATGATGA 
Itch4R  AAACTCATCATTCTGAGAAGCACCC 
Itch5F  CACCGTGAACATGTAGTTTCACCAT 
Itch5R  AAACATGGTGAAACTACATGTTCAC 
Itch6F  CACCGGACTTGTCAATTTGTCTTGA 







Table 2: Oligonucleotides used for sgRNA cloning: 
Bases highlighted in red are primer sequences to allow incorporation of sgRNA sequence (in black) into 
the pLentiCRISPRv2 vector. 
Cloning sgRNA into plasmid vector: 
The plasmid vector being used for transfection was pLentiCRISPRv2 (Addgene plasmid # 
52961) (Sanjana et al., 2014). Restriction maps and gene inserts for all plasmids being used 
can be viewed in Supplementary Figure 1. Before the crRNA sequences can be inserted into 
the plasmid vector, the plasmid itself needs to be opened up and the filler sequence removed. 
The pLentiCRISPRv2 vector (2 μg) was dephosphorylated and digested in a solution of 1 μl 
FastDigest Esp3l (ThermoFisher, Cat.No. FD0454), 2 μl 2x FastDigest buffer (provided with 
restriction enzyme), 0.5 μl Calf Intestinal Phosphatase (NEB, Cat.No. M0290 – discontinued 
as of June 2019), 0.2 μl of 100 mM fresh DTT (Sigma Aldrich, Cat.No. 10197777001) and 
water up to 20 μl. This reaction was incubated for 30 minutes at 37°C. A 0.8% agarose gel 
was prepared to visualise the components of the digested plasmid: 0.4g agarose in 50 ml 1x 
TAE (40 mM Tris base, 20 mM acetic acid and 1 mM EDTA) plus 1 μl of 10 mg/ml 
ethidium bromide solution. After incubation, 2 μl of loading dye was added to the digested 
plasmid and was then loaded onto the gel and run at 40 V for 45 minutes (171 mAmp, 16 W). 
Upon digestion there is a 1.8 kb (filler sequence) band and a 12.8 kb band (plasmid 







Figure 13: Gel image of digested plasmid: 
Plasmid was digested to remove the filler sequence so that sgRNAs could be incorporated into the plasmid 
backbone. UV exposure revealed a 1.8 kb band and a 12.8 kb band corresponding to the filler sequence 
and plasmid backbone respectively. 
Gel Extraction: 
Using a UV source, the 12.8 kb band was excised and weighed; This ensured that it was re-
suspended at the correct concentration when it came to the extraction. The plasmid was then 
purified from the cut-out gel using the QIAquick Gel Extraction Kit (Qiagen Cat.No. 28704). 
This involves dissolving the gel then isolating DNA from the resulting solution by 
centrifugation, which results in a 50 μl elute of the digested plasmid in the elution buffer 
provided with the kit. 
 
Annealing of forward and reverse sgRNA oligonucleotides: 
In each case oligonucleotides were resuspended at 1 nmol/μl in d H2O (Table 3). The pairs of 
oligos were then annealed in the following reaction: 1 μl forward oligo (1:10 dilution – 0.1 
nmol/μl), 1 μl reverse oligo (1:10 dilution – 0.1 nmol/μl), 5 μl NEB buffer 2 (NEB, Cat.No. 
B7002S), 43 μl water. Annealing reagents were put in a thermocycler with the following 














sgRNA Name yield (nmol) H2O volume (μl) 
Itch1F 44.2 44.2 
Itch1R 46.1 46.1 
Itch2F 45.4 45.4 
Itch2R 42.4 42.4 
Itch3F 41.4 41.4 
Itch3R 36.8 36.8 
Itch4F 79.7 79.7 
Itch4R 35.5 35.5 
Itch5F 52.4 52.4 
Itch5R 47.7 47.7 
Itch6F 69.4 69.4 
Itch6R 33.0 33.0 
 
Table 3: Resuspension volumes for sgRNA oligos: 
Yield supplied by manufacturer and the appropriate volume of deionised water to re-suspend oligos at 1 
nmol/μl. 
Ligation of annealed oligos into digested plasmid vector: 
Annealed oligos were then ligated to the digested pLentiCRISPv2 vector using the Roche 
Rapid Ligation Kit (Roche, purchased from Sigma-Aldrich, Cat.No. 11635379001): 5 μl 
water, 1 μl of a 1:10 dilution of annealed oligos, 2 μl digested gel purified pLentiCRISPRv2, 
2 μl 5x DNA dilution buffer, 10 μl 2x digestion buffer, 1 μl ligase. The ligation reaction was 
incubated overnight at 16°C (for this we used a Lucky Reptile Herp Nursery II Incubator). 
 
 
Transformation of vector into STBL3 and bacterial expansion: 
The ligation mix was then transformed into One Shot STBL3 chemically competent E.coli 
(Invitrogen, Cat.No. C737303). 5 μl of ligated vector was added to one tube of STBL3 
thawed on ice and incubated on ice for 30 minutes. The STBL3s were then heat-shocked at 
42°C for 45 seconds before returning to ice for another 2 minutes. 250 μl of LSOC media 
(provided with the bacteria), pre-warmed to room temperature, was added to each tube of 
bacteria and incubated at 37°C with shaking at 225 rpm for 1 hour in an Orbital Incubator 
SI50 (Stuart Scientific). After the incubation period, 200 μl of media was removed from each 
tube and put on ampicillin-treated agar plates and incubated overnight at 37°C. Due to the 
presence of ampicillin in the agar the only colonies that should grow on the plate are bacteria 
that have successfully incorporated a fully ligated plasmid (since lentiCRISPRv2 contains a 
sequence that codes for ampicillin and carbenicillin resistance). After culturing overnight, 
colonies were selected (3 per plate) and expanded in 5ml of LB broth supplemented with 100 
μg/ml carbenicillin for 15 hours at 37°C with shaking. Carbenicillin was used over 
ampicillin, as it is more resistant to degradation. Stocks containing a mix of the bacterial 







The rest of the bacterial solution was centrifuged at 1900 ´g for 6 minutes. The supernatant 
was discarded and DNA was extracted using the QIAprep Spin Mini-prep Kit (Qiagen, 
Cat.No. 27104). Eluted DNA was quantified using Nanodrop (looking for a 260/280 
absorbance ratio of approximately 1.8 for eluted DNA). 
 
Verification of sgRNA incorporation into pLentiCRISPRv2: 
Two methods were used for verifying that the insert had been incorporated into the 
pLentiCRISPRv2 vector: a restriction double digest and plasmid sequencing. A restriction 
double digest was performed on 1 μg of mini-prep DNA that could then be run on an agarose 
gel. Additional reagents for the double digest included: 1μl of EcoR1 (NEB, CatNo. 
R0101S), 1 μl of Nde1 (NEB, Cat.No. R0111S), 2 μl Cutsmart buffer (provided with 
restriction enzymes), 2 μl of loading dye, then made up to 20 μl with water. Uncut solutions 
were also made where the restriction enzymes are substituted out for water; this provided a 
baseline comparison for each sample. Reactions were incubated for 1 hour at 37°C before 
being loaded onto a 2% agarose gel (with 1 μl EtBr) alongside a 1 kb ladder (NEB, Cat.No. 
N3232S) and Hyperladder I (Bioline, Cat.No. BIO-33053) and run at 60 V for 55 minutes. 
The gel was then imaged using a ChemiDoc XRS+ (Bio-Rad), looking for fragments at 




Figure 14: ChemiDoc XRS+ gel images from the restriction double digests: 
 (A.) sgRNA 1 and 2, (B.) sgRNA 3, (C.) sgRNA 4,5 and 6. Arrows indicate presence of desired bands for 
each bacterial colony (A,B or C).  
Samples where bands were present were sent for sequencing at DNAseq based at the 
University of Dundee. Mini-prep samples were re-suspended to get 600 ng in 30 μl of water, 
the sequencing primer used was LKO.1 5’ which was diluted from a stock solution (4 μl of a 
200 μM stock in 250 μl of water) and 2 μl added to the DNA and water; These were then sent 
for sequencing. Plasmid sequencing results were returned within one or two days and the 
sequences were checked to see if they contained the appropriate 20 base pair sgRNA 
sgRNA1 sgRNA2 sgRNA3 







sequence. The glycerol stocks of the positive hits from both the sequencing and restriction 
digest were kept and used for DNA maxi-prep. 
 
DNA Maxi-Prep: 
The glycerol stocks were then used to create a starter culture of bacteria (scraping of the 
stock in 3 ml LB and carbenicillin). Only samples that had been validated by both the 
restriction digest and the plasmid sequencing were used to create the starter cultures (in the 
case where more than one sample came back positive only one was used). These were 
cultured for 8 hours at 37°C with shaking before 1 ml was removed and transferred to 200 ml 
of LB/Carb in a conical flask and cultured overnight at 37°C, shaking at 220 rpm in a New 
Brunswick I-26 incubator shaker. Culture was then transferred to a 500 ml centrifuge bottle 
and spun at 6,000 ´g for 15 minutes at 4°C. The supernatant was then discarded and the 
plasmid was purified using Qiagen’s Endo Free Plasmid Maxi Kit (Qiagen, Cat.No. 12163). 
Resulting protocol yields purified plasmid in a >200 μl suspension, this is then quantified by 
Nanodrop. Purified DNA was then made into aliquots of 1 μg/μl and stored at -20°C. Maxi 
preps were also made for the 2 packaging plasmids used in the transfection stage of the 
CRISPR protocol (see below). 
 
Preparation of lentiviral particles for transduction: 
From this point on only plasmids containing sgRNA 1, 2 and 3 were used to create new 
modified cell lines. To grow lentiviral particles containing the CRISPR-Cas9 system, 
HEK293T cells were used from frozen stocks. HEK293Ts are a derivative of the HEK293 
(Human Embryonic Kidney 293) cell line, one with debatable origin (Stepanenko & 
Dmitrenko, 2015), that have a temperature sensitive variant of the SV40 antigen, which 
allows increased production of desired proteins and/or lentivirus. HEK293T cells were plated 
at a density of 4x106 cells per 10 cm plate and incubated overnight in 10 ml DMEM. 27 µl of 
Mirus Bio TransIT-LT1 Transfection Reagent (Fisher Scientific, Cat. No. MIR2304) was 
added to 1.5 ml of pre-warmed OptiMEM and incubated for 20 minutes. A mix of 
pLentiCRISPRv2 (containing the desired sgRNA sequences targeting Itch or containing a 
scrambled control sequence), PsPAX2 (Addgene plasmid # 12260) and PSDII (also known as 
pMD2.G - Addgene plasmid # 12259) was prepared (Table 4). 
 
Plasmid pLentiCRISPRv2 PSPAXII pMD2.G 
Volume of 1 µg/µl 
plasmid stock (µl) 4.00 3.00 2.00 
Amount of 
plasmid in final 
solution (µg) 
4 3 2 
 
Table 4: plasmids used and volumes of each from maxi-prep stocks. 
 
PsPAX2 and pMD2.G (Supplementary Figure 1) are second-generation packaging plasmids 
and thus facilitate lentiviral production and transfection in-vitro (PsPAX2 and pMD2.G were 
gifts from Didier Trono (Addgene plasmid # 12260; http://n2t.net/addgene:12260; 
RRID:Addgene_12260 and Addgene plasmid # 12259; http://n2t.net/addgene:12259 ; 
RRID:Addgene_12259). Packaging plasmids were developed to introduce a layer of safety 
when working with lentiviral vectors since they are derived from HIV-1 (Sakuma, Barry, & 




an envelope construct and a transfer construct, acts to prevent the formation of RCLs 
(Replication competent lentiviruses) (Sakuma et al., 2012). Second generation packaging 
plasmids are different from first generation packaging plasmids in that they lack certain 
accessory proteins that are not needed for replication in particular cell lines (Zufferey et al., 
1997) 
 
The plasmid mixture was then added to the OPTImem and Mirus solution and incubated for a 
further 30 minutes. The overall solution was then aliquoted onto the plates of HEK293T cells 
and incubated overnight. Existing media and replacing with 4ml of fresh media; At this point 
the cells should start producing lentiviral particles.  
 
After 48 hours total incubation, viral particle-containing media was collected and stored at 
4°C. Fresh media (4 ml) was re-applied to the HEK293T cells and placed back in incubation. 
After 72 hours of exposure to the plasmid mix, the media was once again aspirated from the 
HEK293T cells and combined with the media from 48 hours. The combined media was 
passed through a 0.45 μm syringe filter into a tube containing 8 μg/ml polybrene (Sigma-
Aldrich, Cat.No. TR-1003): This step acts to separate out any cellular debris contained within 
the viral media. The viral media could then be used to infect recipient cells. 
 
Transduction of mammalian cell lines: 
Prior to lentiviral transduction, 5x105 MiaPaCa-2 or Capan-2 cells were seeded onto 10 cm 
dishes (two dishes per plasmid of interest). 4 ml of viral media was then added to the 
recipient cells and kept in the viral incubator for 48 hours. Media was then aspirated and 
recipient cells were trypsinised using TrypLE Express (Gibco, Cat.No. 12604054). This was 
then neutralised with either DMEM or McCoy’s 5A media (depending on cell line) and 
centrifuged at 1,200 rpm for 3 minutes in a Heraeus Labofuge 400R. T-75 flasks were 
prepared containing 20 ml of media (DMEM or McCoy’s) treated with puromycin (4 µM, 
Sigma-Aldrich, Cat.No. 540222). Puromycin acts as a selective pressure: cells that have not 
incorporated the lentiviral construct will not have puromycin resistance and will have 
inhibited growth and/or die. The supernatant was discarded and the pellet re-suspended in 
5ml of media which was then transferred to the respective T-75 flask. Cells were then 
cultured with puromycin selection over 4 days, the selection pressure was removed and cells 
were safe to move back into non-viral incubation after 2 changes of plastic. Downstream 
applications could then proceed. 
 
Transduction of Primary monocytes: 
Viral-particle-containing media from 48 and 72 hours was combined and the media was 
filtered as previously described (see “Preparation of lentiviral particles for transduction” - 
page: 43). viral media (1.5 ml) of was aliquoted onto 6-well dishes containing monocytes and 
osteoclast precursors and incubated for 48 hours. Following this incubation period, the viral 
media was aspirated and the wells washed with PBS. The cells were not trypsinised in this 
case to minimise the risk of losing cells (primary monocytes do not replicate). Cells were 
exposed to media containing 1µM puromycin supplemented with M-CSF as before for 4-5 
days. During this period of incubation the puromycin-containing media was replaced when 
there were many dead cells (assessing the morphology of the cells by microscopy). After this 
period of time the media was replaced with osteoclast differentiation-promoting media (a-






Preparation of RNA for qPCR: 
 
Preparation of RNA lysates: 
Cells were seeded on 6-well plates and were grown until roughly 80% confluence or 24 hours 
after siRNA treatment. Media was then aspirated and wells were washed with ice-cold PBS. 
PBS was removed using an aspirator pump and the plates were placed on-ice at an angle to 
pool any leftover PBS. This was removed using a fine-tipped pastette. RNA was extracted 
and isolated using the Quiagen RNEasy Mini Kit (Quiagen, Cat.No. 74104). Lysis solution 
was prepared by adding 10 µl of b-mercaptoethanol per 1ml of buffer RLT (amount required 
was calculated beforehand based on number of samples. The b-mercaptoethanol-
supplemented RLT is stable at room temperature for up to 1 month). 350 µl of lysis solution 
was added to each well and wells were gently scraped to detach cells from the plate surface 
with a sterile cell scraper. Plates were then left for a couple of minutes to lyse and at an angle 
to pool all the material. Lysates were then transferred to a 1.5 ml Eppendorf tube and labelled 
appropriately. At this point the lysates can be stored at -80°C if desired. Each lysate was 
supplemented with 350 µl of 70% ethanol solution (ETOH, 1:1 ratio) and was mixed by 
pipetting up and down. 700 µl of each sample was transferred to a “RNeasy spin column” 
(which is already placed inside a 2 ml collection tube) and spun at 10,000 rpm for 15sec in a 
Heraeus Fresco-21 centrifuge (Thermo). The flow-through was discarded and the column 
placed back into the collection tube. Any remaining sample was pooled into the 
corresponding spin column and spun again at 10,000 rpm for 15s. 700 µl of buffer RW1 was 
added to each spin column and spun at 10,000 rpm for 15s. The flow-through was discarded 
and spin column placed back into the collection tube. 500µl of buffer RPE (supplemented 
with ETOH prior to extraction as per Quiagen’s instructions) was added to each spin column 
and spun at 10,000 rpm for 2min. Flow-through was discarded and the column was then 
placed into a fresh 2 ml collection tube and spun again at 10,000 rpm for 1min. The spin 
column was removed and placed into a 1.5 ml Eppendorf tube. RNAse-free water (30 µl) was 
applied directly to the membrane of each spin column which was then spun at 10,000 rpm for 
1min to elute the RNA. RNA elute was then stored at -80°C until ready to quantify using 
Nanodrop (using RNAse-free water as a blank, looking for a 260/280 absorbance ratio of 
roughly 2.0 for RNA). 
 
cDNA generation by reverse transcription: 
Reverse transcription was done as per the instructions of the Quiagen QuantiTect Reverse 
Transcription Kit (Quiagen, Cat.No. 205311). Template RNA was thawed on ice whilst 
gDNA Wipeout Buffer, Reverse Transcriptase, RT primers, RT buffer and RNAse-free water 
were thawed at room temperature. To eliminate any genomic DNA (gDNA) that may be in 
the sample a gDNA eliminating reaction was set up in 600 µl tubes as described in Table 5 to 
a total volume of 14 µl. Tubes were flicked to mix the reagents, and centrifuged using an 
Eppendorf mini spin benchtop centrifuge to pool all of the reagents at the bottom of each 










gDNA Wipeout Buffer 7x 2 µl 
Template RNA Variable (up to 1 µg) 
RNAse-free water Variable  
Total reaction volume 14 µl 
 
Table 5: gDNA elimination reaction setup. 
 
Reverse transcription master mix was prepared in a separate Eppendorf tube to be dispensed 
into each of the individual tubes from the gDNA elimination reaction on ice. The volumes 
per sample are described in Table 6 however excess was usually prepared to account for 
potential pipetting error. Tubes were flicked and centrifuged, as previously described to mix 






QuantiTect RT Buffer, 5x 4 µl 
RT Primer Mix 1 µl 
Entire gDNA elimination 
reaction 
14 µl 
Total Reaction Volume 20 µl 
 
Table 6: Reverse transcription reaction setup.  
 
To start the reverse transcription reaction each sample was incubated in a heat block at 42°C 
for 15min. Reverse transcriptase was then inactivated by moving the tubes to a separate heat 
block at 95°C for 3min. After the 3 minutes the samples were placed on ice to cool down. 
Once sufficiently cool the samples were spun again to pool all of the sample at the bottom of 
the tube and then kept at -20°C until needed for qPCR. 
 
Quantitative PCR (qPCR): 
qPCR was done using a Quiagen Rotor-Gene Q (Quiagen) qPCR machine with the 
accompanying software. Tube preparation reagents included Rotor-Gene SYBR Green PCR 
Kit (Quiagen, Cat.No. 204074) and QuantiTECT Primer Assays (Quiagen) for GAPDH and 
Itch. Each individual sample was seeded in quadruplicate for qPCR and was set up as 
described in Table 7 and was aliquoted into Quiagen Strip Tubes and Caps (Quiagen, Cat.No. 
981103). The master mix was prepared separately and aliquoted into tubes before the cDNA 
was dispensed into individual tubes. Separate master mixes were made for each primer. 
Additional tubes were made for each run which were either no-template-controls or no-







SYBR Green 12.5 µl 
Quantitect Primer Assay  2.5 µl 
RNAse-free water Variable 
cDNA Variable 
Total Reaction Volume 25 µl 
 
Table 7: The qPCR tube reaction setup:  
The amount of template cDNA specified in the product handbook is £100 ng/reaction. We assume from 
the reverse transcription reaction that all of the template RNA has been converted into cDNA. 
Reaction tubes were then loaded into the Rotor-Gene Q and the cycler programmed with the 
settings described in Table 8, acquiring on the green channel to detect SYBR Green 
fluorescence. 
 
Step Time Temperature 
PCR Initial Activation Step 5min 95°C 
Two-Step Cycling 
Denaturation 5s 95°C 
Annealing/Extension  10s 60°C 
Number of Cycles 35-40 
 
Table 8: The qPCR cycling parameters for the Rotor-Gene-Q. 
 
Once the plateaux phase in the reaction for each individual sample had been reached, analysis 
of relative gene expression (using GAPDH as a housekeeping gene) could be performed. Ct 
values were calculated by the software after designating a threshold value where each of the 
samples was in the linear phase of the PCR reaction. These values were exported to an Excel 
spreadsheet where relative Itch expression could be calculated for each individual sample 
(DCt) compared to its GAPDH expression. Further analysis of this data included mean and 
standard deviation calculation and normalisation to parental/untreated controls. Data was then 
copied into GraphPad Prism (version 6.2) to draw graphs and perform a Student’s t-test to 
identify statistically significant differences in mean Itch expression between samples. 
 
Preparation of protein lysates for Western Blot: 
Cells were seeded on either 10 or 15 cm2 diameter plates and grown until roughly 80% 
confluent or 24 hours after siRNA treatment, ensuring that no samples were completely 
confluent. When the desired confluence was reached the dishes were removed from 
incubation. A 10 ml aliquot of RIPA lysis buffer (Table 9, “RIPA buffer,” 2006) was used to 











Reagent Volume (ml) Final concentration 
5 M NaCl 3 150 mM 
0.5 M EDTA, pH 8.0 1 5 mM 
1 M Tris, pH 8.0 5 50 mM 
NP-40 (IGEPAL CA-630) 1 1.0% 
10% sodium deoxycholate 5 0.5% 
10% SDS 1 0.1% 
dH2O 84  
 
Table 9: RIPA buffer preparation and reagents 
 
Reagent  Amount/Volume 
RIPA buffer 10 ml 
Phosphatase inhibitor 2 (Sigma Aldrich, Cat. No. P5726) 100 μl 
Phosphatase inhibitor 3 (Sigma Aldrich, Cat No. P0044) 100 μl 
Aprotinin (Sigma Aldrich, Cat. No. SRE0050) 50 μl 




Table 10: Reagents used for preparation of the lysis solution 
 
Culture media was decanted and the dishes were washed twice with ice-cold excess PBS to 
remove any protein-containing media. PBS was then aspirated and the dishes were placed on 
ice at an angle so that any leftover PBS would run off and could be collected using a fine-
tipped Pasteur pipette; This prevents any excess PBS from diluting the lysate if the yield of 
protein is low. lysis solution was then added to each culture dish; cells were then scraped and 
left to lyse with the dishes at an angle so that all the lysed material collected at the bottom to 
make it easier to aspirate. Lysed cells were then transferred to eppendorf tubes and 
centrifuged at 13,000 rpm for 6 minutes at 4°C in a Heraeus Fresco-21 centrifuge, after which 
the supernatant was removed and placed in a fresh tube and stored at -80°C until needed. 
 
Bicinchoninic acid assay (BCA assay) to determine protein concentration:  
To determine the concentration of protein within lysates a BCA assay was used. 5 μl of 
protein lysate was diluted in 45 μl of lysis buffer and placed in borosilicate glass tubes (note: 
lysis buffer used from generating the protein lysates as described before. Buffer is still usable 
if used within a few days and kept refrigerated, water can be used as an alternative for 
dilution). Protein standards were prepared (Table 11) using the albumin standard samples 













Tube Final Conc. 
(μg/ml) 
Vol. 2 mg/ml 
standard (μl) 
Vol. dH2O (μl) 
A 0 0.00 50.00 
B 100 2.50 47.50 
C 150 3.75 46.25 
D 200 5.00 45.00 
E 500 12.50 37.50 
F 1000 25.00 25.00 
G 1500 37.50 12.50 
H 2000 50.00 0.00 
 
Table 11: BCA assay protein standard preparation: 
Protein standards A-H with the final protein concentration, volume of the albumin standard used and the 
volume of water used for each solution. 
In a universal tube 0.5 ml of copper(II) sulfate solution (provided with the kit) was added to 
25 ml of bicinchoninic acid solution (provided with the kit). This results in a green solution 
that was then aliquoted at 1 ml into each of the diluted protein lysate samples and protein 
standards. The tubes were then placed in a water bath at 60°C for 15 minutes. After 
incubation the resulting solution in each of the tubes should be purple: the darker the shade, 
the higher the protein concentration. This was quantified using a Biohit BP800 Microplate 
Reader (filter: 540 nm) with a pre-prepared algorithm within a spreadsheet to calculate 
protein concentration (optical densities of the standards provided a standard curve which was 
then used to estimate protein concentration of each of the test samples). Using the results 
from the spreadsheet, western blot samples were prepared so as to normalise the 
concentration of protein between samples by addition of loading buffer (5´) and lysis buffer. 
  
Western blot protocol: 
 
Antibodies used: 
Antibody Species Supplier Dilution 
Itch (109018) Rabbit Abcam 1:10,000 
Itch (D8Q6D) Rabbit CST 1:1000 
b-Actin (8H10D10) Mouse CST 1:2000 
Cas9 (7A9-3A3) Mouse CST 1:1000 
 
Table 12: antibodies for western blots. 
Antibodies used throughout the project including species, supplier and dilution used. 
Polyacrylamide gel Electrophoresis: 
A western blot was performed using the Laemmli method (Laemmli, 1970) which involves 
using stacking gel to concentrate protein before it enters the resolving gel (reagents for both 
gels are displayed in Table 13). This is due to the different pH of each of the gels providing 
different motility to proteins when subject to a current. Samples to be run on the gel were 
first denatured in a heat block at 60°C for 1 hour whilst a 10% resolving gel and the stacking 




on the gel along with Chameleon Duo protein marker (Licor, Cat.No. 928-60000). 




Resolving gel (10%) 13.5 ml Acrylamide 
15 ml 1 M Tris (pH8.85) 
0.4 ml 10% SDS 
11.1 ml H2O 
0.1 ml TEMED 
(tetramethylethylenediamine) 
0.1 ml AMPS (ammonium persulfate) 
Stacking gel 3.6 ml Acrylamide 
10 ml 0.375 M Tris (pH6.8) 
16 ml H2O 
0.1 ml TEMED 
0.1 ml AMPS 
Running buffer 9.09 g Tris base (Sigma) 
43.26 g Glycine (Sigma) 
30 ml 10% SDS 
dH2O to 3 L 
 
Table 13: Solutions with relevant reagents and volumes for polyacrylamide gel electrophoresis: 
All solutions prepared at room temperature. 
Gel transfer: 
Transfer buffer was prepared along with the transfer membrane and other components 
required for transfer. After the run the gel was removed from the electrophoresis apparatus 
and any sections of the gel that were deemed superfluous were excised. The transfer cassette, 
including the PVDF transfer membrane (pore size 0.45 µm, Immobilon, Cat. No. 
IPVH00010), was assembled and the transfer buffer was prepared (Table 14). The cassette 
was loaded into the transfer tank along with the buffer. Transfer was carried out at 30 V 




Transfer buffer 12.12 g Tris base 
57.68 g Glycine  
dH2O to 4 L 
 
Table 14: Solutions used for gel transfer stage in the western blot protocol and the reagents used to 
prepare them: 







Primary and secondary antibody staining: 
Primary antibodies were diluted in a 50:50 solution of Licor blocking buffer (Licor, Cat.No. 
927-40000) and PBS. The transfer cassette was removed from 4°C and the transfer 
membrane removed, checking to see if the visible bands from the protein marker had 
successfully transferred from the gel to the membrane. Antibody solution was then applied to 
the transfer membrane and incubated overnight at 4°C with gentle rocking.  
 
After incubation the membrane was then washed 3´5 minutes with 0.1% PBS-Tween before 
the secondary antibody solution was applied. Secondary antibodies used were donkey anti-
rabbit (CW800 – Licor, Cat.No. 926-32213) and/or donkey anti-mouse (RD680 – Licor, 
Cat.No. 926-68072) and were both used at a dilution of 1:10,000 in a 50:50 solution of Licor 
blocking buffer and PBS with 0.1% SDS (to eliminate background and potential non-specific 
binding). The membrane was incubated with secondary antibody solution and left at room 
temperature, with gentle rocking, for 45 minutes in the dark: It was then washed again 3´5 
minutes with PBS-T followed by 3´5 min washes with just PBS. The membrane was then 
left to dry on filter paper. Once dry the membrane and bands were imaged and quantified 
using a Licor Odyssey Scanner (Licor) and Image Studio (Licor). Quantified signal in the red 
and green channels was then exported to Excel where background correction and 
normalisation to controls was performed. Data was then copied into GraphPad Prism to draw 




Initially a monoclonal rabbit anti-Itch primary antibody from Abcam was used with a dilution 
of 1:10,000 (as per the manufacturer’s instructions) and mouse β-actin as a loading control 
with a 1:2000 dilution. Washing, secondary antibody application, and membrane 
visualisation were performed as previously described. 
 
When visualised using the Licor Odyssey scanner, presence of b-Actin was confirmed as 
indicated by the red bands at around 42 kDa (Figure 15). However, there was a lack of signal 
in all of the samples for Itch (band size roughly 103 kDa) including parental and scrambled 
controls. The presence of b-Actin indicates that there was nothing wrong with the sampling 
method and that there is indeed protein in the sample meaning that the most likely cause for 







Figure 15: Western blot performed on cell lines: 
Red bands show presence of actin loading control, yellow arrow indicates the predicted area one would 
expect to see Itch (white arrow). 
One possible reason that no signal was present was that there is little to no expression of 
endogenous Itch in the cell types used; This would make it difficult to determine whether the 
knockout was successful in regards to protein level as there would be no distinguishable base 
line from which to compare the results. However, previous studies have performed Western 
blots using MiaPaCa-2 cells and these have been successful (de la Fuente et al., 2015). 
Another possibility is that the primary antibody was simply too dilute. The dilution used in 
the protocol was 1:10,000 (based on the manufacturer’s instructions) which seemed very low 
compared to the dilutions typically used for primary antibodies (usually around 1:1000). 
Lastly, and most simply, the antibody or batch could have been faulty. 
 
To troubleshoot this issue a series of follow-up western blots were performed. To quickly test 
the dilution theory the membrane was re-blocked and the primary antibody was re-applied at 
a 1:1000 dilution, however bands could still not be detected (not shown). A new gel was then 
prepared using existing lysates from three of the four positive control cell lines described in 
the antibody datasheet: MCF7s, HL60s, and K562s. Each of the lysates along with the protein 
marker were aliquoted so as to have four replicates of each. Once the transfer step of the 
Western Blot protocol was completed the membrane was divided into quarters so as to have 
four sections of membrane each with protein marker and one of each of the positive controls. 
Each of the membranes were then subjected to different treatments involving the use of 











Membrane Primary dilution Blocking reagent 
A 1:1000 50:50 Licor blocking buffer/PBS 
B 1:1000 5% Dry Milk powder in PBS 
C 1:10,000 50:50 Licor blocking buffer/PBS 
D 1:10,000 5% Dry Milk powder in PBS 
 
Table 15: antibody dilutions and blocking conditions for each of the four membranes 
 
The membranes were all treated with the same dilution of secondary antibody (1:10,000) in 
different blocking agents depending on what was used with the primary antibody. Upon 
imaging the four membranes (Figure 16) there was still no apparent bands for Itch for any of 
the samples. After this result we concluded that the batch was faulty, which was later 




Figure 16: Western blots performed on control cell lines: 
Cell lines MCF7, HL60, K562 with different antibody dilutions and blocking agents. Licor blocking 
buffer, 1:1,000 ab dilution (A.) and 1:10,000 ab dilution (B.) Dry milk powder 1:1,000 ab dilution (C.) and 













Cell Survival assays: 
Drug Preparation: 
Doxorubicin (Sigma Aldrich, Cat.No. 44583) and gemcitabine (Sigma Aldrich, Cat.No. 
G6423) were made into 10 mM aliquots in 100 µl DMSO (Sigma Aldrich, Cat No. D2660). 
For cytotoxicity experiments 10/1 µM stock solutions in culture media were made for Capan-
2 and MiaPaCa-2 cells respectively. Smaller concentrations were made from various 
dilutions of these stock solutions. For each experiment a vehicle control was prepared which 
contained the equivalent dilution of DMSO for the highest drug concentration for each cell 
line: for Capan-2 cells this was 1:1000 (maximum drug conc. 10 µM) and 1:100,000 for 
MiaPaCa-2 (maximum drug conc. 100 nM). 
 
Irradiation of cell lines: 
Cells were passaged into T25 flasks/6 cm dishes for each test condition and exposed to 0-6 
Gy of g-radiation in a IBL437C Gamma Irradiator (CIS Diagnostic, radioactive source: 
Cs137). Cells were then immediately passaged, resuspended, counted, and dispensed onto 96 
well plates at the densities described below. 
 
SRB and automated cytometry analysis (Celigo): 
Cells being treated with chemotherapeutic drugs (i.e. doxorubicin and gemcitabine) were 
passaged, counted using a haemocytometer, resuspended in fresh media and aliquoted onto 
96 well plates to achieve a specific initial cell density (500 cells/well for MiaPaCa-2 cells and 
2000 cells/well for Capan-2 cells as determined by a preliminary growth curve experiment). 
After 24 hours (to allow cells to adhere to the plate surface) cells were subject to increasing 
concentrations of either gemcitabine or doxorubicin. After 24 hours exposure, drug-
containing media was aspirated and replaced with fresh media. Cells subject to radiation had 
media changed 24 hours after treatment to mimic the conditions of the 
doxorubicin/gemcitabine treated cells. 
 
Over 4 days of incubation, plates were scanned on Celigo every 24 hours, measuring the 
change in confluence (percentage cell coverage, Table 16) in each well over time. A 
sulforhodamine B (SRB) assay was then performed as an end-point measurement of cell 
survival after 4 days (cytotoxicity assay). Cells were fixed with 50 µl of 25% cold 
trichloroacetic acid (TCA) solution and incubated for 1 hour at 4°C. Plates were then washed 
with excess tap water and placed in an oven to dry. 50 µl of SRB staining solution was 
applied to each well and incubated at room temperature for 45 minutes with gentle rocking. 
Plates were then washed with excess 1% glacial acetic acid solution and once again placed in 
an oven to dry. Once dry, wells were incubated with 150 µl of 10 mM, pH 10.5, Tris buffer 
for 1 hour at room temperature with gentle rocking. Plates were then scanned using the Biohit 
BP800 Microplate Reader (filter: 540nm – as previously used for BCA protein 











Algorithm name: Confluence  
Algorithm type Texture 
Intensity threshold 10 
Saturated intensity 4 
Precision High 
Diameter (µm) 9 
Background correction Yes 
Minimum thickness (µm) 3 
Pre-filtering Minimum cluster size of 500 µm2 
 
Table 16: Algorithm settings for analysing cell confluence of cell lines. 
 
Solution Reagents/preparation 
25% Trichloroacetic acid (TCA) 
solution 
Dilute 100% stock TCA. Store at 4°C 
SRB staining solution  0.4% SRB in 1% acetic acid: dissolve 2 g 
of SRB in 1% acetic acid and make up to 
500 ml. Store at 4°C.  
1% glacial acetic acid Dilute 20 ml stock glacial acetic acid with 
distilled water up to a final volume of 2 l. 
Can be stored at room temperature. 
10mM Tris buffer (pH 10.5) Dissolve 1.21 g Tris base in water, adjust 
pH to 10.5 and make up to a final volume 
of 1 l. Store at 4°C. 
 
Table 17: Solutions used in SRB protocol.  
All solutions prepared at room temperature. 
In Excel resultant data was normalised. Both resultant and normalised data was copied into 
GraphPad prism to draw graphs. Student’s t-test was performed to determine statistically 
significant differences between Itch-targeted cells and control conditions. 
 
Separate graphs were generated to compare samples in the doxorubicin/gemcitabine regimens 
that had not received the chemotherapeutic but may have received Itch-targeting gene edits or 
scrambled control. Multiple one-way ANOVAs were used to assess for any statistically 
significant difference between these negative control conditions. 
 
Clonogenicity (clonogenic) assay: 
This was used as a measure of how well cells could form colonies after exposure to different 
modes of treatment and/or different forms of genetic modification. Cells were passaged and 
counted as described previously then seeded on either 6- or 24-well plates at 250/125 cells 
per well respectively. After 24 hours cells were exposed to drug treatment (either 
gemcitabine or doxorubicin, prepared as previously described) and incubated for 24 hours. 
Drug-containing media was then removed and replaced with fresh media which was changed 
every 3-4 days. In the case of radiation; cells were cultured in T25 flasks as previously 




treatment plates were scanned on Celigo using a colony identification algorithm (which 
identifies groups of cells, labelling them as a colony – Table 18).  
 
Algorithm name: Clonogenicity 
Algorithm type Texture 
Intensity threshold 4 
Saturated intensity 0 
Precision High 
Diameter (µm) 6 
Background correction Yes 
Separate touching objects Yes 
Minimum thickness (µm) 12 
Pre-filtering Minimum cluster size of 80,000 µm2 
 
Table 18: Algorithm settings for analysing clonogenicity of MiaPaCa-2 derived cell lines. 
 
Celigo data was exported as a CSV file which was then copied into GraphPad Prism to draw 
graphs. Statistically significant differences in clonogenicity between isogenic cell lines were 
determined via Student’s t-test.  
 




Lysate preparation for SWATH MS is different to that for western blot preparation. Cells 
were seeded in 10 cm2 dishes and were grown until roughly 70% confluence. Once confluent, 
dishes were either lysed immediately or were treated with 1 Gy d-radiation and left for 24 
hours before lysis. Plates were washed with ice cold PBS twice to remove all traces of media. 
PBS was aspirated and the dishes were placed at an angle to allow any excess PBS to drain 
off and be collected using a fine-tip Pasteur pipette. 700 µl of lysis solution (Table 19) was 
added to each of the dishes and cells were detached from the dish using a cell scraper. The 
cells were then left to lyse in solution for a couple of minutes. 
 
Reagent Supplier Final Concentration 
Ammonium bicarbonate 
(AmBic) 
Sigma 50 mM 
Urea Sigma 8 M 
SDC (sodium deoxycholate) Sigma 4% 
TCEP (tris(2-
carboxyethyl)phosphine) 
Sigma 5 mM 
 
Table 19: Lysis solution reagents and concentrations for SWATH. 
 
Lysate was then transferred to a 1.5 ml Eppendorf tube and stored at -80°C until required. A 




then allowed us to calculate the volumes required for subsequent reagents needed for 
SWATH sample preparation. 
 
We wanted to assess the proteomic differences between parental MiaPaCa-2 cells and 
CRISPR-treated Itch knockdown isogenic cell lines and whether treatment with radiation also 
resulted in difference in proteome. In the initial sample preparation the isogenic cell lines 
IKO1a, IKO2, and IKO3 were used as biological replicates for the CRISPR+ cells. Lysates 
were also made for samples that were treated 3 days prior with 1 Gy of gamma radiation. 
 
Tryptic digest: 
The volume for 60 µg of protein in each lysate was used for the peptide digest. Excess lysis 
solution was then added to equilibrate the total volumes between each sample. Iodoacetamide 
was added to a final concentration of 10 mM and incubated for 30 minutes in the dark to 
alkylate cysteine residues. DTT was then added, to quench the iodoacetamide, to a final 
concentration of 20 mM and incubated at room temperature for 10 minutes. The urea in the 
solution then had to be diluted to 1.5 M with AmBic to make it suitable for tryptic digest. 
1:50 MS-grade trypsin (Promega, Cat.No. V5280) was then added and incubated overnight at 
30°C.  
 
Subsequent aspects of the SWATH protocol were performed in the St Andrews Mass 
Spectrometry and Proteomics Facility. 
 
C18 salt clean-up: 
After isolating peptides, salts need to be removed from the solution before proceeding with 
mass-spec. However, before this the peptide solution needs to be acidified to remove any 
detergents: 100% trifluoroacetic acid (TFA) was added to each sample to a final 
concentration of 0.5%. Acetonitrile (ACN) was then added to each sample to a final 
concentration of 5%. Salt clean-up was done in Reverse Phase Chromatography Spin 
Columns (Harvard Apparatus, Cat.No.  74-7242) containing a C18 matrix for this protocol. 
Before addition of samples, the spin columns had to be washed and equilibrated as follows 
(all spin steps were done in an Eppendorf Mini Spin benchtop centrifuge): 
• 1´ wash with 200 µl 100% ACN. Spin at 0.5 rcf for 30s. 
• 2´ wash with 200 ul 50% ACN. Spin at 0.5 rcf for 30s. 
• 3´ equilibrate with 5% ACN, 0.5% TFA. spin at 0.5 rcf for 30s. 
The sample could then be loaded into the spin column: 
• 3´ load sample (divide total volume by 3 and roughly add that much to column for 
each spin), spin at 0.3 rcf for 30sec. 
• 5/6´ wash with 200 µl 5% ACN, 0.5%TFA. Spin at 0.3 rcf for 30s 
• 3´ elute with 30 µl 70% ACN, 0.5%TFA. Spin at 1.5 rcf for 30s. 
Once all the sample had been eluted each sample was placed in a speedvac to dry. 
 
Spectral library preparation and fractionation: 
A spectral library was prepared by making two pooled samples (containing equal amounts of 




exchange chromatography (SCX) was used to fractionate one of pooled samples to reduce the 
complexity of the peptide mixture before Data-Dependent Acquisition (DDA). Ten fractions 
were generated from this sample.  
 
DDA and Data-Independent Acquisition (DIA) runs: 
Both DDA and DIA/SWATH runs were performed on a TripleTOF 5600+ instrument (Sciex). 
Individual samples, pooled sample, and pooled fractions were loaded along with loading 
buffer and iRT peptides that were spiked into each sample to act as references after detection. 
Spectral library was generated by performing a DDA run of the pooled sample and SCX 
fractions. DIA runs were performed afterwards on the 24 individual test samples with 39 













399.5 419.2 0.5 19.7 
418.2 436.2 0.5 18 
435.2 450.7 0.5 15.5 
449.7 463.4 0.5 13.7 
462.4 476.2 0.5 13.8 
475.2 488.1 0.5 12.9 
487.1 500 0.5 12.9 
499 512.3 0.5 13.3 
511.3 524.6 0.5 13.3 
523.6 536.9 0.5 13.3 
535.9 548.8 0.5 12.9 
547.8 560.7 0.5 12.9 
559.7 572.6 0.5 12.9 
571.6 584.1 0.5 12.5 
583.1 595.6 0.5 12.5 
594.6 607 0.5 12.4 
606 618.9 0.5 12.9 
617.9 630.8 0.5 12.9 
629.8 642.7 0.5 12.9 
641.7 655.1 0.5 13.4 
654.1 667.8 0.5 13.7 
666.8 681 0.5 14.2 
680 694.6 0.5 14.6 
693.6 709.5 0.5 15.9 
708.5 724.3 0.5 15.8 
723.3 739.6 0.5 16.3 
738.6 754.9 0.5 16.3 
753.9 770.7 0.5 16.8 

















Table 20: Variable m/z windows (swaths) used for DIA runs performed on a TripleTOF5600+: 
Margin indicates the degree of overlap permitted between each window. 
 
Protein identification, quantification and data analysis: 
All subsequent operations were performed Skyline (MacCoss Lab Software) (Maclean et al., 
2010). Data from the TripleTOF5600+ was imported into Skyline prior to analysis. Protein 
identification in DIA runs was based on results found in the spectral library generated from 
the DDA runs. MS/MS data could then be interpreted to quantify peptide and protein level 
between individual/groups of samples using the MSstats R-plugin (Choi et al., 2014) or 
within the Skyline software and exported to Excel. Two different sets of analyses were 
performed on untreated cells: One comparing all CRISPR-containing (CRISPR+) cells with 
parental cells for two time points (0 and 3 days), and a second set of group comparisons 
comparing individual clones (IKO1a, IKO2, and IKO3) against parental cells. Differences in 
samples in terms of up- or down-regulation of proteins between the groups were displayed as 
pyramid plots that showed fold change against statistical significance. Fold change cut-off for 
up-/down-regulation of proteins was set to ±Log2(2) fold change and P-value cut-off was set 
to -Log10(1.33) indicated by dashed horizontal line on each graph. Proteins that exceeded the 






Tartrate-resistant acid phosphatase (TRAP) staining: 
TRAP staining of osteoclasts was performed using the Acid Phosphatase Leukocyte (TRAP) 
Kit (Sigma Aldrich, Cat.No. 387A). The protocol was adapted slightly to suit plates rather 
than microscope slides. A citrate/acetone fixing solution was prepared by diluting the 
concentrated citrate solution (2 ml concentrate in 18 ml deionised water – 10% solution) and 
then adding 30 ml of stock acetone. Wells were fixed with 50 µl of fixing solution for 30 
seconds at room temperature then washed with excess deionised water and left to air-dry. 
Staining solution was then prepared as described in Table 21. Reagents were added to a glass 
beaker with constant stirring with a magnetic stirrer. 
 
785.4 803.4 0.5 18 
802.4 821.7 0.5 19.3 
820.7 841.6 0.5 20.9 
840.6 864.2 0.5 23.6 
863.2 888.8 0.5 25.6 
887.8 915.6 0.5 27.8 
914.6 948.3 0.5 33.7 
947.3 990.8 0.5 43.5 
989.8 1,045.20 0.5 55.4 
1,044.20 1,118.70 0.5 74.5 







Reagent Volume (ml) 
Deionised water (pre-warmed to 37°C) 44 
Acetate solution 2 
Naphthol AS-BI Phosphoric Acid 2 
Tartrate Solution 2 
 
Table 21: reagents and volumes for preparation of the TRAP staining solution.  
 
The contents of a single GBC Fast Garnet Salt capsule was then added to the solution and 
stirred for a further 60s. The solution was then filtered into a separate beaker and then placed 
in a water bath at 37°C to warm up the staining solution. Once the solution had reached 37°C, 
100µl of staining solution was aliquoted onto each well using a multi-channel pipette, plates 
were then moved to an incubator set at 37°C and kept in the dark for 1-hour. Plates were then 
washed with excess deionised water for 3 minutes. Acid Haematoxylin solution was 
aliquoted onto each well (100 µl) and incubated at room temperature for 5 minutes. Plates 
were washed in excess deionised water for 3 minutes and left to air dry. TRAP+ cells were 
viewed under a brightfield microscope. Numbers of osteoclasts per well were quantified 
using cell-count algorithms adjusted for identification of TRAP+ cells and mature osteoclasts 
on Celigo (Table 22, 23, and 24). All data generated in Celigo was exported as CSV files. 
 
Algorithm name: Osteoclast Confluence  
Algorithm type Texture 
Intensity threshold 7 
Saturated intensity 0 
Precision Low 
Diameter (µm) 50 
Background correction Yes 
Minimum thickness (µm) 8 
Pre-filtering Minimum cluster size of 50 µm2 
 
Table 22: Algorithm settings for analysing cell confluence of osteoclasts in 96-well plates. 
 
Algorithm name: TRAP Staining  
Algorithm type Dark object 
Intensity threshold 5 
Precision High 
Cell Diameter (pixels) 80 
Background correction Yes 
Separate touching objects Yes 
 










Algorithm name: Mature OCs 
Algorithm type Dark object 
Intensity threshold 1 
Precision High 
Cell Diameter (pixels) 80 
Background correction Yes 
Separate touching objects No 
Pre-filtering  Area >2179 pixels2 
 
Table 24: Algorithm settings for assessing the number of mature osteoclasts in 96-well plates. 
 
Nuclear staining using Hoechst 33342 to identify multinucleate bodies: 
To complement the data produced from TRAP staining of osteoclasts, a nuclear stain was 
also performed. Each well of a 96-well plate containing TRAP-stained osteoclasts was 
incubated with 100 µl of 1:10,000 Hoechst solution (Life Technologies, Cat.No. H3570) in 
PBS for 10 minutes at room temperature, in the dark. The plate was removed from the dark 
and scanned on Celigo, looking at both brightfield and blue fluorescence channels. The blue 
and brightfield channels were combined and multinucleate bodies in each well were 
identified and counted manually. Numbers of multinucleate bodies per well and test 
conditions were recorded in a spreadsheet. 
 
Data for confluence, trap-staining, mature osteoclast formation, and nuclear staining 
determined through Celigo was copied into GraphPad Prism where graphs were created. 

























Chapter 3 – The Effects of Transient Itch Knockdown In 
Pancreatic Cell Lines Using siRNA: 
 
Pancreatic cancer, whilst having a relatively low incidence among other cancer types, is one 
of highest causes of cancer-related mortality in the world (Ilic & Ilic, 2016; McGuigan et al., 
2018; Vincent et al., 2011) with one of the lowest 5-year survival rates, of approximately 5%. 
This is mainly attributed to the fact that pancreatic cancer is clinically silent until the disease 
has reached an advanced stage. The only curative treatment of a solid pancreatic tumour is 
complete surgical resection. This may or may not be accompanied by adjuvant or neo-
adjuvant therapy in the form of radiotherapy or chemotherapy. However the effectiveness of 
these additional forms of treatment is widely debated, particularly with neo-adjuvant therapy: 
whilst it can help make previously non-resectable tumours resectable, neo-adjuvant therapy 
delays surgery which remains the only curative method of treatment (Gillen et al., 2010; Ilic 
& Ilic, 2016). Another issue with pancreatic cancer is that since the disease is usually already 
at an advanced stage at the time of diagnosis, complete surgical resection is not always 
possible and the incidence of recurrence is high as it is more likely that the disease has 
metastasised to secondary sites. Furthermore, since the 5-year survival rate is so low, one 
must also consider patient quality-of-life following a pancreatectomy and subsequent 
adjuvant therapy. Pancreatic cancer and pancreatic cell lines are notoriously resistant to 
standard chemotherapeutic and radiotherapeutic treatment regimens (de la Fuente et al., 2015; 
Deorukhkar et al., 2010; Krempien & Roeder., 2017) which is why alternative methods need 
to be considered to potentiate current therapies for pancreatic cancer.  
 
As mentioned, one area of study in terms of sensitising tumours to existing treatment is 
genetic manipulation and application of synthetic lethality. De la Fuente et al. found that 
knockdown of Itch using si/shRNA via a nanoparticle vector increased sensitivity of 
xenograft mice to a sub-therapeutic dose of gemcitabine after being transplanted with 
MiaPaCa-2 cells (a human pancreatic cell line) (de la Fuente et al., 2015). A later study also 
noted that Itch is upregulated in pancreatic cancer tissue biopsies compared to normal 
pancreatic tissue and correlates with increased cell metastatic potential of pancreatic cell lines 
(Luo et al., 2016). To explore the role of Itch in pancreatic cancer cell lines siRNA was used 
to induce a transient (i.e. short-term) knockdown of Itch in the pancreatic cell lines MiaPaCa-
2 and Capan-2. MiaPaCa-2 cells were used as they have been used with success in previous 
published studies, Capan-2s was also used as they are p53 wild-type (Deer et al., 2010). Itch 
specifically targets the p53 homologue p73 for degradation via the proteasome (Rossi et al., 
2005; Wu & Leng, 2015) which can facilitate cell-cycle arrest and apoptosis independent of 
p53 as it can transcriptionally activate many of the same genes (Clarke et al., 1997; Levrero 
et al., 2000; Annie Yang et al., 2002). However, whereas p53 is commonly mutated in 
cancer, p73 is not. In pancreatic cancer specifically, the gene mutation frequency of p53 is 
roughly 70% (Cicenas et al., 2017) This is one of the reasons why Itch has been a target of 
genetic manipulation, as a means to increase cellular p73 stability and thereby promote 
apoptosis in cancer tissue/cell lines (Bongiorno-Borbone et al., 2015; de la Fuente et al., 
2015; Levy et al., 2007; Rossi et al., 2014; Rossi et al., 2005). Since Capan-2 cells are p53 
wild-type, we hypothesise that Itch knockdown has a reduced effect in increasing sensitivity 
to therapeutics in this particular cell line compared to MiaPaCa-2s (since MiaPaCa-2s are p53 





siRNA is a form of RNA-interference (RNAi) that involves generation of an antisense RNA 
strand that is loaded onto the RNA-interfering silencing complex (RISC). RISC then cleaves 
the target mRNA thus downregulating gene expression as the mRNA can no longer be 
translated to protein (Rao et al., 2009; Robb & Rana, 2007). The siRNA can enter a cell 
either as completely processed siRNA (which can directly associate with RISC) or as long 
siRNA duplexes (double stranded RNA – dsRNA), which needs to first be processed by 
Dicer (an endonuclease that cleaves dsRNA to form siRNA) before it can be loaded onto 
RISC - as determined through Dicer-/- studies on mice (Murchison et al., 2005). Entry of 
siRNA into a cell requires overcoming the hurdle of the plasma membrane blocking 
unfacilitated siRNAs/dsRNAs from directly entering. This can be achieved through several 
methods, however in this project Lipofectamine RNAiMax was used. This product utilises 
lipofection, using lipids to gain passage through the plasma membrane via endocytosis 
(Felgner et al., 1987). These lipids are generally cationic (positively charged) so that they can 
more-easily form complexes with anionic (negatively charged) genetic material including 
siRNAs, dsRNAs and plasmids. siRNA/dsRNA technology provides a convenient tool that 
can be used to quickly assess the effect of knockdown of specific genes both in-vitro and in-
vivo. 
 
However, there is the potential for specific off-target activity where the siRNA/RISC 
complex associates and cleaves non-target mRNAs. Furthermore siRNA-mediated 
knockdown is transient meaning that the effect of the knockdown disappears over time as the 
material is used up, RNAs naturally degrade, or the knockdown effect gets diluted through 
cell division. Where a more long-lasting knockdown or knockout is desired, alternative gene-
editing techniques need to be employed. 
 
This series of experiments aims to test the hypothesis that silencing Itch activity in pancreatic 
cell-lines increases cell-line sensitivity to existing therapeutics including g-radiation, 
doxorubicin, and gemcitabine. The reason why these three methods of treatment were used is 
because each causes DNA damage via different mechanisms which may be important in 
assessing the relevance of p53 mutational status between the two cell lines being used. 
Although this investigation technically utilises dsRNA to generate siRNA intracellularly via 





Successful transient Itch knockdown in MiaPaCa-2 and Capan-2 cells: 
Ability of the siRNA to reduce Itch expression in pancreatic cell lines was assessed by both 
qPCR and western blot. MiaPaCa-2 and Capan-2 cells were transfected with Itch-targeting 
siRNA, using Lipofectamine RNAiMax as the transfection reagent, for 24 hours before 
lysates were taken. Untreated cells, in addition to cells treated with a scrambled siRNA 
duplex combined with Lipofectamine, were cultured to act as negative controls and confirm 
that any knockdown activity was solely due to the Itch-targeting duplex. Successful 
knockdown was determined by analysing the data produced from both western blot (protein 
level) and qPCR (mRNA level); comparing Itch expression in the test cells in relation to that 
of both negative controls. In MiaPaCa-2 cells we saw over 90% reduction in Itch protein 
expression compared to untreated cells (Figure 14: A. and B.). This result was also reflected 
in the qPCR results (Figure 14: C.) where there was a >80% knockdown at the mRNA level. 




that the level of Itch knockdown using the same concentration of siRNA that was used for 
MiaPaCa-2 cells (12.5nM) was not statistically, or biologically, significant when analysed by 
western blot. Increasing doses of siRNA were tested and analysed by western blot and qPCR 
(Figure 14: D., E., and F.). Significant Itch knockdown at the protein level was apparent with 
25 and 100 nM siRNA (Figure 14: D. & E., columns 4 & 6) with a ~30% reduction in Itch 
protein, however not for 50 nM (Figure 14: D. & E., column 5). This did not seem to be 
reflected in the qPCR results as although mean Itch mRNA expression dropped the difference 

































Figure 14: siRNA mediated knockdown of Itch in pancreatic cell lines: 
MiaPaCa-2 cells were cultured and subject to either 12.5nM of scrambled siRNA or Itch-targeting siRNA 
(Test) or were left untreated. After 24 hours media was removed and cells were lysed. Itch (green bands) 
knockdown by siRNA was confirmed by western blot using b-Actin (red bands) as a loading control (A.). 
Band fluorescence intensity was quantified and analysed in Image Studio (Licor) (B.). qPCR was also 






































































































































































































control was found to be statistically significant at both the protein level (p=0.0393) and mRNA level 
(p=0.0009).  Capan-2 cells were found to be more resistant to siRNA treatment and thus were subject to 
increasing concentrations of siRNA. Itch knockdown was first confirmed by Western blot (D. and E.). 
Statistically significant knockdown was identified with [siRNA] of 25nM (p=0.0342) and 100nM 
(p=0.034). 25nM concentration was then used for qPCR assessment (F.) however the difference in mRNA 
expression was not statistically significant. Statistical significance in each case was determined by 
Student’s T-test. 
An additional experiment was performed to assess the longevity of the silencing effect by 
siRNA. RNA lysates were taken every 24 hours over a 5-day time course reflective of the 
duration of the cell survival assays to be carried out. Analysis of relative Itch expression by 
qPCR revealed that even after 5-days post-transfection that there is a significant reduction of 
Itch mRNA (~80%) in MiaPaCa-2 cells compared to those treated with a scrambled control 
siRNA (Figure 15). 
 
 
Figure 15: siRNA Itch silencing activity persists over a 5-day time course: 
qPCR analysis of RNA lysates from MiaPaCa-2 cells treated with either si-Scr or si-Itch taken every 24 
hours post-transfection. Student’s t-tests detected significant difference at each time point; p = 3.87´10-3, 
2.02´10-4, 3.57´10-5, 8.14´10-7, and 1.9´10-4 for each time point respectively. No significant difference 
was observed when comparing the degree of Itch silencing at each time point. Data normalised to Itch 








































Transient Itch knockdown is sufficient for inhibiting cell growth in MiaPaCa-2 cells and 
is further potentiated by radio- and chemotherapy:  
After confirming that Itch had been knocked down by siRNA, cell survivability assays to test 
the hypothesis that silencing Itch increases the sensitivity of pancreatic cell lines to anti-
cancer therapeutics including g-radiation, doxorubicin and gemcitabine. siRNA solution and 
cells were aliquoted onto 96-well plates. siRNA-containing media was then removed after 24 
hours and replaced with drug-containing media for another 24 hours in regard to doxorubicin 
and gemcitabine treatment. In the case of treatment with g-radiation, cells were first irradiated 
and then transfected with siRNA. MiaPaCa-2 cells were then cultured over 4 days; every 24 
hours plates were subject to automated cytometry analysis (Celigo) to measure well 
confluence over time and a sulforhodamine B assay (SRB) was used at the end of the culture 
period to measure cytotoxicity/cell survival.  
 
For all treatment regimens in MiaPaCa-2 cells, treatment with siRNA (si-Itch) caused a 
significant decrease in cell viability as indicated by the resultant data for each treatment 
(Figure 15: A., B., and C., left graphs), including instances where no additional therapeutic 
was added Figure 15: E. & F.). Resultant cell viability was determined from the raw OD 
values obtained from the degree of SRB staining in each well. Resultant data for scrambled 
cells (si-Scr) was similar, if not almost identical, to levels seen for the untreated controls 
despite the presence of Lipofectamine in these samples. This shows that transient Itch 
knockdown alone is sufficient to inhibit cell growth and viability.  
 
To correct for the apparent inherent cytotoxicity caused by siRNA-mediated Itch knockdown, 
SRB data was normalised relative to vehicle control to determine if treatment regimen had 
any impact on the trend of cell viability as the dose is increased between si-Itch, scrambled, 
and untreated cells and if there is any increase in sensitivity in combination with siRNA. 
Upon treatment with g-radiation, doxorubicin, or gemcitabine cell viability decreases even 
further. Whilst the trend in relative response remained roughly the same for cells treated with 
doxorubicin (Figure 16: B., right graph), this was not the case for g-radiation- or gemcitabine-
treated cells. In the case of g-radiation, relative cell-viability dropped significantly upon 
reaching 2 Gy which contrasts with what is seen for untreated and scrambled controls (Figure 
16: A.). The largest difference was observed in gemcitabine-treated cells; In both the 
resultant and normalised data there is a significant drop in cell viability of si-Itch cells upon 
between 7.5-10 nM (Figure 16: C.). However, for either control there is no apparent decrease 
in cell-viability until between 25-50 nM. Analysis of the curve for the gemcitabine data 
reveals a shift in IC50 si-Itch cells which indicates an increase in sensitivity to gemcitabine 




















































Figure 16: Transient Itch knockdown inhibits cell survival which is further potentiated by anti-
cancer therapeutics as determined by SRB: 
Resultant (left) and normalised (right) SRB cell-survival curves for MiaPaCa-2 cells treated with siRNA in 
combination with additional treatment. A. Cells treated with 0-2 Gy g-radiation; in resultant data OD 
readouts for all doses of radiation were statistically significant compared to untreated controls (p = 
3.97´10-12, 6.25´10-13, 1.47´10-12, and 1.73´10-14 for 0, 0.5, 1, and 2 Gy respectively). Normalised cell 























































































* * * *




















































































100 nM doxorubicin (plotted as log10[doxorubicin]); resultant data showed significant difference for 1, 2.5, 
5, 10, and 25 nM doxorubicin (p = 1.73´10-6, 1.61´10-6, 1.44´10-5, 3.78´10-5, and 8.14´10-6 respectively). 
Normalised cell viability showed no significant difference between si-Itch and controls. C. Cells treated 
with 0-100 nM gemcitabine (plotted as log10[gemcitabine]); resultant data showed significant difference 
for all doses (p = 1.05´10-6, 8.07´10-6, 4.33´10-7, 6.37´10-3, 7.01´10-7, 3.54´10-6, 1.09´10-8, 6.94´10-9, 
and 2.93´10-6 for 1, 2.5, 5, 7.5, 10, 25, 50, 75, and 100 nM respectively). Normalised cell viability showed 
significant difference between si-Itch and untreated cells for 25, 50, 75 and 100 nM (p = 1.63´10-3, 
9.54´10-7, 1.73´10-7, and 3.78´10-4 respectively). Data was normalised to a vehicle control in the case for 
doxorubicin and gemcitabine. Radiation data was normalised to cells that did not receive radiation. An * 
donates statistically significant difference in mean as determined by Student’s t-test. D. & E. Viability of 
cells treated with just the vehicle control shows significant decrease in cell viability when just the si-Itch is 
present compared to both control conditions. Number of asterixis donates degree of statistical significance 
of a one-way ANOVA between conditions (** = p < 0.01, **** = p < 0.0001).  
Transient Itch knockdown inhibits Capan-2 cell survivability: 
When performing calibration plots to optimise the range of drug concentration to use, Capan-
2 cells were found to be more resistant to drug treatment compared to MiaPaCa-2 cells 
(Figure 17: A. & B.). Based on the results displayed in this figure a concentration range of 0-
30µM was used for the chemotherapy component of the cytotoxicity assays. 
 
Capan-2 siRNA transfection followed the same protocol as MiaPaCa-2 cells. Similar to the 
results seen in MiaPaCa-2 cells, siRNA-mediated Itch knockdown in Capan-2 cells was 
sufficient to decrease cell-viability (Figure 18: A., B., & C. left graphs, D. & E.). Once again, 
results for scrambled control appeared to be in agreement with the results of the untreated 
control providing further evidence that the engineered siRNA is solely responsible for the 
decrease in cell viability. A wider range dose of radiation was also used on the assumption 
that Capan-2 cells may be more resistant to irradiation, as was seen for doxorubicin and 
gemcitabine. However, for the siRNA experiments the effective inhibitory dose was low 
(1Gy), and further increase in dose failed to elicit further cytotoxicity (confirmed through 
biological repeats – Supplementary Figure 2). For both doxorubicin and gemcitabine, 
addition of chemotherapeutic agent only caused a slight additional decrease in resultant cell 
survivability, meaning that inhibition occurred over a smaller range of concentrations. 
Normalisation of results (Figure 18: A., B., & C. right graphs) revealed no increase in 






































Figure 17: Capan-2 cells are more resistant to doxorubicin/gemcitabine treatment:  
SRB dose-response curves of MiaPaCa-2 cells (left) and Capan-2 cells (right) treated with doxorubicin 
(A.) and gemcitabine (B.), used to calibrate an appropriate range of drug concentrations to use for future 
experiments. Compared to MiaPaCa-2 cells, where for both treatment regimens a curve could be 
established between 0-100nM, Capan-2 cells required higher doses and with a larger concentration range 
to elicit a suitable dose-response curve (1-10,000 nM). Based on these calibration curves, a concentration 
range of 0-30 µM was used for Capan-2 cells. Lowest plotted doses represent non-treated negative controls 


























Capan-2: doxorubicin dose-response curve












Capan-2: gemcitabine dose-response curve
A. 
B. 











MiaPaCa-2: doxorubicin dose-response curve






















































Figure 18: Transient Itch knockdown in Capan 2 cells inhibits cell growth and is potentiated by 
chemotherapy at lower doses: 
Resultant (left) and normalised (right) SRB cell-survival curves for Capan-2 cells treated with siRNA in 
combination with additional treatment. A. Cells treated with 0-6 Gy g-radiation; in resultant data OD 
readouts for si-Itch treated cells across all doses of radiation were statistically significant compared to 
untreated controls (p = 5.71´10-15, 4.17´10-115, 6.83´10-14, 8.97´10-13, 2.46´10-14, and 8.97´10-15 for 0, 
0.5, 1, 2, 4, and 6 Gy respectively). Normalised cell viability showed no statistically significant increase in 























































* * * * * *



















































































































sensitivity of si-Itch cells. B. Cells treated with 0-30,000 nM doxorubicin (plotted as log10[doxorubicin] 
(nM)); resultant data showed significant difference for 1, 5, 10, 50, and 100nM doxorubicin (p = 3.55´10-4, 
8.90´10-6, 5.41´10-7, 3.78´10-5, 1.16´10-4, and 1.56´10-5 respectively). Only statistically significant 
increase in sensitivity for normalised data was for 10 nM (p = 4.14´10-3. C. Cells treated with 0-30,000 
nM gemcitabine (plotted as log10[gemcitabine](nM)); resultant data showed significant difference for si-
Itch cells for dose range 1-1000 nM gemcitabine (p = 1.02´10-7, 1.24´10-6, 2.74´10-5, 7.44´10-6, 9.29´10-
4, 2.26´10-3, 4.08´10-4, and 2.25´10-3 for each dose respectively). Normalised cell viability showed no 
significant increase in sensitivity upon being treated with siRNA. Data was normalised to a vehicle control 
in the case for doxorubicin and gemcitabine. Radiation data was normalised to cells that did not receive 
radiation. An * donates statistically significant difference in mean as determined by Student’s t-test. D. & 
E. Viability of cells treated with just the vehicle control shows significant decrease in cell viability when 
just the si-Itch is present compared to both control conditions. Number of asterixis donates degree of 
statistical significance of a one-way ANOVA between conditions (** = p < 0.01, *** = p < 0.001, **** = 
p < 0.0001). 
 
Discussion: 
siRNA-mediated transient Itch knockdown in pancreatic cell lines: 
Itch knockdown was achieved in pancreatic cell lines through lipofection of dsRNA. 
Significant knockdown was seen in MiaPaCa-2 cells using 12.5nM of siRNA, with ~80% 
reduction in Itch mRNA and ~90% reduction in protein (Figure 14: A., B., and C.). Although 
the degree of knockdown seen in Capan-2 cells was not as significant as was seen with 
MiaPaCa-2 cells, there was still a 30% reduction in Itch protein seen when using 25nM 
siRNA (Figure 14: D., E., and F.), which was viewed as biologically relevant enough for 
downstream assays. There was almost no difference seen when increasing the concentration 
of siRNA to 100 nM in Capan-2 cells: any further increase would have increased the number 
of cytotoxicity assays without adding to discriminatory value of results. During the project it 
had been noted that Capan-2 cells tended to be more resistant to multiple modes of treatment 
in regard to toxicity compared to MiaPaCa-2 cells, so it may be that Capan-2 cells are also 
more refractory to genetic knockdown by lipofection of si/dsRNA as well. Longevity of 
siRNA silencing activity was also confirmed in MiaPaCa-2 cells which showed an 80% 
reduction in Itch mRNA even at 120 hours post-transfection (Figure 15). 
 
Transient Itch knockdown inhibits survivability of pancreatic cell lines: 
For both pancreatic cell lines used there was a significant decrease in resultant cell 
survivability of si-Itch treated cells (as indicated by SRB OD readout) meanwhile levels for 
scrambled and untreated controls mostly mirrored each other. This indicates that the presence 
of the Itch-targeting siRNA duplex is sufficient for causing increased cell death in both cell 
lines regardless of further experimental parameters (i.e. addition of cancer therapeutic), 
highlighted in Figures 16/17: E. & F. where the only experimental parameter was siRNA 
transfection. In most cases, additional treatment with radiation or chemotherapeutic drug 
caused cell survivability to decrease further however this effect was mirrored in both 





Only in a select few cases did the application of si-Itch significantly increases the sensitivity 
of cells to either g-radiation, doxorubicin, or gemcitabine as shown by the relative 
(normalised) response. The only instances for MiaPaCa-2 cells where there was an increase 
in sensitivity compared to control samples was with 2 Gy d-radiation (Figure 16: A.) and 
low-dose gemcitabine (7.5-10 nM – Figure 16: B.). Capan-2 cells showed no clinically 
significant difference in relative response for all three modes of treatment when combined 
with si-Itch. In terms of whether or not the data presented accepts or rejects the hypothesis of 
Itch knockdown sensitising cell lines to treatment is difficult to clarify completely. The 
differences between the resultant and normalised data for each treatment regimen suggest that 
decrease in cell viability from Itch silencing is independent from any subsequent anti-cancer 
therapy. Whilst one could say that in the strictest sense the data rejects the hypothesis as a 
lack of change in relative response (and the pattern of growth) to treatment after siRNA 
application indicates no change in the sensitivity of both MiaPaCa-2 and Capan-2 cells.  
 
On the other hand, the fact that transfection of Itch-inhibiting siRNA causes such a large 
decrease in cell survivability could be interpreted to mean that cells have been made more 
sensitive to cell death in general. The resultant SRB data shows a significant baseline shift in 
survivability which indicates a shift in cell-fate decisions that favours death as opposed to 
survival and that any additional treatment has an additive, rather than multiplicative effect. 
From the experiments performed and the data generated, it would be difficult to classify Itch 
as an oncogene as nothing was done to assess the metastatic ability of the cells post Itch 
knockdown (for example a wound healing assay). However, the evidence shown does present 
a strong case that Itch is a potent mediator of cell survival. It would be interesting to assess 
whether or not a similar phenomenon would be seen in healthy tissue cultured in-vitro after 
loss of Itch function.  
 
Another interesting point is that, as the decrease in survivability is seen in both cell lines, the 
effect caused by si-Itch is observed regardless of p53 mutational status. This indicates that the 
response of cells to transient Itch knockdown is not solely due to potential p73 compensation 
as previous literature would suggest. Furthermore, these results demonstrate that Itch has a 
more global effect on transcriptome and proteome when it comes to regulating cell fate 
decisions and managing cytotoxicity, as we would expect from the numerous Itch substrates 
described previously (Figure 7).  
 
Transient nature of siRNA and its use in-vitro: 
A potential weakness identified was that since siRNA was only applied once at the beginning 
of the experiment, the knockdown may have only been present at the start and that Itch levels 
may have recovered over the course time due to the transient nature of siRNA (Järve et al., 
2007; Rao et al., 2009). One of the concerns with the experimental design was uncertainty 
about the longevity of the siRNA-mediated knockdown. Previous literature has described that 
the approximate half-life of siRNAs is about 48 hours as indicated by fluorescent tagging 
RNAs (Järve et al., 2007; Rao et al., 2009). It may be that knockdown of Itch at the beginning 
inhibits cell growth/induces apoptosis in cells that take up the siRNA but once the resultant 
material (siRNA & lipofectamine) is depleted, the cells recover and continue to grow as per 
normal regardless of the addition of a therapeutic agent. This could explain why resultant 
survivability of cells exposed to si-Itch is so low, yet the trend seen in response to treatment 
and the normalised data is similar to the two control conditions. On the other hand, other 




dependent on the cell doubling time rather than the half-life of siRNA in-vivo and in-vitro 
with the silencing effect in fast-dividing  cells being roughly 5-7 days (Novina et al., 2002; 
Tuschl, 2002) and potentially persisting for at least 3 weeks in quiescent cells (Omi, 
Tokunaga, & Hohjoh, 2004; Song et al., 2003). A kinetics-based study by Bartlett and Davis 
looked at several variables regarding siRNA-mediated silencing activity including siRNA 
concentration, cell doubling time, number of doses of siRNA, and siRNA half-life (Bartlett & 
Davis, 2006). They found that the most significant variable to be cell doubling time, the 
rationale being that the silencing effect gets diluted as cells divide. Despite this they observed 
that even in fast-dividing cells (doubling time 0.8 days) that luciferase activity (which was 
stably expressed in each cell line and the target of the knockdown) was restored back to 
control levels after roughly 7 days. MiaPaCa-2 cells have a doubling time of approximately 
40 hours/~1.7 days according ATCC (http://www.lgcstandards-atcc.org/products/all/CRL-
1420.aspx?geo_country=gb#characteristics) however confluence based growth curves from 
Celigo seem to indicate that MiaPaCa-2 doubling time is actually closer to 27 hours 
(Supplementary Figure 3). In the aforementioned study in cell line with a doubling time of 
1.6 days, luciferase was not restored to control levels until roughly 10 days post-transfection. 
However, at the 5-day mark (endpoint for cell survivability assays in this project) luciferase 
activity had been restored to about 50% of control levels indicating a degree of loss of 
silencing activity.  
 
This was addressed by measuring the silencing effect of siRNA over the same timeframe as 
the cytotoxicity assays (Figure 15) and confirmed that the silencing effect persists in 
MiaPaCa-2 cells (the fastest dividing cell line of the two used) even after 5 days. 
Furthermore, cell-survivability experiments were repeated in MiaPaCa-2 cells for all three 
treatment regimens with supplementary doses of siRNA spaced 48 hours between each 
application. The preliminary data obtained indicates that there is little to no difference in 
response to supplementary si-Itch application when compared to single-dose application data 
across all three modes of treatment (Supplementary Figure 4: A. & C.). There was a slight 
decrease in cell viability of si-Scr treated cells of the doxorubicin and radiation treatment 
regimens (however, this was not seen in gemcitabine-treated cells and the effect in irradiated 
cells was only apparent at low-doses of radiation and to a very minor degree. Combined with 
the fact that the relative response to treatment appeared to remain unchanged from that seen 
in the data for single application of siRNA makes it more likely that this phenomenon is 
likely attributed to toxicity induced by repeated lipofection (Barreau, Dutertre, Paillard, & 
Osborne, 2006) as opposed to potential off-target activity of the scrambled siRNA.  
 
Alongside the RNA lysates, protein lysates could have also been taken to provide further 
validation of the silencing effect of siRNA over the 5-day time-course. Another experiment 
that could be performed could be to assess Impact of si-Itch on cell-line specific doubling 
time through use of Celigo. Change in the growth-rate can be extrapolated from well 
confluence data over a specific time-course after application of siRNA (with both scrambled 
and untreated controls within the same 96-well plate for comparison). 
 
Addressing potential Off-target activity of siRNA: 
Although there is strong evidence based on the western blot and qPCR data that there is 
indeed a significant siRNA-mediated knockdown of Itch in both cell lines (Figure 14: A., B., 
D., and E.), it would be naïve to ignore the possibility of the siRNA having potential off-
target activity. off-target activity is defined as unintended changes to genome expression 
caused by RNAi (Rao et al., 2009). This can be broken down into specific off-target activity, 




activity, where the RNAi process causes cytotoxicity or generates an immune response in the 
case of in-vivo studies. In context of these particular experiments in general cytotoxicity due 
to lipofection can likely be ruled-out as there was little difference in resultant and normalised 
cell viability between si-Scr and untreated cells in almost all cases where there was single 
application of siRNA. It is however possible that si-Itch could have specific off-target 
activity with gene transcripts other than Itch. This may be especially the case for Capan-2 
cells where the degree of Itch knockdown was minimal even at higher concentrations of 
siRNA duplex (Figure 14: D., E., & F.). Despite the minimal changes in levels of Itch 
expression the effect of si-Itch on cell viability was significantly large (Figure 18). With the 
technology available in our lab it would be difficult to determine whether there was a 
significant degree of specific off-target activity without outsourcing and utilisation of a high-
throughput RNA screening method such as RNA-seq (Chu & Corey, 2012; Nagalakshmi et 
al., 2008). Performing a BLAST search on the forward and reverse strands of the siRNA 
duplex reveals candidate mRNAs from genes that may be affected (although none of them 
had 100% sequence alignments as the returned Itch transcripts did). Determination of protein 
and mRNA levels for these additional genes following si-Itch transfection could be 
considered as further work to confirm whether or not they are also affected by the 
knockdown. If any results were deemed significant then the function of said genes and the 






























Chapter 4 – Stable Knockdown of Itch In Pancreatic Cell 
Lines Using CRISPR-Cas9: 
 
CRISPR gene editing allows irreversible ablation of a gene of interest through sgRNA-
guided Cas9 endonuclease activity. After observing that transient Itch knockdown inhibits 
cell survival and has potential synergism in MiaPaCa-2 cells with radiation and gemcitabine, 





Western blot was used to confirm reduction in Itch protein levels for multiple lentiviral 
constructs in both cell lines (3 for MiaPaCa-2 cells and 2 for Capan-2 cells) before 
proceeding with cellular cytotoxicity assays. Level of Itch protein was normalised to b-Actin 
levels and expression was quantified relative to parental untreated cells: in MiaPaCa-2 cells 
the degree of knockdown seen ranged from 85-95% for all three isogenic cell lines (IKO1a, 
IKO2, and IKO3 – Figure 19: A.). In Capan-2 isogenic cell lines IKO1a and IKO2 showed 
95% and 75% reduction in Itch protein respectively (Figure 19: C.).  
Protein expression of Cas9 was also measured as additional confirmation that the plasmid had 
been successfully incorporated into the cell lines. Both MiaPaCa-2 and Capan-2 cells were 
found to have significantly increased Cas9 in samples treated with Itch-targeting constructs 
compared to parental cells (Figure 19: B. & D.) as was expected since Cas-9 is not 
endogenously expressed in eukaryotic cells. There was no significant difference in expression 
of Cas9 between scrambled and parental controls identified by western blot. This was 
contrary to what was anticipated as one would expect the scrambled-treated cells to still 
express Cas-9 as they were transduced with the same lentiviral construct, albeit with non-
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Figure 19: Successful CRISPR-Cas9 mediated knockdown of Itch in pancreatic cell lines:  
Western blot performed showing the expression of Itch (A.) and Cas9 (B.) in MiaPaCa-2 cells and the 
same in Capan-2 cells (C. and D.) using b-Actin as a loading control. Reduced expression of Itch was 
observed in all cases where pLentiCRISPRv2 which was accompanied by an inverse expression of Cas9 in 
the respective cell lines.  qPCR was also performed for both cell lines (E. and F.) to evaluate mRNA 
expression (using GAPDH as a housekeeping gene). Largest degree of knockdown was seen for construct 
IKO1a (note: IKO1b is a biological replicate of IO1a). IKO2 and IKO3 had smaller degree of knockdown 
(Supplementary Figure 5). Difference in mean protein and mRNA level between parental and each 
individual CRISPR construct was determined by unpaired Student’s t-test (number of asterixis dictates the 
degree of statistical significance; * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p <0.0001). 
qPCR was used to quantify mRNA levels of Itch as an alternative means of extracting Itch 
expression in isogenic pancreatic cell lines. The largest reduction in Itch mRNA was only 
seen in samples IKO1a and 1b (Figure 19: E. and F.) with a >90% knockdown observed in 
MiaPaCa-2 cells and 60-70% in Capan-2 cells. Meanwhile for constructs IKO2 and IKO3 
mRNA knockdown ranged from 20-40% (Supplementary Figure 5). Although this is not in 
agreement with the protein data, this may be due to weakness in primer design not being 
specific for each pLentiCRISPRv2 construct.  
 
CRISPR-mediated Itch knockdown increases MiaPaCa-2 cell line sensitivity to low-dose 
radiation and doxorubicin: 
Cell survivability in response to CRISPR-mediated Itch knockdown in combination with 
either g-radiation, doxorubicin, or gemcitabine was quantified using SRB. The same 
experimental parameters used for the transient knockdown series of experiments were used to 
provide a means of comparing the two gene editing techniques. To correct for any inherent 
growth impairment caused by lentiviral infection of MiaPaCa-2 cells, OD values were plotted 
as resultant data and normalised data when generating SRB curves. 
 
Post-normalisation IKO1a MiaPaCa-2 cells were shown to be more responsive to low-doses 
of both g-radiation (0.5-1 Gy) and doxorubicin (5-10 nM) (Figure 20: B. & D.) in addition to 
higher doses of gemcitabine (50 & 100 nM, Figure 20: F.) as indicated by decrease in 
normalised OD values compared to scrambled and parental controls. Resultant OD values for 
g-irradiated cells was also found to be lower in IKO1a cells compared to parental cells at 0.5 
and 1 Gy (Figure 20: A.). Fitting an IC50 curve to the normalised data also revealed an 
increase in sensitivity of IKO1a cells to each mode of treatment compared to parental and 



















































Figure 20: Effect of CRISPR-mediated stable Itch knockdown on MiaPaCa-2 cell sensitivity to 
therapeutics:  
Resultant (left) and normalised (right) SRB cell-survival curves for parental (blue), scrambled (red), and 
IKO1a (green) MiaPaCa-2 cells in 96-well plates. A. Cells treated with 0-6 Gy g-radiation; in resultant 
data OD readouts for low doses of radiation (0.5 and 1 Gy) were significantly lower compared to parental 
cells (p = 8.44´10-7, and 4.59´10-15 respectively). Normalised cell viability showed only a significant 
increase in response for 2 Gy (p = 2.05´10-8 ). B. Cells treated with 0-100 nM doxorubicin (plotted as 
log10[doxorubicin](nM)); IKO1a cells had higher OD readouts in resultant data compared to both 








































































































































































scrambled and parental controls. Normalised cell viability showed significant increase in sensitivity of 
IKO1a cells to doxorubicin at doses 5, 7.5 and 10 nM (6.99´10-3, 3.07´10-4, and 5.46´10-3 respectively). 
C. Cells treated with 0-100 nM gemcitabine (plotted as log10[gemcitabine](nM)); resultant data once again 
showed that IKO1a cells had greater OD readouts indicating greater numbers of cells. Normalised cell 
viability showed IKO1a had greater sensitivity to gemcitabine at doses 50 and 100nM (p = 3.50´10-4, and 
7.18´10-5, 1.73´10-7 respectively). Data was normalised to a vehicle control in the case for doxorubicin 
and gemcitabine. Radiation data was normalised to cells that did not receive radiation. An * donates 
statistically significant difference in mean as determined by Student’s t-test. D. & E. Viability of isogenic 
cell lines treated with just vehicle control provides further evidence of IKO1a clone being more clonogenic 
compared to the parental cells as resultant mean OD readout is higher. 
 Parental Scrambled IKO1a 
Radiation (Gy) 2.608 3.811 2.345 
Doxorubicin (nM) 12.04 15.06 10.40 
Gemcitabine (nM) 65.99 119.8 48.54 
 
Table 25: Summary of IC50s for isogenic cell lines: 
Calculated IC50s for each isogenic cell line (colour coded to match previous figure) based on the data in 
Figure 20. Calibration curves and IC50s determined in GraphPad Prism. 
 
Stable Itch knockdown in MiaPaCa-2 cells increases cell-line clonogenicity: 
In almost all experiments involving MiaPaCa-2 cells it was noted that IKO1a cells appeared 
to grow faster than either control condition (through visual observation during the 
cytotoxicity experiments). Resultant OD values from the cytotoxicity assays in the 
doxorubicin and gemcitabine experiments provided evidence that this might be the case in the 
instances where there was little no drug (Figure 20: C., E., G., & H.). To confirm that the 
knockdown of Itch by CRISPR caused the cells to become more clonogenic a series of 
clonogenicity assays were performed. An algorithm was designed in Celigo to select for 





























































Figure 21: Clonogenicity of MiaPaCa-2 isogenic cell lines:  
A. Sample wells of untreated cells with identified colonies in green (images from doxorubicin experiment). 
Clonogenicity of Parental (blue), Scrambled (red), and IKO1a (green) cells with or without treatment. B. 
Cells were irradiated at either 0, 1 or 4Gy before being distributed at a low cell density on a 6-well plate 
(250 cells/well). C. & D. cells were passaged onto 24-plates (125 cells/well) and were treated with either 


















































































media after 24 hours. Number of colonies was determined using a colony count algorithm on Celigo after 
1-week incubation post-treatment.  
 
In the absence of any therapeutic agent IKO1a cells showed a greater ability to form colonies 
after being passaged at low cell density (Figure 21: B., C., & D.) indicating that they are 
more clonogenic. However, from the data presented and subsequent biological replicates 
(Supplementary Figure 6) it was difficult to interpret the degree of response of each group of 
cells to specific treatment regimens. Treatment with 1 Gy of radiation or 10 nM doxorubicin 
caused the number of colonies formed for IKO1a cells to decrease to levels seen for the two 
control conditions. This increase in relative response mirrors what was seen for the same 
doses in the cell survivability assays (Figure 20: B. & D.). However there were instances in 
the biological replicates where this was not the case (Supplementary Figure 6) but a major 
weakness in the clonogenicity experiments was reliance on Celigo alone to count colonies 
which can be erroneous when used to examine plates with larger well sizes as resolution 
begins to decrease as it scans the periphery of large wells (since it takes individual pictures of 
different parts of the well then stitches them together).  
 
CRISPR-mediated knockdown of Itch in Capan-2 sensitises cells to gemcitabine: 
Capan-2 cells transduced with CRISPR-Cas9 were also assessed for their response to 
treatment with radio-/chemotherapy after stable Itch knockdown. Similar to what was seen 
with IKO1a MiaPaCa-2 cells, cells appeared more clonogenic as indicated by the increase in 
resultant OD of untreated cells (Figure 22: G. & H.). Normalisation of the SRB data showed 
that IKO1a cells are more sensitive to doxorubicin and gemcitabine (Figure 21: D. & F.) with 
a decrease in IC50 for doxorubicin specifically (IC50 = 159.8, 114.5, 104.7 nM for parental, 
scrambled and IKO1a cells respectively). Although there appears to be a shift in IC50 in the 


































































Figure 22: Effect of stable Itch knockdown on Capan-2 response to radio-/chemotherapy:  
Resultant (left) and normalised (right) SRB cell-survival curves for parental (blue), scrambled (red), and 
IKO1a (green) Capan-2 cells in 96-well plates. A. resultant and normalised data show no difference in 
response/sensitivity of IKO1a isogenic Capan-2 cells to radiation compared to untreated and scrambled 
cells. B. Cells treated with 0-10,000 nM doxorubicin (plotted as log10[doxorubicin] (nM)); IKO1a cells had 
comparable OD readouts to parental cells in the resultant data however both exceeded those of scrambled 
cells. Normalised cell viability showed significant increase in sensitivity of IKO1a cells to doxorubicin at 









































































































































































doses 50, 75, 100, 150, and 200 nM (8.34´10-5, 3.24´10-4, 1.22´10-4, 1.03´10-5 and 1.91´10-4 
respectively). C. Cells treated with 0-10,000 nM gemcitabine (plotted as log10[gemcitabine](nM)); 
resultant data showed no difference in OD readout between isogenic cell lines except at the lowest dose. 
Normalised cell viability showed IKO1a had greater sensitivity to gemcitabine for all doses above and 
including 10 nM (p = 3.02´10-6, and 2.67´10-5, 6.15´10-5, 9.53´10-8, 1.51´10-4, 5.37´10-7, 2.02´10-4, and 
4.20´10-5 respectively). Data was normalised to a vehicle control in the case for doxorubicin and 
gemcitabine. Radiation data was normalised to cells that did not receive radiation. An * donates 
statistically significant difference in mean as determined by Student’s t-test. D. & E. Viability of isogenic 
cell lines treated with just vehicle control provides further evidence of IKO1a clone being more clonogenic 
compared to the parental cells as resultant mean OD readout is higher. 
 
Screening MiaPaCa-2 isogenic cell lines using SWATH to identify candidate proteins 
and pathways affected by CRISPR-Cas9: 
Sequential windowed acquisition of all theoretical mass spectra (SWATH) or data-
independent acquisition (DIA) is a mass-spec technique that allows for almost complete 
characterisation and quantification of proteomic expression within multiple samples (Gillet et 
al., 2012; Huang et al., 2015). In contrast to data-dependent acquisition (DDA), which only 
selects the most abundant fragment ions (precursors) within each cycle if a sample is too 
complex (has too many precursors), DIA records all fragment ions within a particular m/z 
(mass/charge ratio) window (typically 25 Da) with several windows stacked to cover a very 
large mass range each cycle (mass range typically 400-1200 m/z) (Gillet et al., 2012; 
Vowinckel et al., 2013). DIA then relies on a spectral library consisting of previously defined 
precursors and proteins identified by past DDA runs to identify and quantify proteins within a 
sample or across multiple samples (Han et al., 2008; Lam et al., 2007).  
 
To determine any potential changes in MiaPaCa-2 proteome expression due to CRISPR 
treatment, SWATH-MS was performed on parental, IKO1a, IKO2 and IKO3 cells. In this 
context SWATH was used to screen for potential protein or pathway candidates that have 
been up-/downregulated by CRISPR-Cas9 activity. Samples consisted of protein lysates from 
parental and CRISPR+ cells which were either irradiated or left untreated. A spectral library 
was created from DDA runs performed on the same TripleTOF5600+ machine. Data 
extracted from the DIA runs was processed and analysed using Skyline and MsStats (Choi et 
al., 2014; Maclean et al., 2010) where samples were categorised based on both whether or not 



































Figure 23: Initial SWATH fold-change analysis of isogenic cell lines:  
Pyramid plots displaying log fold-change vs p-value to summarise data analysis of SWATH DIA runs. 
Samples were grouped based on whether they were CRISPR+ (includes IKO1a, IKO2, and IKO3) or 
parental. A. includes data from all cells that did not receive 1Gy radiation whilst B. is from untreated 
samples from a day 3 time point. Grey dots indicate proteins with non-significant changes in expression. 
Proteins that would be overexpressed in CRISPR+ samples would show up as red dots (positive log fold-
change) whilst those that would be under expressed would show up as blue dots (negative log-fold 
change). Statistical analysis of DIA data was performed in Skyline with the MsStats R-plugin. Fold change 
cutoff for up-/down-regulation was set to ±Log2(2) fold change and P-value cutoff was set to -Log10(1.33) 
(indicated by dashed horizontal line on each graph). 
Despite the comprehensiveness of the library and the DIA data, there was no statistically 
significant up- or downregulation of proteins between parental and CRISPR+ cells in both test 
groups as determined by log fold change vs p-value significance (Figure 23: A. & B.). This 
would appear to reject the hypothesis of altered expression based on the results seen from the 
resultant cell survivability of IKO1a cells and clonogenic assays which indicated a change in 
gene expression due to Itch loss resulting in increased survival capabilities even in the 
absence of treatment and differing responses to low-dose treatment regimens compared to 
scrambled and parental controls. However, upon re-evaluating the experimental approach and 
revisiting the SWATH data it was likely that the CRISPR+ group was too complex and 
contained too much variance as it was a culmination of IKO1a, IKO2, and IKO3 clones. A 
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clones against parental cells (Figure 24: A., B., & C.). Re-analysis of the data revealed 
candidate proteins that were up- or down-regulated in CRISPR+ clones compared to parental 
cells. IKO1a cells were found to have increase fold-change of MBLC1 (metallo-beta lactase 
domain containing protein 1) and reduced fold-change of IFRD2 (interferon related 
developmental regulator 2, Figure 24: A.). Whilst IKO2 cells did not seem to have appear to 
have any statistically significant difference in protein fold-change it was interesting to note 
that NEK3 (NIMA-related kinase 3) could be up-regulated which was the case in IKO3 cells 
(Figure 24: B. & C.) IKO3 cells also showed downregulation of TWF1 (twinfillin actin 
binding protein 1) and DHRS4 (dehydrogenase/reductase 4). Despite these hits, there is not a 
sufficient number of changes in proteome within groups to perform any form of pathway 
analysis. This is likely due to the fact that for the secondary analyses there were a lack of 
replicates to measure and increase the statistical power of the analysis of each individual 
clone. It is likely that if the experiment was performed again, focusing on individual clones 
and with more replicates, that more diverse changes in proteome would become apparent, 





















































































































































































Figure 24: Secondary SWATH fold-change analysis of isogenic cell lines reveals potential 
candidates:  
Pyramid plot displaying secondary analysis of SWATH DIA data where the results from individual 
isogenic cell lines were compared against those of parental cells (plotted as Isogenic cell line vs parental 
cell line). Dots on the graph represent proteins: blue dots represent proteins that are under-expressed 
compared to parental cells and red dots represent proteins that are over-expressed. A. IKO1a cells showed 
over-expression of MBLC1 (metallo-beta lactamase domain containing protein 1) and under-expression of 
IFRD2 (interferon related developmental regulator 2). B. Although the analysis suggests that there was no 
statistically significant difference in protein fold change between IKO2 and parental cells, NEK3 (NIMA-
related kinase 3) is highlighted in green as it reoccurs as being upregulated in IKO3 cells and is therefore 
of particular interest. C. IKO3 cells showed upregulation of NEK3 and downregulation of TWF1 
(twinfillin actin binding protein 1) and DHRS4 (dehydrogenase/reductase 4) compared to parental cells. 
DIA data group analysis was performed within the Skyline software. Fold change cutoff for up-/down-
regulation was set to ±Log2(2) fold change (indicated by vertical lines on each graph) and P-value cutoff 




Itch-targeting crRNAs were cloned into a lentiviral plasmid vector for transduction, alongside 
a scrambled control, into both MiaPaCa-2 and Capan-2 cell lines. Significant Itch knockdown 
in CRISPR+ isogenic cell lines was confirmed by western blot. To determine whether or not 
these Itch-deficient isogenic cell lines would be more sensitive to radiation, doxorubicin 
and/or gemcitabine, cell survival assays were performed using the same protocol and dose-
parameters as was used in the transient Itch knockdown experiments. In MiaPaCa-2 derived 
cell lines, CRISPR-mediated Itch knockdown caused an increase in relative response to low 
doses of radiation and doxorubicin (0.5-1 Gy and 5-10 nM respectively). However, from both 
the resultant data of the cell survivability assays and the clonogenicity assays IKO1a cells 
were observed to form greater cell numbers within 96-well plates and form more colonies 
than parental and scrambled cells (indicating that they may divide faster or more frequently). 
Meanwhile in Capan-2 cell lines, IKO1a appeared to have an increased relative response to 
gemcitabine doses ranging from 0.01-1 µM which was contrary to MiaPaCa-2’s which 
showed no change in response. From the 5-day time frame and the resultant data for Capan-2 
dose-response curves, it is tenuous to suggest that stable Itch knockdown causes Capan-2 
cells to be more clonogenic as with MiaPaCa-2 cells (resultant difference in OD of untreated 
wells was small or non-existent). Furthermore, during culture and experiments it was noted 
that Capan-2 cells had a much longer doubling time meaning any experiments performed to 
assess Capan-2 clonogenicity would require a considerable timeframe before any conclusive 
results could be drawn. 
 
We hypothesised that stable Itch knockdown causes cells to adapt to Itch loss of function that 
may confer a survival advantage. As an attempt to clarify any potential difference in 
proteome between parental and CRISPR+ cell lines, SWATH-MS was performed to 




revealed no significant differences in protein fold change, comparison of each of the 
CRISPR+ clones against parental cells revealed a few differences in basal protein levels. 
Unfortunately, these secondary analyses lacked significant statistical power due to lack of 
replicates for each of the individual clones. It is likely that there are more differences in 
proteome caused by loss of Itch that could be revealed if the experiment was repeated. 
 
For both cell lines the construct IKO2 showed the smallest degree of Itch knockdown: one 
could theorise that this could be due to the sgRNA sequence having lower efficacy in terms 
of Itch knockdown however, this was not pursued as the reduction in Itch expression was still 
significantly large (85/75% reduction in Itch protein for MiaPaCa-2 and Capan-2 cells 
respectively). Another possible explanation is that the sgRNA sequence for IKO2 had more 
off-target or mismatch activity in the host genome. 
 
The reason why the term “knockdown” is used over the term “knockout” is due to the fact 
that there is still a small amount of Itch expression. Most studies that employ CRISPR-Cas9 
rely on clonal expansion of genetically identical cells that incorporate the desired gene-edit, 
usually confirmed by deep sequencing. This results in a population of clones that can then be 
considered “knockouts.” Meanwhile in this investigation the cells have not been tampered 
with after puromycin selection: this results in a population of cells that are not necessarily 
clones of each other. This is more representative of an environment in-vivo where gene-edits 
are introduced into an already living organism rather than generated at conception through 
crossbreeding of parents with specific genotypes. Furthermore the nature of how CRISPR-
Cas9 works in regards to generating indels means that the edit created in one cell is unlikely 
to be the same as that in another due to different indel lengths, whether the balance leans 
towards insertions or deletions during there generation, or if the DNA repair mechanism used 
was different (i.e. HDR rather than NHEJ). What we hoped to obtain, and indeed did, was a 
mixed population of cells which, on the majority, were negative for Itch expression.  
 
Degree of Itch knockdown at the protein level for all CRISPR+ cell lines was very 
convincing, with both biological significance (inferred from the strength of the Itch bands for 
CRISPR+ cells compared to parental and scrambled controls) and statistical significance 
(after quantifying and analysing differences in band fluorescence) (Figure 18: A. and C.). 
However, this was not necessarily seen for Itch mRNA levels quantified by qPCR. Although 
this presents a potential weakness in the investigation, characterising CRISPR 
knockdown/knockout using qPCR has inherent problems that become clearer when referring 
back to basic principles of the central dogma. For a gene to be expressed DNA must be 
transcribed to mRNA which is then translated to protein after which it can then perform its 
function (assuming it is correctly folded and has the appropriate post-translational 
modifications). Cas9 creates double stranded breaks in DNA which result in indels formed 
from NHEJ which are random in length between individual cells. As these edits are generated 
at the DNA level it is highly likely that a viable transcript can be formed resulting in mRNA, 
albeit a mutated version. It is therefore possible that primers used for qPCR to elicit gene 
expression for a gene of interest could produce false positive results unless primers were 
individually tailored for each sgRNA target site (i.e. generating primers that branch the cut 
site). The main problem with this being that it is not always possible to create suitable 
primers that branch the cut site dictated by a specific sgRNA due to issues with primer design 
and stability in the PCR reaction. 
 
With this information in mind it is far more likely that you would see a change in protein 




likely not translate into a viable protein resulting in their degradation via the proteasome. 
This would explain why for some of the lentiviral constructs i.e. IKO2 and IKO3 we could 
see a significantly large reduction in Itch protein (Figure 18: A. and C.) but not in Itch mRNA 
(Supplementary Figure 5). Reduction in protein level is probably also far more relevant in 
regard to assessing the functional and physiological consequences of gene-editing techniques 
rather than strictly looking at mRNA. The major weakness in relying on protein expression is 
in the case where the basal level of a protein is usually very low as this then becomes difficult 
to assess any differences between negatives, positives and test conditions through traditional 
western blot in which case different methods of quantifying protein must be used. 
Fortunately, in this case basal levels of Itch were suitable enough to provide clarity of gene-
editing techniques used in this project.  
 
 
siRNA data vs CRISPR data - adapting to a life without Itch: 
One of the most pressing concerns following the results presented in figures 20 & 22 when 
compared to the corresponding data of the transient siRNA knockdowns is the degree of 
response for each experimental condition was significantly different to what was seen for the 
stable knockdown. Whilst the siRNA-mediated Itch knockdown had almost no effect in terms 
of increasing the sensitivity of cells to additional treatment (with the exception of 
gemcitabine in MiaPaCa-2 cells) the resultant OD values of the siRNA-treated wells was far 
lower than that of the si-Scr and untreated cells (for both pancreatic cell lines). In contrast, 
stable Itch knockdown appeared to increase the sensitivity of both cell lines to all modes of 
treatment (as indicated by the normalised data and shifts in IC50s – Table 25). Meanwhile the 
resultant data from both the OD readouts from SRB and the number of colonies identified by 
Celigo show IKO1a cells are more clonogenic and/or have an increased ability to divide 
compared to scrambled and parental cells. 
 
 The initial question presented why there is such a disparity between each method of Itch 
silencing (transient by siRNA or stable by CRISPR) in terms of cell survivability (i.e. the 
resultant data). Assuming that Itch promotes cell survival as the siRNA data indicates, then 
one could hypothesise that CRISPR+ cells may have adapted to a “life without Itch”.  
 
In the case of a transient knockdown of Itch, cell survivability is only impaired temporally as 
the knockdown effect gradually dissipates. This means that any surviving cells which either 
temporarily altered their gene expression to cope or did not take up the dsRNA at all (and 
thus were not subjected to the knockdown) simply recovers the wild-type population (Figure 
25). However, this is not the case for cells being treated with CRISPR-Cas9: Itch silencing in 
this system is irreversible so long as the cells are successfully transduced with the lentiviral 
construct. This means that any cells that survive the initial loss of Itch function would need to 
continually upregulate other proteins (and/or pathways) or acquire further mutations that 
circumvents the loss-of-function of Itch as they are prevented with a more severe “adapt or 
die scenario”. Furthermore, the plasmid used also allows production of a gene that grants 
antibiotic resistance to puromycin which is used to provide a positive environmental selection 
pressure for cells that have been successfully transduced - a scenario that is similar in 
principle to how bacteria acquire antibiotic resistance. The combination of the loss of gene 
function and the selection pressure could generate cells that would have a survival advantage 
over the original cell line which would explain the what is observed in the resultant data from 
the cytotoxicity experiments. This hypothesis combined with the evidence already presented 
in the results identifies a potential flaw in the use of stable knockdown/knockout gene editing 




investigative timeframe. If stable knockdown/knockout of a gene with unknown function 
(and consequences if ablated) is desired in-vitro then it may be worth performing transient 
knockdown first to identify and note any short-term cellular responses. Based on the findings 
from transient silencing, one can then decide the appropriateness of an irreversible ablation.  
However, as noted at the start of the discussion, IKO1a cells were more sensitive to radio-
/chemotherapy according to the normalised viability data, which was not seen for si-Itch 
cells. This indicates that there could be potential impairment of pathways associated with 
coping with cytotoxicity and/or DNA damage resolution. Especially considering that all three 
modes of treatment exert there cytotoxic effect via inducing DNA damage, albeit via slightly 












Figure 25: Hypothesis for differing response between transient and stable Itch knockdown/knockout 
cells – antibiotic resistance analogy:  
(A.) several bacterial colonies grow from inoculations on an agar plate. When an antibiotic is applied to 
the dish only strains of bacteria that have or have recently acquired antibiotic resistance are able to survive 
whilst all none-resistant strains die. Under this positive selection pressure the resistant colony is able to 
expand further without competition from other strains. This principle could be used to explain the 
difference between transient and stable Itch knockdown phenotypes and response to radio-/drug therapy 
(B.). In transient Itch knockdown (i.) Itch function is only temporarily impaired in cells that are 






gets diluted-out as cells divide eventually replenishing the wild-type population as Itch function is 
restored. Meanwhile in a stable knockdown/knockout scenario (ii.) As the loss of Itch function is 
irreversible, cells may need to permanently alter gene expression to survive. Furthermore there may be 
additional selection pressure in the form of antibiotic resistance genes introduced in the same plasmid used 
for the stable knockdown/knockout. The resultant surviving population of cells would then be altered to 
have a survival advantage when compared to wild-type cells.   
 
Better optimisation of SWATH: 
Sequential windowed acquisition of all theoretical mass spectra (SWATH-MS) was used to 
identify any potential changes in protein levels as a result of Itch knockdown by CRISPR-
Cas9. However, during the first set of analyses, there were no significant differences in 
protein fold change between parental and CRISPR+ cells by the SWATH analysis despite the 
cell-survivability and clonogenicity experiments indicating otherwise. This was likely due to 
the fact that all the individual CRISPR+ clones were grouped and compared to parental cells 
which likely added a substantial degree of variance and error. Degree of Itch knockdown at 
protein and mRNA between each clone was different as seen from the western blot and qPCR 
data (Figure 19). It is therefore possible that each clone could have there own unique 
proteomic profile. To address this, analysis of individual clones compared to parental cells 
was performed which discovered differences in fold change for a select few proteins (Figure 
24). One example of a potentially interesting protein that was discovered was NEK3. NEK3 
was found to be upregulated in IKO3 and potentially upregulated in IKO2 as well. NEK 3 is 
a member of the NIMA-related serine/threonine-protein kinases that have been reported to be 
important in both cell cycle regulation and cancer progression (O’Regan et al, 2012; Moniz et 
al., 2011). Although NEK3 specifically has not been well characterised previously, a recent 
study reported that NEK3 overexpression is a poor prognostic marker in gastric cancer: 125 
out of 168 tissue biopsies showed high immunostaining for NEK3 (Yang et al., 2018). As this 
is potentially upregulated in two of the Itch negative clones it would be interesting to see if 
there was any molecular or pathway interaction between these two proteins. 
 
However, the statistical power of this second set of analyses was considerably weak due to 
the lack of replicates. To pull out potentially more candidate proteins and/or pathways 
effected by CRISPR-mediated Itch loss the experiment would likely need repeating with 
focus on generating sufficient replicate lysates of individual clones and comparing them to 
those of parental cells. Lack of replicates for each clone would also affect the robustness of 
the spectral library. Although it has the potential to be very high-throughput, DIA is 
dependent on spectral libraries that it needs to reference for each precursor within a given m/z 














Alternative CRISPR-based approaches: 
In this project an early form of CRISPR-Cas9 technology was used where DSBs are 
generated from an sgRNA-guided Cas9 to encourage indel formation and subsequent stable 
Itch knockdown. Dual nickase Cas9 endonucleases can be used to induce DSBs with greater 
accuracy and less off-target activity at the cost of some knockdown efficiency (Ran et al., 
2013). Additionally, adenine base editors (ABEs) can be conjugated to catalytically inactive 
Cas9 to enable precise base-editing via conversion of A•T to C•G to introduce/correct point 
mutations in genomic DNA (Gaudelli et al., 2017; Liang et al., 2017). One particular 
application of CRISPR-Cas9 that may be interesting to explore in relation to this project is 
the area of inducible CRISPR-mediated knockouts. Early interpretations of this such as 
iCRISPR involved transfection of a plasmid encoding transcriptional information for the 
synthesis of Cas9. Addition of doxycycline induces the expression of Cas9 resulting in DSBs 
in combination with the relevant sgRNA, which is either incorporated in the same or a 
separate plasmid, or added at the same time as doxycycline (Dow et al., 2015; González et 
al., 2014). Inducible CRISPR-Cas9 systems allows one to control the time point at which 
Cas9 endonuclease activity takes place as well as providing some degree of spatio-temporal 
control. Obviously, some form of selection would still be needed to isolate cells of interest 
but this can take place independent of DNA cleavage. The main issue with this particular 
form of inducible CRISPR-mediated knockout is that it is relatively slow: before any 
endonuclease activity can take place, Cas9 must first be transcribed and translated after 
application of doxycycline causing significant delay in silencing activity.  
 
Photosensitive CRISPR-Cas9 systems can also be used as light-dependent inducible system 
which offers the potential of even greater temporal control (as light can be focussed or 
filtered in a way to only hit a certain population of cells). This approach relies on a 
heterodimerisation of photoreactive proteins (such as CRY2 and CIB1) that respond to blue 
light conjugated to traditional CRISPR components. This has been used as a means of both 
inducing DSBs via Cas9 endonuclease activity (Nihongaki et al., 2015), and as a means to 
transcriptionally activate a gene expression via an inactivated dCas9 coupled to a 
transcriptional activator such as VP64 (Nihongaki et al., 2015; Polstein & Gersbach, 2015). 
This method also allows one to toggle the system “on-and-off” as light exposure is easily 
controllable. Although seemingly a very powerful application of inducible CRISPR, it 
requires specialised equipment for blue light generation usually only found in specialist labs.  
 
iCas is a chemically-inducible form of Cas9 developed by Liu et.al. that allows toggleable 
activity of Cas9 through supplementation of 4-hydroxytamoxifen (4-HT) (Liu et al., 2016). 
Multiple hormone binding domains of the oestrogen receptor (ERT2) were fused to Cas9 and 
upon addition of 4-HT, ERT2 associated Cas9 translocates to the nucleus from the cytoplasm, 
after which Cas9 can induce DSBs in genomic DNA. Depletion of 4-HT then causes the 
modified Cas9 to be localised in the cytoplasm where it cannot act, hence the alleged “off” 
function. However, although the paper mentions iCas’ capacity to be switched on or off 
based on 4-HT dictating the construct’s subcellular localisation, it does not necessarily mean 
that silencing activity would follow the same pattern (i.e. silencing could be turned on and 
off) if DSB breaks result in indel formation from NHEJ, which is necessary to silence that 








The reason why an inducible CRISPR system might be interesting in regard to exploring Itch 
function and particularly its potential role as an oncogene is that one could suddenly “turn-
off” Itch and observe the downstream consequences e.g. cell viability. It would be interesting 
to observe whether or not the response of cells undoing the inducible knockout would mirror 
that seen in the siRNA-treated cells where Itch was only knocked-down transiently. 
Assuming Cas9 is used (or any DNA-specific Cas variant) this particular method could also 
better elicit whether the drop in cell survivability upon application of siRNA was due to 
potential off-targets interactions of the siRNA-RISC complex with other RNAs.  
 
One could adapt the method of a toggleable system with a recently conceived REPAIR-based 
(RNA editing for A to I replacement) RNA editing system to avoid irreversible gDNA edits. 
Inactivated Cas13b (dCas13b) conjugated to a crRNA can bind to mRNA rather than DNA 
(Ali, Mahas, & Mahfouz, 2018; Cox et al., 2017). An attached deaminase (ADAR2) converts 
adenosine to inosine which is functionally similar to guanine. This means that precise base 
edits can be made in mRNAs allowing one to perform knockdowns of specific protein 
isoforms encoded by alternatively spliced mRNA transcripts. Coupling this system with one 
of the aforementioned methods of induction (biological, chemical, light-based, etc.) would 
provide a construct that allows toggleable silencing activity that could be stably expressed in 
cell lines (e.g. via lentiviral or AAV transduction) that would not cause indel formation in 
gDNA due to DSBs from traditional Cas9 endonucleases. In addition to the knockdown of 
specific isoforms, one could even incorporate several REPAIR constructs within the same 
plasmid (for example – a ribonuclear protein approach using lipofection or nucleofection for 
entry could be used but then this would be transient rather than stable), under control of the 
same or even separate inducible systems to perform either a more comprehensive, blanket-
knockdown of gene expression or being able to influence the levels of several protein 
isoforms simultaneously. As previously mentioned, technology already exists that allows 
transcriptional control of target genes through activator/repressor-associated-dCas9 (Gilbert 
et al., 2013; Maeder et al., 2013; Qi et al., 2013) coupled to photoreactive proteins. Whilst 
this does achieve toggleable transcriptional control it is restricted by the need of a PAM 
sequence (for Cas9-DNA binding) which Cas13b does not require.  
 
Additional verification of CRISPR+ cell lines – enzyme mismatch cleavage assay: 
In hindsight, one additional form of verification that may have been useful to perform before 
proceeding with qPCR and Western blot is an enzyme mismatch cleavage (EMC) assay. 
EMC assays can be used to verify the presence of mutations induced by CRISPR, TALEN 
and other forms of genome editing (i.e. indels). It is based on the preferential enzymatic 
cleavage of mismatched DNA over Watson-Crick base pairing (Vouillot, Thélie, & Pollet, 
2015). Usually one of two types of mismatch cleavage enzymes is used when verifying 
indels. CELI is an endonuclease that is found in many plants and within various plant tissues 
(Oleykowski et al., 1998) and cleaves 3’ of the site of mismatch. This led to the development 
of the commercially available CELII (Surveyor™ nuclease) that is able to detect mismatches 
due to single base substitutions as well as insertions of various lengths (Qiu et al., 2004). 
T7E1 (T7 endonuclease 1) is a bacteriophage resolvase whose substrates are dsDNA 
undergoing some sort of conformational change (e.g. extrahelices, bulges, and kinks) and 
does not pair well with perfectly Watson-Crick paired DNA (Déclais et al., 1995; Sakurai et 
al., 2014; Vouillot et al., 2015). Although both enzymes have been shown to work for 
mutation detection it is reported that T7E1 is more efficient and has a greater signal to 





In an EMC assay, PCR primers are designed to flank the mutational region of interest (in the 
case of CRISPR this would be the sgRNA target site), making sure that the site of mutation is 
offset from the centre of the two primers. Amplification of the target region by PCR from 
genomic DNA extracts takes place, followed by hybridisation of PCR products. This creates 
homoduplexes from amplicons where the target site is wild type, and heteroduplexes from 
amplicons where the target site is mutated in some way. Heteroduplexes have mismatches or 
extrahelical loops which are more prone to cleavage by EMC enzymes (Vouillot et al., 2015). 
When gel electrophoresis is performed on the enzyme-treated PCR product, one should see a 
larger, full-length band from homoduplex DNA, which is wild type, and smaller bands from 
heteroduplex DNA where the enzyme has cleaved the mismatch site. It is at this point that the 
importance of the positioning of the mutation site between the two PCR primers comes into 
play as, if the target site is central to the two primers, only one band will be seen on the gel in 
heteroduplex DNA: the enzyme will cleave the PCR product centrally, producing two equal-
sized bands when visualised on a gel. Alternatively, different sized cleavage products can be 
viewed using a Bioanalyser alongside the full-length section of DNA (Vouillot et al., 2015). 
This technique would have allowed provided an initial confirmation step to determine 
whether or not indels had been created in transduced cells before validating Itch protein and 







































Chapter 5 – The Effect of Itch Knockdown In Osteoclast 
Differentiation And Function: 
 
Previous studies have implicated a role for Itch in the regulation of bone remodelling by 
acting as a negative regulator of the development and function of osteoclasts and osteoblasts 
(Li et al., 2017; Liu et al., 2017; Zhang et al., 2013; Zhang & Xing, 2013). This part of the 
project explores the role of Itch in regulation of osteoclast differentiation using a human ex-
vivo model. Based on previous work looking at the differentiation potential of monocytes 
from Itch-/- mice a series of experiments was designed to see if this translated to human 
monocytes derived from whole blood. Thus, the hypothesis is that genetic knockdown of Itch 
in primary human monocytes promotes the differentiation and function of mature osteoclasts. 
For this investigation whole blood samples were taken from volunteers and used to isolate 
peripheral blood monocytes (PBMCs) (Henriksen et al., 2012; Marino et al., 2014). After an 
appropriate cell culture protocol was developed and refined, genetic knockdown of PBMCs 
was attempted using either previously-validated siRNA or CRISPR-Cas9 before adding 
RANKL to culture media to promote osteoclast differentiation (Kim & Kim, 2016; 




Successful isolation, culture, and differentiation of primary PBMCs to osteoclasts: 
After whole blood was collected and separated into plasma, the buffy coat (containing 
leukocytes and platelets), and erythrocytes (red blood cells), the buffy coat was extracted 
using a Pasteur pipette and the cells were washed. Cells were cultured in a-MEM containing 
20ng/ml M-CSF to specifically culture monocytes. After 7 days of media was supplemented 
with 50ng/ml RANKL which was replaced every two days to encourage mature osteoclast 
differentiation (Figure 26: A.). Mature osteoclasts are morphologically characterised as large 
multinucleate bodies (due to multiple cells combining) and can be histologically 
characterised using tartrate resistant acid phosphatase (TRAP) staining (Blumer et al., 2012; 
Burstone, 1959), which makes cells appear purple/brown. After 7 days RANKL treatment, 
cells were fixed and stained for TRAP activity (Figure 26: B.).  
 
 
Successful siRNA-mediated knockdown of Itch in primary PBMCs ex-vivo: 
After isolation and 7 days of PBMC culture with M-CSF, cells were subject to 12.5 nM 
siRNA for 24 hours before media was changed. 48 hours post-transfection cell lysates were 
taken to assess both protein and mRNA levels of Itch to confirm the knockdown. Results 
from western blot (Figure 27: A. lanes 1, 4 and 5 & B.) showed an average 75% Itch protein 
knockdown compared to untreated and scrambled controls. This was mirrored by a 80% Itch 
mRNA knockdown as confirmed by qPCR (Figure 27: C.).  
 
Stable knockdown of Itch by CRISPR-Cas9 was also attempted in a separate batch of 
PBMCs. After transduction with lentiviral particles CRISPR+ there was a large degree of 
cellular toxicity and cell death. Cells appeared to have burst or damaged nuclei with cellular 
debris scattered within the cytoplasm as well as in the media (Figure 28). Several cellular 




appearance. When protein lysates were taken from the affected cells the protein level was too 
low to be able to tell if the knockdown was successful (Figure 27: A. columns 2 and 3); both 
CRISPR-Itch and CRISPR-Scr lanes had reduced red fluorescence from b-Actin compared to 
the other lanes, indicating a significant reduction in total protein. Qualitatively, the level of 
Itch (green fluorescent bands) for CRISPR-Itch and CRISPR-Scr was so low that any 






















Figure 26: Culture of PBMCs ex-vivo: After isolation from whole blood:  
PBMCs were cultured with 20 ng/ml M-CSF for 7days before exposure to 50 ng/ml RANKL. Cells were 
imaged using an inverted light microscope to monitor osteoclast differentiation (A.). After 7days RANKL 















































Figure 27: Attempted knockdown of Itch using siRNA and CRISPR-Cas9 in PBMCs:  
PBMCs were either incubated with siRNA or CRISPR targeting Itch. A. western blot of cells shows 
successful transient knockdown of Itch in PBMCs compared to a scrambled and negative control (lanes 1, 
4, and 5). CRISPR treatment caused cell death in transduced wells, resulting in too little protein being 
extracted to elicit the degree of Itch knockdown between CRISPR-Itch and CRISPR-Scr (scrambled) 
(lanes 2 & 3). B. quantification of Itch protein relative to untreated controls for siRNA-mediated 
knockdown. C. RT-PCR results showing relative Itch mRNA levels of siRNA-treated PBMCs. GAPDH 
















































































































































Figure 28: Effect of CRISPR-Cas9 on PBMCs:  
Images taken of PBMCs/osteoclasts 14 days post CRISPR treatment. Untreated cells (left) appeared to 
develop normally, forming large multinucleate cells formed from the fusion of individual osteoclast 
precursors. However scrambled (middle) and Itch-targeting (right) CRISPR
+
 cells appeared damaged 
and/or dead with fragmented nuclear material and only some cellular structures remaining adherent to the 
plate for example the plasma membrane. 
 
Knockdown of Itch promotes survival and differentiation of mature osteoclasts ex-vivo: 
In order to see if silencing Itch can affect osteoclast differentiation PBMCs were cultured on 
two types of 96-well plates; either a plain-surface plate or an Osteo-surface Assay Plate 
(osteo-plate) (Rao et al., 2010). Cells were exposed to siRNA for 24 hours before changing to 
RANKL-containing media to promote osteoclast differentiation (A supplementary dose of 
siRNA was applied at day 4 RANKL exposure). As determined using Celigo, it was found 
that in the regular 96-well plate there was a significant decrease in well confluence for cells 
that had been treated with scrambled siRNA (Figure 29: A.). No biological, or statistical, 
difference in confluence was seen between untreated and si-Itch-treated wells. It was 
hypothesised that this difference in confluence could be due to lipofection toxicity however 
this same pattern was not seen in the osteo-plate (Figure 29: B.) where confluence averaged 
at 20% for all three test conditions with little variation. Comparison of percentage confluence 
between both plates revealed a 10% difference in mean well confluence for untreated and si-
Itch wells with no observed difference mean well confluence of scrambled wells between 































Figure 29: Scrambled siRNA treatment inhibits cell survival of PBMCs and osteoclasts on plain 
surface plates: 
Using Celigo, average well confluence (%) was determined for all test conditions for both plain surface 
and Osteo-Surface assay plates. In the plain surface plate (A.) the average well confluence for the 
scrambled-treated wells was significantly lower than both the untreated (p = 0.0001) and si-Itch wells (p = 
0.0012). There was no difference observed in the Osteo-Surface plate (B.). Mean confluence between 
plates was also compared and analysed (C.). Mean well confluence in the osteo-surface plate was ~10% 
lower for both untreated and si-Itch treated wells (p = 2.33x10-5 and 2.21x10-5 respectively). No significant 
difference was seen in scrambled-treated wells between both plates. Statistically significant difference in 



























































































Cells were fixed and stained for TRAP activity to confirm the presence of osteoclasts (Figure 
30: A.). A cell-counting algorithm was designed in Celigo to identify and record TRAP+ 
objects in each well of the 96-well plates (Figure 30: B.). Wells treated with scrambled 
siRNA had lower numbers of TRAP+ cells compared to untreated and si-Itch-treated wells 
(Figure 30: C.). Interestingly, for the osteo-plate, despite confluence levels across each test 
condition being comparable (Figure 29: B.), the mean (µ) number of TRAP+ cells for 
scrambled-treated wells was significantly lower than that of untreated wells (µ = 330 and 449 
respectively, p = 0.0005). si-Itch treated wells had significantly higher mean for TRAP+ cells 
(µ = 532, t-test comparing si-Itch vs untreated p = 0.0048) (Figure 30: D.).  
 
As previously mentioned, mature, fully differentiated osteoclasts are large multinucleate 
bodies formed from the fusion of several cells. To determine if siRNA-mediated silencing of 
Itch promotes the formation of mature osteoclasts the same plates were scanned with a 
second cell-count algorithm that was designed to select for TRAP+ objects above a particular 
surface-area threshold (Figure 30: E.). In both plain-surface and osteo-surface plates, wells 
treated with si-Itch had significantly higher numbers of hits (µ = 63 & 9 for plain and osteo-
surface plates respectively) indicating an increase in the number of mature osteoclasts 
compared to the untreated controls (µ = 54 & 4 respectively) (Figure 30: F. & G.). 
Scrambled-treated wells displayed far lower numbers compared to untreated wells in both 
plate formats µ = 18 & 2 for plain and osteo-surface plates respectively. Cells on the plain-
surface plate were also nuclear-stained with Hoechst33342 and scanned again using a blue 
fluorescence (461nm emission) and a brightfield filter to identify multinucleate bodies with 
TRAP+ activity (Figure 30: H.). Concurrent with the previous results, si-Itch treated wells 
had significantly higher numbers of multinucleate bodies (µ = 25) compared to both 
untreated (µ = 17) and scrambled-treated (µ = 9) wells (Figure 30: I., t-test comparing si-Itch 
vs untreated, p < 0.0001). These results combined confirm that genetic knockdown of Itch 







































































































































































































































Figure 30: Knockdown of Itch in primary human monocytes increases osteoclast differentiation ex-
vivo: 
(A.) Osteoclast formation in 96-well plates was verified by TRAP staining for each test condition and 
imaged under a light microscope (10x magnification); untreated (left), scrambled (middle) and si-Itch 
(right). After TRAP staining of plates, automated cytometry analysis (Celigo) was used to count TRAP+ 
cells. Image B. shows a section of a well before (left) and after (right) the algorithm was applied, 
highlighting positive hits in green. This algorithm was then applied to the plain surface plate (C.) and the 
osteo-surface assay plate (D.). The difference in mean number of TRAP+ cells between si-Itch and 
untreated wells was found to be statistically significant in the osteo-surface plate (p = 0.0048). Similar 
algorithm was designed for identification of mature osteoclasts (E.). Once again this was applied to both 
plate types of plate (F. and G.) and the difference in mean number of mature osteoclasts between si-Itch 
treated and untreated wells was found to be significant in both plain and osteo-surface plates (p = 0.0376 
and p = 0.0099 respectively). Nuclei of cells on the plain surface plate were stained with Hoechst 33342 
(H.) to identify multinucleate bodies (red arrows) which were counted for each well (I.). Statistically 
significant difference in mean number of multinucleate cells was seen between untreated and si-Itch 





The aim of this part of the project was to confirm that silencing Itch facilitates osteoclast 
differentiation and function and see whether or not the phenotype in primary human 
monocytes mirrors what is seen in Itch-/- mice (Li et al., 2017; Zhang et al., 2013) whilst also 
being a more translatable model system.  
 
PBMCs were isolated and cultured from whole blood samples. Any residual T-cells or B-
cells that also would have been in the buffy coat would be washed out with media changes as 
they are non-adherent. Furthermore M-CSF containing media specifically promotes 
differentiation of monocytes into osteoclast precursors (Marino et al., 2014), meaning that it 
would be unlikely that any residual T-cells would undergo activation and clonal expansion as 
the culture conditions lacked critical cytokines for these processes.  
 
Itch knockdown facilitates differentiation of osteoclasts from primary human PBMCs: 
After standardising and adapting a protocol for cell culture of PBMCs and their 
differentiation into osteoclasts, PBMCs were subject to gene silencing techniques to assess 
the physiological consequences of an Itch knockdown. Whilst transient siRNA-mediated 
silencing was successful, monocytes were refractory to the lentiviral based CRISPR stable 
knockdown approach. Western blot and qPCR techniques confirmed silencing of Itch at both 
the protein and mRNA level in siRNA-treated cells. Unlike what was observed with 
pancreatic cancer cell lines, siRNA-mediated silencing of Itch did not affect the survivability 
of monocytes in-vitro as indicated from the confluence data. If desired this could be re-




experiments. Furthermore, it was observed that lipofection induced toxicity in the si-Scr 
treated monocytes which was absent in si-Itch treated cells indicating Itch knockdown might 
be protective against said toxicity.  Silencing of Itch by siRNA in monocytes and premature 
osteoclasts increased there ability to differentiate into mature osteoclasts, as indicated by the 
increased number of multinucleate, TRAP+ bodies present in 96-well plates (Figure 30). The 
software used was limited in that it was unable to distinguish multiple individual nuclei 
within a single body. In an ideal scenario one would be able to create an alternative algorithm 
that would be able to combine recordings of large cellular bodies with multinucleate bodies 
to get a more absolute number for osteoclastogenesis.  
 
Cellular mechanism for the role of Itch in osteoclast differentiation: 
Overall these results not only support previous in-vivo and in-vitro data performed in/from 
mice (wt or Itch-/-) but also confirms that the mechanism by which Itch effects 
osteoclastogenisis is also translatable to humans. This opens up an exciting avenue of 
possible treatment strategies in diseases caused by, or are associated with, dysregulation of 
bone remodelling for example rheumatoid arthritis and osteoporosis. This aspect of the 
project also describes a repeatable, robust, and efficient method of siRNA-mediated gene 
silencing of primary human monocytes for experimentation ex-vivo. Although a small 
amount of cytotoxicity was observed in scrambled-treated cells, likely due to the transfection 
method used, there is room for further optimisation to limit further cytotoxicity (for example 
by comparing different transfection strategies such as electroporation or nanoparticle-
mediated delivery). 
 
In an adult organism, upregulation of proteins associated with increased osteoclastogenesis or 
osteoblastogenesis is usually due to localised inflammation causing persistent NF-kB 
signalling (Liu et al., 2017; Zhang et al., 2013). In the case of osteoclasts, TRAF6 is required 
to transduce RANKL/RANK signalling to promote NF-kB transcriptional activation. 
Although Itch normally acts to regulate the immune response and inflammatory signalling 
pathways, in this series of experiments there is a lack of external inflammatory agents, with 
the only additional cytokines being M-CSF and RANKL with the activity of siRNA being 
intracellular. This reinforces the fact that the action of Itch in regulating osteoclastogenesis 
specifically, is intrinsic in monocytes rather than strictly extrinsic. To promote NF-kB 
transcriptional activity, TRAF6 polyubiquitinates itself subsequent to RANKL signal 
transduction (Lamothe et al., 2007; Zhang et al., 2013). Deactivation of TRAF6 results from 
a complex formed from Itch and CYLD, a deubiquitinating enzyme (DUB), which acts to 
remove Ub from activated TRAF6 (Jin et al., 2008). Although this aspect of the project is 
consistent with the hypothesis that Itch inhibits osteoclast differentiation via inhibition of 
TRAF6, no steps were taken to completely validate that this mechanism. As there is no 
evidence to suggest changes in transcription of CYLD and TRAF6 genes in 
osteoclastogenesis, quantification of mRNA may not be the best approach. Likewise, strictly 
looking at protein levels may not yield conclusive results in this investigation as whilst levels 
of Itch change (due to the addition of siRNA) the suggested mechanism involving CYLD and 
TRAF6 does not involve proteasomal degradation. However, one could look at the levels of 
polyubiquitinated TRAF6: Zhang’s group used the DUB inhibitor N-ethylmaleimide 
(Emmerich & Cohen, 2015) to block the action of CYLD before enriching for ubiquitinated 
proteins through a pull-down assay and labelling with an anti-TRAF6 antibody (Zhang et al., 
2013). Furthermore, one could attempt to immunoprecipitate CYLD, TRAF6 and Itch in the 
presence and absence of Itch-targeting siRNA to confirm their interaction (although this does 




the most attractive strategy for treatment of bone-remodelling dysregulation, Itch has several 
target substrates and chaperone proteins which may cause off-target activity and side-effects 
in an in-vivo setting. To achieve a higher degree of on-target activity in this context, a more 
appropriate strategy may be to modulate TRAF6 signalling or CYLD DUB activity in aims to 
regulate osteoclastogenesis more specifically. 
 
Effect of lipofection on well confluence and cell survivability: 
An interesting observation was the effect the transfection had on average well confluence for 
each plate. For the plain-surface plate, the wells treated with scrambled siRNA showed a 
significant decrease in well confluence (Figure 29: A.) which potentially carried over into the 
TRAP staining data (Figure 30: C.). Meanwhile wells that underwent Itch knockdown had 
similar confluence levels and TRAP+ objects to the untreated controls (Figure 29: A. & 
Figure 30: C. respectively) but having a significantly higher number of mature osteoclasts 
(Figure 30: F. & I.). One of the possibilities for this difference seen the respective treatment 
regimens is that lipofectamine confers a certain degree of toxicity to PBMCs/immature 
osteoclasts, as cytotoxicity due to lipofection has been reported before (Barreau et al., 2006; 
Zhang et al., 2007). It could be reasonable to think that therefore Itch knockdown prevents 
this apparent lipofectamine toxicity however it is also possible that since the si-Itch treated 
wells showed higher numbers of more mature osteoclasts, which morphologically are larger 
and more spread-out (large cell bodies with more finger-like cellular processes protruding 
from the cell), that those wells would also have greater confluence as they occupy more 
space. Looking at the cells under a microscope after TRAP staining (Figure 30: A.) showed 
that si-Itch treated wells had more terminally differentiated cells compared to other wells 
(pictures taken from plain surface plate). Whether or not the si-Itch treated wells actually had 
the same number of surviving cells compared to untreated wells would be difficult to assess 
with the methods used in this project mainly due to the fusion of cells to form mature 
osteoclasts. One could attempt to count the total number of nuclei as a surrogate for the 
number of surviving cells at the end of the treatment regimen however, Celigo is unable to 
distinguish multiple individual nuclei within the same cellular body as separate entities, 
hence why multinucleate bodies were counted manually after staining and scanning.  On the 
other hand, the effect of treatment on confluence was not seen in the osteo-plate (Figure 29: 
B.) where all three test conditions had similar degrees of confluence. Furthermore whilst 
average well confluence for untreated and si-Itch wells was roughly 10% lower in the osteo-
plate compared to the plain-surface plate (Figure 29: C.), the average well confluence for the 
scrambled regimen between both plate types was not significantly different (µ = 23.5 and 
21.3 for plain and osteo-plates respectively). Previous literature has reported that osteoclasts 
cultured on dentine promoted cell survival (Zhang et al., 2013); a similar effect might be 
taking place with the osteo-plate providing pro-survival factors to seeded cells. 
 
Future optimisation of stable knockdowns in PBMCs: 
A difficulty in this investigation was achieving sufficient cell numbers for culture and 
experimentation. When cultured, numbers of PBMCs do not increase as they cannot divide 
(van Furth, Raeburn, & van Zwet, 1979). This meant that at the point of seeding onto a 
surface, monocyte numbers could only decrease; be that due to failure to attach or cell death. 
One of the challenges in culturing osteoclasts was ensuring sufficient initial cell-densities so 
that individual pre-osteoclasts could fuse without overpopulating the plates/wells and 





The obstacle of numbers was perhaps more exaggerated in the attempted CRISPR 
knockdown: Lentiviral transduction of both scrambled and Itch-targeting sgRNA’s with Cas9 
caused a significant degree of cell death (Figure 28). The plasmid pLentiCRISPRv2 contains 
a puromycin selection marker to allowing one to isolate CRISPR+ cells (Sanjana et al., 2014) 
upon addition to culture media. Although the precise mechanism of puromycin’s action on 
prokaryotes and eukaryotes is poorly understood, it is known to interfere with the translation 
of mRNA to protein (Azzam & Algranati, 1973). To test this to see if addition of puromycin 
was the cause of the observed apoptotic phenotype, the same concentration was added to 
untreated PBMCs to see if a similar result was obtained. Although there was a drop in cell 
number (as expected as the cells did not have the resistance gene), the phenotype was not that 
of what was seen for the CRISPR-treated cells: dead cells had completely detached (not 
shown) as opposed to leaving behind what appeared to be a monocyte “husk” which still 
appeared attached to the cell-culture surface. Furthermore, surviving cells appeared 
morphologically normal, therefore the phenotype observed for CRISPR-treated cells was 
likely not due to the addition of puromycin to culture media. 
 
Another possibility is that lentiviral transduction of CRISPR-Cas9 is toxic to monocytes. 
Previous retroviral gene editing techniques could only work on mitotically active cells 
(Miller, Adam, & Miller, 1990). The advantage of using HIV-1-derived lentiviral 
transduction methods is the ability to integrate and edit quiescent cells and thus expand the 
pool of editable cell lines (Naldini et al., 1996). Although initially this seems to suggest that 
pLentiCRISPRv2 should be able to silence gene activity in PBMCs, previous work on 
PBMCs and lentiviral constructs have shown that they are resistant to HIV-1 lentiviral 
transduction vectors and that it led to an increased cellular toxicity (Mühlebach et al., 2005; 
Neil et al., 2001; Sirven et al., 2002), however the nature of observed toxicity is not described 
in the literature. Despite this small lack of clarity, it is far more likely that the cell-death 
phenotype observed in this investigation is likely due to toxicity caused by the lentiviral 
vector as opposed to puromycin. Although it has been observed that derivatives of monocytes 
can be transduced, it is unknown whether osteoclasts specifically can be transduced. 
Additionally, for the purposes of this series of experiments gene silencing of Itch post-
differentiation would not assist in the experimental aims of the project (i.e. whether or not 
Itch knockdown effects osteoclast differentiation). 
 
In order to generate a stable Itch knockdown in PBMCs and their derivatives therefore 
requires a different approach, most notably a different vector. Cas-9 should still be able to 
induce guide-mediated double stranded breaks which result in silencing of the target gene 
provided it can get into the cell and translocate to the nucleus. Potential problems with stable 
gene-editing technologies such as CRISPR, TALENs, and ZFNs in PBMCs start to become 
apparent when it comes to identification and enrichment of edited cells for downstream 
applications. For the generation of mature osteoclasts, a relatively high cell-density of pre-
osteoclasts (and by association monocytes) is required so that cells close enough to each 
other to be able to fuse together to form large multinucleate cells. This makes gene editing 
techniques that rely on some form of selection pressure (antibiotic resistance genes) or cell 
sorting (i.e. FACS) to get an enriched culture of edited cells problematic due to the potential 
loss of un-edited cells. To re-establish a suitable cell density to promote the fusion of 
premature osteoclasts, cells that have successfully incorporated the edit would likely have to 
be re-seeded. Although in this series of experiments with transient siRNA no method of 
determining how many PBMCs taking up the siRNA was used (e.g. fluorescent labelling of 




recorded in a culture of non-dividing cells indicates a high level of transfection efficiency 
(Figure 27).   
 
An alternative method of silencing Itch in PBMCs and osteoclasts would be through the use 
of small-hairpin-RNA (shRNA). shRNA knockdown involves transfection of cells with a 
plasmid that can be transcribed in the nucleus by RNA polymerase II/III (without needing to 
integrate into the host genome) to produce premature gene-targeting shRNAs (Rao et al., 
2009). These are then processed like naturally produced microRNAs (miRNA) by Dicer in 
the cytoplasm before being incorporated into RISC to cleave target mRNAs. shRNA 
approaches are considered long-lasting compared to traditional siRNA-mediated knockdown 
methods as the plasmid persists in the transfected cell. Usually shRNA begins to lose its 
effect when cells divide as the plasmid is not passed on to daughter cells. Over time the 
silencing effect gets diluted until non-significance compared to wild-type cells. However this 
would not be an issue in non-dividing cells like PBMCs: due to lack of cell division the 
longevity of the gene-silencing effect from shRNA would appear stable provided successful 
transfection and continuous translation of the plasmid. Furthermore plasmids can be 
engineered to express a marker or reporter gene to confirm uptake and transcription of the 
plasmid in addition to using western/qPCR to analyse knockdown efficiency (Hong, Zhang, 
& Cai, 2010). On the other hand, despite siRNA-mediated gene silencing being transient, 
there is evidence that it can be very long-lasting in quiescent cell-lines as the silencing effect 
is not diluted upon cell division (Omi et al., 2004; Song et al., 2003).  
 
Assessment of Itch knockdown on osteoclast bone-resorptive activity: 
Several studies have reported functional assessment of osteoclasts (i.e. resorption of bone 
matrix) through the use of dentine discs (Henriksen et al., 2012; Marino et al., 2014). These 
provide a suitable bone-matrix-like substrate that can be cut to specific sizes for cellular 
assays. Upon distribution of PBMCs onto these discs and differentiation into osteoclasts, 
their function can be characterised by the formation of “pits” in the dentine due to resorptive 
activity. Number of pits formed or size of pits can then be used to quantify osteoclast 
resorptive activity. As a substitute for dentine discs, this project used Corning Osteo-Assay 
Surface plates: cell culture plates coated with an artificial bone matrix in each well (Rao et 
al., 2010). To test the hypothesis that Itch knockdown increases the resorptive function of 
osteoclasts, PBMCs were plated onto osteo-plates in parallel with the other experiments. 
Whilst growth and differentiation was uncompromised between the two types of plates 
(Mean total well confluence only differed by a maximum of 10% across all conditions – 
Figure confluence), there was significant loss of cells when it came to staining the wells for 
TRAP activity, as indicated by the large difference in TRAP+ bodies between the osteo-
surface and plain-surface plate (Figure 30: A.). 
 
To determine whether or not this was due to technical error during the TRAP staining process 
or if there is an underlying physiological/cellular mechanism that could cause this apparent 
loss of cells, both plates were re-analysed with the confluence algorithm post-TRAP staining. 
In the plain surface plate mean confluence remained unchanged post-TRAP staining 
regardless of whether the wells had been treated with scrambled siRNA, Itch-targeting 
siRNA, or left untreated (Supplementary Figure 7: A.). However, in the osteo-surface plate 
confluence of wells post-TRAP staining decreased by over 50% across all three treatment 
regimens (Supplementary Figure 7: B.) compared to mean well confluence prior to TRAP 
staining. As both plates were fixed and TRAP-stained in parallel (using the same reagents 
and protocol) and since the results show no significant change in well confluence in the plain-




adherent to the osteo-surface plate. Furthermore, the fact that there was a ~10% difference in 
average well confluence in untreated and si-Itch treated wells between the two plate types 
prior to TRAP staining (Figure 29: C.) further supports the argument that cells are less 
adherent to the osteo-surface plate. Since there was no difference seen for scrambled wells 
one can rule-out the possibility that passaging cells onto the osteo plate inhibits cell survival: 
if this were the case then the cytotoxic effect seen with the scrambled treatment in the plain-
surface plate would be additive with any cytotoxic effect that passaging onto the osteo-
surface plate would cause thereby decreasing confluence further. This evidence also supports 
the idea that the osteo-surface may promote cell-survival of attached cells similar to what has 
been reported with dentine (Zhang et al., 2013). 
 
To perform their function effectively, mature osteoclasts need the combined excretory 
machinery of many cells to maintain an acidic environment between the osteoclast and bone 
matrix against a steep concentration gradient (Väänänen et al., 2000). When the bone-
resorption process begins, a “sealing zone” is made around the periphery of the osteoclast, 
leaving a pocket of space to allow the resorbing osteoclast to secrete hydrogen ions and 
digestive enzymes. One could argue that during this experiment if osteoclasts were actively 
resorbing the synthetic bone matrix of the osteo-surface plates then adherence to the plate 
may be weaker than for a regular tissue culture surface as physical attachments are only made 
at the cells periphery as opposed to throughout the cell body (however formation and 
degradation of podosomes is a dynamic process). On the other hand, attachment to bone 
tissue via the sealing zone when actively resorbing tissue needs to be strong as it is important 
that there is no leakage of hydrogen ions or resorptive enzymes into the extracellular space 
(Väänänen et al., 2000). Therefore, it is difficult to predict any differences in attachment 
strength of functionally-active and passive osteoclasts and by extension whether the change 
in confluence seen pre- and post- TRAP staining in the osteo-surface plate is simply due to it 
being less adherent without further experimentation. If osteoclasts were actively resorbing the 
synthetic bone then one would suspect that the resorption pits would still be visible. Wells 
were washed with a 10% bleach solution as per the protocol described in the literature to 
remove cells and visualise any pits formed from actively-resorbing osteoclasts (Rao et al., 




























Chapter 6 – Discussion:  
 
Itch is a HECT domain-containing E3 ubiquitin ligase that was originally shown to play an 
important role in the regulation of the immune system, but has a role in bone formation and 
in processing several proteins implicated in cancer. This project examined the potential role 
of Itch in cancer progression and bone remodelling processes as well as critically evaluating 
different gene-editing techniques within specific experimental contexts.  
 
siRNA-mediated transient knockdown of Itch in MiaPaCa-2 and Capan-2 pancreatic cell 
lines inhibited cell survival significantly independent of any subsequent form of treatment 
based on resultant OD values from SRB assays. Combination of siRNA-mediated 
knockdown with chemotherapy or radiotherapy had an additive, rather than amplified, effect 
on cell death: this was evident from the fact that whilst cell survivability continued to 
decrease, the normalised response to irradiation, doxorubicin, or gemcitabine remained 
unchanged compared to controls. Treatment of cells with a scrambled siRNA control had no 
effect on cell survival (although a minor increase in cell death is seen with repeated 
lipofection over a short timeframe) indicating that any change in SRB data was solely due to 
silencing Itch.  
 
Following the positive results seen with transient Itch knockdown, CRISPR-mediated stable 
Itch knockdowns were generated in MiaPaCa-2 and Capan-2 cells. However stable 
knockdown of Itch did not produce the same results under similar experimental conditions:  
Whilst the stable knockdown did increase the sensitivity of the cell lines to chemo-
/radiotherapy, little-to-no significant difference was seen in the resultant dose-response of 
either cell lines with evidence to suggest that edited cells may be more clonogenic. It was 
hypothesised that cells CRISPR+ cells had adapted to the irreversible, long-term loss of Itch 
function which granted a survival advantage compared to scrambled or parental cells. This 
presents a potential weakness and caveat for the interpretation of data generated from stable 
knockouts. SWATH MS was used to screen parental and CRISPR+ cells for any differences 
in proteome that could clarify the observed difference in response. Through analysis of 
individual clones 5 candidate proteins were either upregulated or downregulated at basal 
levels compared parental controls. Unfortunately, due to the lack of necessary replicates, this 
analysis was not robust enough and did not yield enough proteomic differences for any 
conclusions to be made or pathway analysis to be performed.  
 
It was hypothesised that silencing Itch expression in primary human PBMCs increases there 
ability to differentiate into osteoclasts. Although stable Itch knockdown could not be 
achieved in primary human monocytes, siRNA-mediated transient Itch knockdown was 
confirmed in PBMCs validated by both qPCR and western blot. A series of in-vitro assays 
confirmed that cells treated with Itch-targeting siRNA formed more mature osteoclasts in-












Targeting Itch as a therapeutic strategy: 
 
In the case of anticancer therapeutics, the fact that transient Itch knockdown decreased cell 
survival and was even synergistic with chemo-/radiotherapy is an exciting prospect as the 
gene now presents itself as a possible druggable target for small molecule inhibitors. Studies 
have already shown that Itch is upregulated in pancreatic, breast and chronic lymphocytic 
leukaemia (Luo et al., 2016; Salah et al., 2014; Sampath et al., 2009) and a crystal structure 
for Itch protein in its inactive/closed state has been resolved (Zhu et al., 2017). Although a 
crystal structure of active/open Itch has not been determined yet, which could potentially 
enhance our ability to develop small molecules that specifically block the HECT domain (i.e. 
the catalytically active site), an alternative biochemical approach for inhibiting Itch utilising 
the closed structure data could be achieved through blocking the association of adaptor 
molecules like Ndfip or the  phosphorylation sites targeted by proteins such as JNK-1 
(Gallagher et al., 2006; Oliver et al., 2006; Zhu et al., 2017). This approach would lock Itch 
in its inactive state, preventing transthiolation, and ubiquitination of target substrates whilst 
not effecting Itch translational activity. Avoiding inhibition of the HECT domain may also be 
desirable so as to not exhibit any off-target activity with other HECT domain E3 ligases 
which could have unpredictable consequences (Fajner, Maspero, & Polo, 2017; Sluimer & 
Distel, 2018).  
 
Targeting Itch E3 ligase activity may also be a viable therapeutic strategy in the treatment of 
osteolytic diseases such as arthritis and osteoporosis as well. However, contrary to what 
would be desired in the treatment of cancer tissue, in this case one would want to increase 
Itch signalling, specifically in localised areas worst affected by resorptive osteoclast activity. 
Itch inhibits the formation of both osteoclasts and osteoblasts (Li et al., 2017; Zhang & Xing, 
2013), cells with antagonistic functions in balancing the bone remodelling process. This 
poses a potential issue in specifically targeting one subset of cells in-vivo as both osteoclasts 
and osteoblasts, despite being derived from different precursors (hematopoietic and myeloid 
stem cells respectively), differentiation occurs within the same stem-cell niche (Ikeda & 
Takeshita, 2016). However in the context of age-related disease this may not be a problem: 
both osteogenesis and osteoclastogenesis is reduced with age in both rodents and humans 
(Almeida, 2012; Becerikli et al., 2017) meaning bone remodelling and healing processes are 
reduced in older individuals. As the generation of healthy bone tissue requires the activity of 
both cell types, upregulating Itch signalling in the bone marrow stem-cell niche may be an 
effective method of preventing weakening of bone tissue, age-related fracture incidences, and 
facilitating bone healing.  
 
One question in regards to targeting Itch as a therapeutic strategy is what effect it could have 
on the immune system. In Itch-/- mice and humans the dominant phenotype is severe 
autoimmunity (Aki et al., 2018.; Lohr et al., 2010; Perry et al., 1998) therefore could 
downregulation of Itch in mouse models or patients cause a similar phenotype? Although 
autoimmunity associated with lack of Itch is discouraging, this phenotype could solely be due 
to problems during development of an organism when functional copies of Itch are not 
present. Itch is important for regulating key pathways linked to the differentiation of specific 
immune cell lineages (Aki et al., 2018; Fang et al., 2002; Theivanthiran et al., 2015; 
Venuprasad et al., 2015) as well as genes involved with foetal development such as Notch 
and Oct-4 (Chastagner, Israël, & Brou, 2008; Liao et al., 2013; Qiu et al., 2000). But there is 




function, in regard to the effect on immunity on a fully developed organism. Although the 
study by De La Fuente’s group showed that inhibiting Itch activity in xenograft mice inhibits 
cancer progression with negligible toxicity, these mice were immunocompromised to allow 
the graft to take place without inducing an innate immune response and rejecting the 
transplanted cells (de la Fuente et al., 2015). Additionally, no study has yet been performed to 
observe the long-term consequences of an induced Itch knockout after development. Taking 
all the above points together it is still unclear to determine the safety of an Itch inhibition 
therapeutic strategy with regards to its effect on host immunity. 
 
Previous literature has identified several substrates of Itch E3 ligase activity that are linked to 
cancer development and progression including p73, LATS, TXNIP, and Smad-7 (Hansen et 
al., 2007; Ho et al., 2011; Levy et al., 2007; Liu et al., 2016; Park et al., 2015). It is therefore 
difficult to completely characterise which substrates or molecular pathways are responsible 
for eliciting the recorded response of increased cell death in pancreatic cell lines or whether it 
is more due to the combination therapy. Further work is required to better understand and 
elicit possible changes in gene expression and proteome before developing any Itch-targeted 
therapy. However, in terms of treating cancer, the fact that Itch knockdown/inhibition could 
have a very wide-spread impact on cellular signalling pathways may be an advantage as it 
increases the number of potential synthetic-lethal interactions.  
 
It is also unknown as to whether inhibiting Itch in healthy cells could cause unwanted toxicity 
and cell death as is seen in cancer cell lines in-vitro and in-vivo. One of the main safety 
concerns during translational experiments is possible side-effects due to possible off-target 
activity of the treatment in question. Although several steps during the are usually taken to 
limit off-target activity and its associated effects, reaction with healthy tissue is almost an 
inevitability.  
 
Linking cancer, bone, and Itch - cancer-associated osteolysis: 
One question presented by this project is can both Itch’s effect on cancer progression and 
bone progression interplay with each other in a more physiological setting? Osteolysis is 
another term given to active bone resorption by osteoclasts and can sometimes be associated 
with tumour metastasis, notably in breast and prostate cancer (Goltzman, 2001; Lemma et al., 
2017; Marino et al., 2019). Diseased cells which metastasise to bone tissue often release 
factors that promote osteoclastogeneis for example growth factors, cytokines and a soluble 
form of RANKL (Goltzman, 2001) whilst inhibiting release of OTP from osteoblasts. This 
causes increased localised differentiation of osteoclasts from monocytes, thus increasing 
osteolysis. Although it may seem that manipulating Itch E3 ligase activity may, in the above 
context, have an effect on cancer-associated osteolysis it is difficult to determine what the 
overall effect would be. Localised genetic knockdown of Itch may decrease cell survivability 
of any metastasised cells and thus prevent the release of osteoclastogenic factors from cancer 
cells. On the other hand, we have also shown that knockdown of Itch increases the ability of 
monocytes to differentiate into osteoclasts, most likely due to persistent TRAF6 
ubiquitination. This could mean that even though there would be a reduction in 
osteoclastogenic factors from any metastasised tumour cells, osteolysis could persist due to 
increased numbers of mature osteoclasts from precursors. Another important point to 
consider however is that Itch also regulates osteoblast numbers (Zhang & Xing, 2013). If the 
ratio of osteoblasts to osteoclasts was maintained (and/or if the rate of differentiation) and the 
ratio of OTP and RANKL was the same, then there may not be any net-difference in bone 




application of any Itch-targeting therapy may be difficult to achieve all the desired effects on 
all three cell types. 
 
Synthetic Lethality 
The hopeful outcome of Itch knockdown on cancer cell lines is akin to synthetic lethality i.e. 
the concept that knockout/knockdown of two genes results in cell death (or growth 
impairment in regards to synthetic sickness but this is often grouped with synthetic lethality) 
but loss of function in just one of either gene does not. Synthetic lethality was a concept 
initially observed by Bridges in Drosophila melanogasta (Bridges., 1922) but the term 
“synthetic lethality,” was not coined until a few years later. One of the first instances of genes 
discovered to be synthetic-lethal in Drosophila was the eye pigment genes deep orange (dor) 
and rosy (ry) (Luchessi., 1967). Further advances in synthetic lethality were done in yeast 
which lead to the development of synthetic lethality screens. One such screen called a 
synthetic genetic array (SGA) involves crossing a mutant of interest with random mutants 
plated in wells, looking for synthetic lethal phenotypes (Tong et al., 2001). Another example 
is synthetic lethal analysis by microarray (SLAM), which is similar to SGA except 
microarrays, rather than plates, are used to compare the genotype of a transformed and 
control yeast knockout pool (Ooi, Shoemaker, & Boeke, 2003). Synthetic lethality provides a 
good framework for the discovery of novel anticancer therapeutics: Where cancer cells are 
mutant for a specific gene one can perform a screen to look for any potential synthetic lethal 
interactions; this can be done either through a small molecule screen or a genome-wide 
knockdown. Treatment based on synthetic lethal genetic interactions can preferentially kill 
the cells of interest as healthy cells will have only one of two (or several) genes impacted by 
the treatment regimen and will therefore not yield the genetic lethal phenotype. Synthetic 
lethal/drug screens also give valuable insight into the molecular mechanisms of cellular 
pathways, identifying upstream and/or downstream components that were previously 
unknown. ataxia telangiectasia and Rad3 related (ATR) is a DNA damage response (DDR) 
gene that many cancers rely on to cope with oncogenic stress (Bartek, Bartkova, & Lukas, 
2007) which was found to be synthetically lethal with various other genes involved in DDR 
and cell-cycle progression such as p53, ERCC1 and ATM (Mohni, Kavanaugh, & Cortez, 
2014; Reaper et al., 2011). ATR inhibition, either by small molecule treatment or RNA 
interference (RNAi), is therefore a strong area of interest in terms of anticancer therapy, 
being shown to be synergistic with gemcitabine in treating pancreatic tumours (Fokas et al., 





3D cell culture – a more accurate model of the tumour microenvironment: 
For an Itch-targeted therapeutic strategy is to be pursued then it would be necessary to 
perform further experiments using 3D cell culture. All the experiments performed during this 
project were all performed within the context of a 2D environment in that cells were cultured 
and manipulated on flat surfaces. However, this is not necessarily completely representative 
of disease in-vivo where the tumour grows in a complex 3D microenvironment where 
additional factors such as vascularisation, immune-interactions, and extracellular matrix 
(ECM) play large roles in disease progression. In the pancreatic cell line 2D experiments, 
drugs or any other form of therapy could achieve fairly uniform distribution throughout the 




is more exposed to any treatment regimen (Jamieson, Harrison, & Campbell, 2015). 
Treatment methods need to therefore be adapted and/or optimised so that they are able to 
penetrate to the innermost cells (i.e. the “tumour core”), a feature that would be important to 
prevent recurrence in a clinical setting.   
 
Multicellular tumour spheroids (MTS) can be developed in a research environment from cell 
lines to more accurately model 3D tumour architecture and better elicit drug response in-
vitro. Previous studies have already noted disparities in the dose-response of cell-lines to 
several different therapeutics when grown in 3D vs 2D (Melissaridou et al., 2019; Patra et al., 
2016; Souza et al., 2018) indicating that bioavailability is a significant factor in assessing the 
effectiveness of potential therapies. Difference in drug sensitivity could also be attributed to 
differences in the global gene expression of cells cultured in 3D compared to 2D: Changes in 
gene expression in 2D cells in generally uniform across the population of cells being tested 
however, cells grown in 3D show variable expression of specific biomarkers, e.g. stem cell 
markers, depending on there localisation within the MTS (Jamieson et al., 2015; Melissaridou 
et al., 2019; Souza et al., 2018).  
 
In contrast to standard 2D cell culture, 3D culturing requires conditions to be that cells 
preferentially adhere to each other rather than to any culture surface and gradually form 
MTS’. This can be achieved through a variety of methods however a couple of the more 
popular examples are the use of either a spinner flask or an ultra-low attachment (ULA) plate. 
Spinner flasks rely on a magnetically-generated current to maintain constant agitation of cells 
in media so they cannot form attachments with the flask itself: whilst this is a relatively 
simple way to get lots of spheroids relatively quickly, the size of multiple MTS’ is generally 
inconsistent and the speed of the flasks needs to be monitored and adjusted over time (as 
spheroids grow larger, a faster current is needed to prevent them from settling). ULA plates 
are similar to standard multi-well plates (e.g. 96-well) but surface of each well is coated in a 
way that prevents cell attachment to the culture surface. Provided that the same number of 
cells are passaged into each well, MTS’ formed in ULA plates should be relatively uniform 
in size. The main issue with this method is that care needs to be taken when replacing media 
or applying drug to not accidently aspirate or damage spheroids once they have formed.  
 
Basic dose-response analysis can be extrapolated from changes in spheroid size as growth is 
limited or as cells die and dissociate from the MTS as their cell-cell attachments weaken. 
However, this relies on homogenous shape and size of spheroids or precise measurement 
over multiple time-points to analyse percentage change in size and may be inconsistent 
between different cell lines due to differences in morphology and/or strength of cell-cell 
attachments in a normal environment. Melissaridou et.al.  assessed clonogenicity and cell 
viability of cells grown in 3D vs 2D by trypsinising spheroids prior to passaging them onto 
12/96 well plates (for clonogenicity and cell viability respectively) (Melissaridou et al., 
2019). For cell viability cells were immediately incubated with a commercial fluorescence-
based viability assay kit whilst the cells distributed on 12 well plates for assessing 
clonogenicity were cultured for a further 7 days before crystal violet staining.  
 
Histological or immunological methods can be used to analyse the spatial expression of 
specific markers within the spheroid as a whole including markers associated with apoptosis, 
necrosis, hypoxia, and the immune response after fixing and embedding spheroids in paraffin. 
Additionally, to analyse protein or mRNA by western blot and qPCR respectively, spheroids 





Flow cytometry could be a powerful technique for comparative studies of cells grown in 2D 
vs 3D (Patra et al., 2016). Flow cytometry is able to quantify different molecular and 
physiological characteristics on a cell-by-cell basis through identification of cell-surface 
antigens, fluorescent markers (through gene editing or an assay kit that relies on cellular 
machinery), or cellular staining (e.g. DAPI). differential response to treatment regimens can 
be readily characterised between cells cultured in 2D and 3D (albeit after spheroid 
dissociation). In the case of a cytotoxicity assay for example, although it would be difficult to 
ensure that the number of cells between 2D and 3D culture entering a flow cytometer would 
be the same, one could measure the proportion of cells that exhibited a specific response to 
clarify any difference between the two culture techniques. The main limitation of the use of 
flow cytometry is that a lot of cells are required which means several technical replicate 
spheroids may be needed for a single experiment. In the study the group circumvented this 
issue with a microfluidics chamber that could culture 5000 uniformly sized spheroids 
simultaneously (Patra et al., 2016).  
 
In the context of this project performing gene-edits and assessing the effect of Itch 
knockdown on spheroids adds an additional layer of experimental complexity. If silencing 
Itch decreases cell survivability, as seen in the data in this project, then will it affect the cells’ 
ability to form spheroids for downstream applications. Obviously the effect of Itch 
knockdown on the ability of cells to form spheroids could be an experiment itself: siRNA-
mediated transient Itch knockdown could be performed prior to passaging cells onto a ULA 
plate, ability of spheroid formation could then simply be characterised by average spheroid 
diameter (as an indicator for overall size) under a microscope with image analysis software. 
If however, genetic knockdown of Itch does influence MTS size and thus spheroid formation 
then in any subsequent comparative cytotoxicity studies transient knockdown would have to 
be performed after initial formation of spheroids as one would ideally want to begin with 
MTS’ of uniform size. Previously there have been no successful accounts of siRNA-mediated 
transient gene knockdown of spheroids in-situ. One study however identified that a simple 
modification to standard 2D transfection protocol overcame this ongoing issue in 3D 
transfection: they found that use of 10% serum media increased siRNA entry in spheroids as 
opposed to serum-free OptiMEM that is typically used in for 2D siRNA transfection (Morgan 
et al., 2018). The exact mechanism of this phenomena is unknown and is interesting as it is 
the complete opposite of what you see in a 2D context (serum-containing media is ineffective 
for transfecting cells in 2D culture). Although it was observed that in colorectal cell lines 
LS174T and SW1463 there was a transient mRNA knockdown of CTNNB1 (the gene that 
encodes b-catenin), there was no noticeable decrease in protein. However this may be due to 
fact that b-catenin has a relatively long half-life particularly in cancer cell lines with 
upregulated Wnt signalling (Kirschner et al., 2000). If siRNA-mediated transient knockdown 
of mRNA and protein reduction can be confirmed in MTS’ then any of methods of measuring 
and comparing cytotoxicity in 2D and 3D can be applied. However, if not then an alternative 
knockdown approach would be required. 
 
shRNA and CRISPR-Cas9 gene editing protocols in 3D spheroids and organoids are effective 
and well established (Koo, Sasselli, & Clevers, 2013; Matano et al., 2015). However, this 
approach typically involves the performing transfection/transduction in a 2D context then 
forming (or re-forming of secondary MTS’/organoids after primary dissociation in some 
cases) new 3D structures. Although it is unknown how efficient update and efficiency of 
shRNA/CRISPR in MTS’/organoids would be in-situ, in the context of the experiments being 
performed in this project the aforementioned method of forming MTS’ post-gene edit may be 




performed using an inducible knockdown/knockout system as spheroids grown from IKO1a 
cells may be drastically different in phenotype and response compared to those that 
experience a sudden loss of Itch. One could transfect/transduce parental cell lines with a 
plasmid/viral construct designed to mediate gene silencing of Itch under the control of a 
specific stimulus. After application of said stimulus, efficiency of silencing would need to be 
assessed once again before moving on to any downstream assays. The issue then becomes the 
ability of the stimulus to penetrate deep enough into the MTS to activate gene-silencing 
machinery, be it shRNA- or Cas-mediated. Whilst MTS’ provide a more representative view 
of tumour microenvironment and are an overall better in-vitro model over 2D monolayer 
cultures, there are still significant areas that are lacking compared to a living organism which 
will have many more complex barriers to overcome in terms of translational therapeutics. 
 
Gene-editing technologies and modern clinical application - 
overcoming hurdles in translational medicine: 
 
Gene-therapy for treatment of disease is an attractive prospect due to increased specificity 
compared to drug treatments as well as the having the possibility to target multiple genes 
within a single application (Bumcrot et al., 2006; Mansoori et al., 2014). Furthermore gene-
editing strategies combined with existing drug regimens have the potential for overcoming 
resistance mechanisms employed by bacteria and cancer cells. However, when discussing the 
use of genetic manipulation for clinical practice the main factors to consider are whether it is 
ex-vivo or in-situ, the nature of the edit (transient or stable), efficiency of the system used, 
and method of delivery.  
 
Ex-vivo gene editing: 
Ex-vivo applications of gene therapy presents with fewer complications in terms of patient 
safety: cells are removed from the patient and edited in the lab, where the correct sequence 
can then be verified, selected, and expanded before re-introduction into the patient. Stable 
gene edits are more suited to ex-vivo applications as the modified cells can pass on any 
changes to daughter cells once re-introduced into the host. Considering the genetic 
manipulation takes place outside the host, this broadens the range of modification techniques 
that can be used effectively. Provided accurate verification of the edit being made any of 
CRISPR, TALEN, shRNA, ZFNs, or viral methods of gene-editing can be used.    
 
As modified cells are recognised as “self” by the hosts immune system it is highly unlikely 
that an innate immune response will be generated after reintroduction. However, for the very 
same reason, it is paramount that the modification is verified completely in-vitro through the 
use of several verification techniques e.g. western blot, qPCR, gene sequencing etc. 
Obviously different forms of verification would be needed depending on the exact 
modification being made.  
 
Application of CRISPR in Car-T gene therapy: 
One example and recent advancement in the use of ex-vivo genetic manipulation in 
anticancer therapeutics is the development of Car-T therapy in the treatment of non-solid 
tumour types such as B-cell acute lymphoblastic leukaemia and non-Hodgkin lymphoma, 
approved by the FDA in 2017 (Lee & Kim, 2019). Chimeric antigen receptor T cells (or CAR 




reprograms their sensitivity and selectivity to more efficiently target tumour tissue (Eyquem 
et al., 2017; Lee & Kim, 2019; Maus et al., 2013; Newick et al., 2017). T-cells are extracted 
from the patient and are modified ex-vivo to express a chimeric antigen receptor (CAR). 
CARs allow T-cells to recognise any cell-surface antigen with high specificity via a single-
chain variable fragment derived from an antibody rather than being limited to solely 
recognising the MHC (major histocompatibility complex).  
 
Since its inception, various labs have been looking into ways to improve and/or adapt CAR-T 
therapy to increase its efficacy, longevity, or broaden its therapeutic applications. Currently 
DNA encoding CARs are introduced into the host genome via clinical grade viruses which 
induces significant cost and concerns of random integration of CAR genes. Roth et.al. 
employed CRISPR-Cas9 to an insert antigen-targeting CAR into a specific site in the genome 
through non-viral means (Roth et al., 2018). CRISPR-Cas9 has also been used to 
simultaneously disrupt the TCR and PDCD1 locus (Ren et al., 2017). Loss of PD-1 (gene 
product of PDCD1) caused increased antitumour effect in mouse models. Meanwhile the 
disruption of the TCR complex creates non-alloreactive   CAR-T cells (i.e. they do not 
invoke an innate immune response) allowing the possibility of donor-derived T-cells and 
preventing graft-versus-host disease (GVHD). In a similar vein, TCR disruption in CAR-T 
cells has also been achieved through use of TALEN-mediated gene editing (Qasim et al., 
2017). These modified cells were then introduced into two infants diagnosed with relapsed 
refractory CD19+ B cell acute lymphoblastic leukaemia and were found to have remission 
within 28 days.  
 
Despite these exciting advancements in this technology, CAR-T gene therapy is still limited 
by the fact that it is only effective in haematological cancers and ineffective or 
underwhelming in solid tumours, which make up 90% of malignancies (Lee & Kim, 2019; 
Newick et al., 2017). This is due to several obstacles that solid tumours present that are 
absent for haematological malignancies namely antigen heterogeneity across different tumour 
types, tumour microenvironment (TME) hostility, bioavailability, and immune suppression in 
the TME (Newick et al., 2017). Despite this several groups have already begun attempts to 
try and circumvent the challenges presented by specific diseases to make CAR-T gene 
therapy more universal. 
 
In-situ gene editing: 
Ex-vivo gene editing is well suited to treatment of diseases where clonal expansion of a 
single modified cell can produce therapeutically relevant results. This could take the form of 
modified immune cells (as is the case with Car-T gene therapy) or introduction of cells that 
can produce healthy protein in a patient that endogenously produces a mutant version (e.g. 
production of functional CFTR in cystic fibrosis patients). However, there are cases where 
this approach would not be viable/appropriate, for example in treatment of solid tumours 
where if gene therapy were to be used it would have to be in-situ. The problem is for in-situ 
gene editing to become common clinical practice several additional hurdles need to be 
overcome to ensure effectiveness of treatment and patient safety. As previously discussed, 
the most likely rationale for genetic manipulation of diseased tissue in-situ is to either correct 
mutated gDNA or increase its sensitivity to an existing therapeutic (to achieve a pseudo 
synthetic-lethal affect). However, gene-editing technologies that work within a living 
organism need to be fulfil the following criteria: they need to be highly specific to diseased 
tissue with minimal impact on healthy tissue, be able to effectively reach the diseased tissue, 




entirety, and needs to employ a safe yet effective method of delivery that does not invoke the 
host’s innate immune response.  
 
Use of stable gene-editing technologies, such as CRISPR, ZFNs, and TALEN, in this context 
presents with many potential risks as any cells which take up the edit will be irreversibly 
changed with genome edits that are also heritable to daughter cells. Whilst with ex-vivo 
approaches, specific cells are edited and screened outside the patient, with in-situ there is a 
risk of the gene-editing machinery being introduced into non-target cells which could have 
unpredictable consequences. Whilst off-target activity is almost non-existent for ZFN- and 
TALEN-based gene editing (Gaj et al., 2013), previous reports off-target cleavage using 
CRISPR has been reported extensively (Cradick et al., 2014; Fu et al., 2013; Lin et al., 2014; 
Ran et al., 2013). Many current projects aiming to improve on this aspect as off-target gDNA 
cleavage runs the risk of causing random mutagenesis that could have significant clinical 
consequences. Although ZFNs and TALENs are considered to be lower risk in terms of off-
target activity, care would still need to be taken in vector design so as to not 
transduce/transfect healthy cells with gene-editing machinery.  
 
Transient knockdown of gene function avoids the potential of irreversible genetic changes to 
healthy tissue, with the associated drawback that several applications may be needed based 
on the total time-course of the treatment. Transient methods also avoid the possibility of cells 
adapting to ablation of gene function, as was seen with the experiments in IKO1a cells that 
lacked functional Itch. The results shown in this project demonstrate that, in the case of 
targeting Itch, a more effective therapeutic strategy is to simultaneously knock-down the 
target gene and apply a synergistic therapeutic. Studies employing transient RNAi-based 
strategies have been in development for a long time now, achieving positive results (de la 
Fuente et al., 2015; Judge et al., 2009; Manunta et al., 2013) and several proceeding to 
clinical trial stages (Chakraborty et al., 2017; Kristen et al., 2019).  
 
Both shRNA and siRNA methods have been used in the aforementioned studies and trials 
with each having their own associated advantages and disadvantages when compared to the 
other. shRNAs generally have higher specificity and efficiency over siRNAs as they employ 
endogenous cellular machinery to generate the RNAi effect; they also have greater longevity 
as so long as an shRNA plasmid enters the nucleus of a cell it will be continually expressed 
(Mansoori et al., 2014; Rao et al., 2009). Whilst both siRNAs and shRNA-containing 
plasmids can induce an interferon response (as introduction of exogenous nucleic material is 
characteristic of a viral attack) this is less of an issue for shRNA due to low copy numbers 
required and use of endogenous RNAi machinery for continuous silencing activity rather as 
opposed to repeated siRNA doses (large dsRNAs in particular invoke a greater immune 
response). Exogenous siRNAs meanwhile are simpler and cheaper to manufacture (needing 
only a 19-21bp sense and antisense strands to achieve an effect), and a greater degree of 
control can be exhibited over their administration: siRNA levels can be “topped-up” when 
desired, shRNA silencing is constitutive. Control can be exhibited in shRNA by introducing 
some sort of stimulus-response-based promoter however one would need to ensure the 
stimulus would not carry additional risks. shRNAs can also induce cellular toxicity by 
oversaturating the cells endogenous RNAi machinery which siRNA avoids (Grimm et al., 
2006). 
 
Vehicles for delivering gene-editing machinery in-situ: 
Another area of safety concern in the use of gene-editing strategies in-situ is choosing an 




whilst protecting nucleic acid cargo from degradation, alternatively plasmids containing 
incorporation components can be introduced into cells through lipofection or electroporation. 
Although viral methods of delivery are generally very efficient and well tolerated in pre-
clinical studies there is a stigma surrounding their use in humans due to the potential of 
random mutagenesis caused by transposon machinery into host genomic DNA (Cornu et al., 
2017; Nayerossadat, Maedeh, & Ali, 2012; Thomas et al., 2003) and irreversible genetic 
alteration of healthy tissue is still an issue.  
 
Plasmids are a popular vector of choice in regard to gene-therapy pre-clinic and can deliver a 
variety of different gene-editing platforms including protein-coding sequences, CRISPR, 
TALENs, shRNAs, and ZFNs. Individual cells that are transfected will constitutively express 
the plasmid for as long as they live and can be inherited if viral components are incorporated 
(however as mentioned above this may be undesirable in-situ due to safety concerns). 
Plasmid transcription can also be controlled through a stimulus-responsive transcriptional 
promotor or repressor. Plasmids can elicit a host immune response, particularly those that are 
rich in unmethylated CpG motifs: a prevalent feature of bacterial DNA that is not present in 
vertebrates (Krieg, 2002; Manunta et al., 2011). However, CpG free plasmids can be 
generated to prevent this in clinical application. Like all exogenous nucleic acids plasmids 
need to be transfected into cells as they cannot get through the plasma membrane of 
eukaryotic cells. This can be achieved through methods including intramural injection, 
lipofection, and electroporation. One example of plasmid gene-editing technologies being 
taken to clinical trials is in the treatment of melanoma. Intramural injection and/or 
Electroporation of a plasmid encoding IL-12 gene was used to treat melanoma patients with 
distal and local remission recorded to varying degrees (Cha & Daud, 2012; Daud et al., 2008; 
Mahvi et al., 2007). IL-12 is an immunomodulatory cytokine that potentiates the 
differentiation of naïve T-cells into TH1 cells as well as stimulate natural killer (NK) cell 
activity (Del Vecchio et al., 2007). In this case IL-12 expression was increased in malignant 
areas to promote long-lasting antitumor immunity. 
 
A particularly exciting area of study in regard to delivery of gene-editing technologies is the 
ongoing development of lipid nanoparticles (LNPs). Based on lipofection methods, Cationic 
LNPs are assembled with anionic nuclear material, such as RNAs or DNA, which is 
energetically favourable, the LNPs can then easily pass through the anionic plasma 
membrane of cells via endocytosis (Cornu et al., 2017). LNPs are further modified with 
protein-based surface antigens or binding domains to increase their selectivity for specific 
cell types. This technology has been coupled with RNAi technologies to exhibit transient 
knockdown of target genes to potentiate therapy with minimal toxicity or adverse effects (de 
la Fuente et al., 2015; Manunta et al., 2011; Yu-Wai-Man et al., 2016). A study by Zuris et.al. 
also demonstrated that proteins coupled to negatively supercharged proteins can also be 
incorporated into commercial lipofection reagents (such as Lipofectamine) and delivered into 
cells successfully (Zuris et al., 2014). Using this approach Zuris’ group managed to 
successfully deliver Cre-recombinase, TALE-proteins, and sgRNA-Cas9 complexes both in-
vitro and in-vivo to mouse inner-ear hair cells (however it was found that sgRNA-Cas9 was 
already sufficiently negatively charged and did not need conjugation of a supercharged 
protein). This opens up the possibility of developing LNPs that contain proteins rather than 
just nuclear material. Although commercial lipofection reagents have been reported to induce 
a degree of toxicity in cells (Barreau et al., 2006) modified LNPs that are specifically targeted 
to diseased tissue may be circumvent this problem to some degree (i.e. causing lipofection-









Concluding Statement:  
Gene editing technologies are powerful tools with exciting clinical potential. However, 
several hurdles in regard to safety-of-use and translation need to be overcome before gene 
editing can become common medical practice. In a research context gene editing allows the 
identification and characterisation of disease-linked genes, clarification of biomolecular 
pathways, and provides a means to mass-produce biological material for research and/or 
commercial use. Careful selection of which gene-editing techniques to use is essential as each 
method has associated strengths and weaknesses which dictate their suitability for particular 
experiments. In this project both siRNA and CRISPR-Cas9 gene-editing techniques have 
been used to clarify the role of Itch in different pathological contexts through a wide range of 
in-vitro and ex-vivo physiological assays. Furthermore, this project has demonstrated and 
outlined some of the potential issues surrounding both techniques and how these may be 
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Supplementary Figure 1: plasmids used in the generation of CRISPR+ cell lines:  
sequence maps for pLentiCRISPRv2 (A.) and packaging plasmids psPAX2 (B.) and pMD2 (C.) 









































































































































































































































Supplementary Figure 2: Biological repeat of Capan-2 siRNA-mediated transient Itch  
knockdown cell survival experiments:  
Resultant (left) and normalised (right) SRB cell-survival curves for Capan-2 cells treated with 
siRNA in combination with additional treatment. A. Cells treated with 0-6 Gy g-radiation; for both 
resultant and normalised data there was no statistically significant differences between samples. B. 
Cells treated with 0-25,000 nM doxorubicin (plotted as log10[doxorubicin]); resultant data showed 
significant difference for 5 and 10 nM (p = 1.60´10-5, and 4.12´10-4 respectively). No significant 
increases in sensitivity was observed. C. Cells treated with 0-25,000 nM gemcitabine (plotted as 
log10[gemcitabine]); no statistically difference was seen for both resultant and normalised data. Data 
was normalised to a vehicle control in the case for doxorubicin and gemcitabine. Radiation data was 
normalised to cells that did not receive radiation. An * donates statistically significant difference in 
mean as determined by Student’s t-test. D. & E. Viability of cells treated with just the vehicle 
control shows significant decrease in cell viability when just the si-Itch is present compared to 
untreated cells (** = p <0.01). Number of asterixis donates degree of statistical significance of a 








































































Supplementary Figure 3: Summary analysis of MiaPaCa-2 basal doubling time in-vitro: 
Confluence data generated every 24 hours of the cytotoxicity experiments on Celigo was analysed to 
produce doubling times for each well (A.). Data sets were obtained from 0Gy treated MiaPaCa-2 
cells (example data set highlighted in red – appears as data set 2 in following table). To estimate 
doubling time of MiaPaCa-2 cells in hours statistical analysis was performed on 3 doubling time 
data sets generated from 3 independent experiments (B.). Mean, standard deviation, and median 
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Supplementary Figure 4: Continuous transient Itch knockdown of MiaPaCa-2 cells inhibits 
cell survival:  
 
Resultant (left) and normalised (right) SRB cell-survival curves for MiaPaCa-2 cells treated with 
siRNA in combination with additional treatment. A secondary dose of siRNA was applied at 48 
hours post-treatment. A. Cells treated with 0-4 Gy g-radiation; resultant data showed significant 
reduction in OD readout in si-Itch cells compared to si-Scr for doses 0, 0.5, 1, and 2 Gy (p = 
1.40´10-5, 7.88´10-4, 1.01´10-5, and 1.02´10-4 respectively – scrambled was chosen to compare 
against in this case as the OD values were closer to those of si-Itch). No statistically significant 
increase in sensitivity was observed upon normalisation of the data. B. Cells treated with 0-100 nM 
doxorubicin (plotted as log10[doxorubicin]); resultant data showed significant difference for 1, 5, 2.5, 
5, 7.5 and 10 nM between si-Itch and untreated cells (p = 7.25´10-6, 7.93´10-6, 2.22´10-5, 5.08´10-6, 
5.59´10-8, and 3.45´10-3 respectively). Significant difference was also seen when compared to si-Scr 
for doses 5 & 7.5 nM (p = 1.47´10-3 and 6.51´10-5 respectively). No significant increases in 
sensitivity was observed upon normalising the data. C. Cells treated with 0-100 nM gemcitabine 
(plotted as log10[gemcitabine]); resultant data showed significant reduction in OD readout for si-Itch 
across all doses of gemcitabine (p = 1.05´10-7, 8.58´10-6, 1.31´10-7, 1.00´10-9, 9.06´10-9, 5.95´10-7, 
2.92´10-6, 2.93´10-6, and 5.16´10-5  for each dose respectively - compared against untreated 
control). Increase in sensitivity of si-Itch was seen at 7.5 and 10 nM gemcitabine (p = 8.15´10-4 and 
2.89´10-3 respectively. Data was normalised to a vehicle control in the case for doxorubicin and 
gemcitabine. Radiation data was normalised to cells that did not receive radiation. An * donates 
statistically significant difference in mean as determined by Student’s t-test. D. & E. Viability of 
cells treated with just the vehicle control shows significant decrease in cell viability when just the si-
Itch is present compared to untreated cells. Number of asterixis donates degree of statistical 
















































Supplementary Figure 5: qPCR of MiaPaCa-2 and Capan-2 isogenic cell lines IKO2 and IKO3 
generated from additional lentiviral constructs: 
Itch mRNA expression of cells transduced with pLentiCRISPRv2 with alternative sgRNAs was 
measured by qPCR to assess degree of Itch knockdown with biological replicates. In MiaPaCa-2 
cells IKO2 isogenic cells had a ~40% reduction in Itch mRNA compared to parental controls and 
IKO3 had a 40-50% knockdown (A.). In Capan-2 cells specific degree of knockdown was 
inconclusive for IKO3 cells as percentage knockdown was too varied between biological replicates 
(B.). Mean percentage Itch knockdown for IKO2 cells ranged from 40-30%. Statistical significance 
was calculated using a Student’s t-test. Number of asterixis donates degree of statistical significance 
























































































































































































Supplementary Figure 6: Biological repeats of clonogenic assays in MiaPaCa-2 isogenic cell 
lines:  
Clonogenicity of Parental (blue), Scrambled (red), and IKO1a (green) cells with or without 
treatment. A. Cells were irradiated at either 0, 1 or 4Gy before being distributed at a low cell density 
on a 6-well plate (250 cells/well). Repeat of radiation data mirrored what was seen in prelimary 
experiment. B. & C. cells were passaged onto 24-plates (125 cells/well) and were treated with either 
0, 5, 10 or 50nM doxorubicin/gemcitabine respectively. Drug-containing media was replaced with 
fresh media after 24 hours. Clonogenicity data for drug regimens was inconsistent with preliminary 
data and was repeated again however results remained inconsistent with each other. This could be 
due to issues with colony distinction and counting on Celigo. If repeated further, recommended to 























































































































































































































































































































































































Supplementary Figure 7: Osteoclasts are less adherent to osteo-surface plate through analysis 
of well confluence pre- and post-TRAP staining: 
Confluence algorithm designed to select for osteoclasts was used to analyse well confluence in both 
the plain-surface plate (A.) and the osteo-surface plate (B.). The algorithm was run both before 
TRAP staining (top row of images – blue bars in graphs) and after TRAP staining (bottom row of 
images – purple bars). In the plain surface plate there was no significant difference in mean well 
confluence across all three treatment regimens (untreated, scrambled, and si-Itch) as determined by 
students t-test. Meanwhile in the osteo-surface plate the TRAP-staining protocol caused significant 
cell loss with >50% reduction in confluence across all three treatment regimens (p = 2.52x10-11, p = 
1.45x10-10, and p = 2.97x10-10 for untreated, scrambled, and si-Itch respectively). As confluence 
remained unchanged for the plain-surface plate, the results indicate that cells are less adherent to the 
osteo-surface plate. Statistically significant difference between pairs of means was determined by 

















































































Supplementary Figure 8: Original western blot images of siRNA-mediated Itch knockdown in 
pancreatic cell lines: 
Licor images of membranes labelled for Itch (green) and b-Actin (red) protein. In MiaPaCa-2 cells 
(A.) 12.5 nM siRNA duplex solution (si-Itch) was sufficient to reduce Itch protein compared to 
untreated (UT) and a scrambled siRNA control (Scr). (B.) In Capan-2 cells original trials with 
12.5nM did not significantly decrease Itch protein levels. Experiment was therefore repeated with 
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Supplementary Figure 9: Biological repeats of qPCR runs to assess siRNA-mediated 
knockdown of Itch in MiaPaCa-2 and Capan-2 cells: 
qPCR runs performed in biological repeat samples of MiaPaCa-2 (A.) and Capan-2 (B.) cells treated 
with Itch-targeting siRNA. In both repeats for MiaPaCa-2 cells a statistically significant 80% Itch 
knockdown was achieved (p<0.0001) using 12.5 nM siRNA. Meanwhile for Capan-2 cells, as was 
seen previously, knockdown at mRNA level was not significantly different to negative controls 
despite protein results suggesting otherwise. Statistically significant difference between pairs of 











































































































































































































































































































































































































Supplementary Figure 10: Biological repeat of MiaPaCa-2 siRNA-mediated transient Itch  
knockdown cell survival experiments:  
Resultant (left) and normalised (right) SRB cell-survival curves for MiaPaCa-2 cells treated with 
siRNA in combination with additional treatment. A. Cells treated with 0-4 Gy g-radiation; resultant 
data showed significant reduction in OD readout in si-Itch cells compared to untreated cells for 
doses 0, 0.5, 1, 2 and 4 Gy (p = 9.21´10-11, 8.03´10-11, 3.57´10-8, 5.86´10-10, and 2.95´10-11 
respectively). No statistically significant increase in sensitivity was observed upon normalisation of 
the data. B. Cells treated with 0-100 nM doxorubicin (plotted as log10[doxorubicin]); no statistically 
difference was seen for both resultant and normalised data. C. Cells treated with 0-100 nM 
gemcitabine (plotted as log10[gemcitabine]); resultant data showed significant reduction in OD 
readout for si-Itch with 50 nM gemcitabine compared to si-Scr (p = 6.46´10-4). No statistically 
significant increase in sensitivity was observed upon normalisation of the data. Radiation data was 
normalised to cells that did not receive radiation. Doxorubicin and gemcitabine data were 
normalised to a vehicle control. A * donates statistically significant difference in mean as 
determined by Student’s t-test. D. & E. Viability of cells treated with just the vehicle control shows 
significant decrease in cell viability when just the si-Itch is present compared to untreated cells in the 
case of the doxorubicin regimen. Number of asterixis donates degree of statistical significance of a 






























































































































































Supplementary Figure 11: Sample confluence curves generated from Celigo:  
During the siRNA cytotoxicity experiments well confluence was recorded every 24 hours for 
irradiated (A.), doxorubicin-treated (B.), and gemcitabine-treated (C.) cells. Celigo algorithm detects 
and records all objects from a series of images from each well that fulfil a specific set of criteria 
programmed by the user. Images are then stitched together and a total percentage confluence per 
well is provided. Subsequent time-points can be recorded and used to plot graphs for each well 
























































Supplementary Figure 12: initial western blot characterisation of CRISPR-mediated stable 
Itch knockdown in pancreatic cell lines: 
Whole western blot membrane image of initial characterisation of stable Itch knockdown (A.). Lanes 
1-3 contain lysates from cell-lines reported to be positive controls for Itch expression (MCF-7, 
HL60, and K562 respectively). However little green fluorescence was detected in K562 cell lysates. 
MiaPaCa-2 negative controls (in terms of knockdown activity) i.e. parental and scrambled in lanes 4 
& 5 respectively had greater band intensity for Itch than the CRISPR+ isogenic cell lines (IKO1a/b, 
IKO2, and IKO3) in lanes 6, 7, and 8. Lanes 9-13 consist of lysates from Capan-2 cells with 
untreated and scrambled controls in lanes 9 & 10 and CRISPR+ isogenic cell lines in the subsequent 
two lanes. Qualitatively all CRISPR+ cells had reduced band intensity for Itch whilst having 
comparable b-Actin bands (housekeeping gene used - red fluorescent bands) with negative controls. 
Quantification and normalisation of fluorescence confirmed a <10-fold reduction in Itch protein in 
CRISPR+ MiaPaCa-2 cells compared to parental cells (B.). Meanwhile in Capan-2 cells, 
quantification of band fluorescence intensity showed a knockdown of >90% for IKO1a/b cells and 



































































































































Supplementary Figure 13: Biological repeat of western blot for CRISPR transduced MiaPaCa-
2 cells: 
Western blot image of isogenic MiaPaCa-2 cells looking at Itch protein level with technical 
replicates (A.). Band fluorescence intensity was quantified and plotted (B.) – also featured in 
CRISPR chapter (see Figure 19), bands featured in CRISPR chapter are the same samples as this 

































Supplementary Figure 14: Biological repeat of western blot to validate CRISPR in Capan-2 cells: 
Western blot image of isogenic Capan-2 cells looking at Itch protein levels in parental (Par), scrambled 
(Scr), IKO1a and IKO2 cells (A.). Band fluorescence was quantified Band fluorescence intensity was 








































































Supplementary Figure 15: Original western blot images of Cas9 expression in Itch-targeting 
CRISPR+ cell lines: 
Licor image membrane probing for Cas9 and b-Actin protein (both mouse primary antibodies hence both 
have red fluorescence) in MiaPaCa-2 (A.) amd Capan-2 (B.) cell lines. Isogenic cell lines transduced with 
an Itch targeting construct showed increased expression of Cas9 compared to parental controls (Par). 
Interestingly, despite being transduced with lentiviral particles that shuld allow expression of Cas9, 
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Supplementary Figure 16: Biological repeat of MiaPaCa-2 CRISPR-mediated stable Itch 
knockdown cell survival experiments:  
Resultant (left) and normalised (right) SRB cell-survival curves for MiaPaCa-2 CRISPR-treated isogenic 
cell lines in combination with additional treatment. A. Cells treated with 0-6 Gy g-radiation; resultant data 
showed significant reduction in OD readout in IKO1a cells compared to parental cells for doses 0 and 1 Gy 
(p = 1.16´10-6 & 1.09´10-9 respectively). No statistically significant increase in sensitivity was observed 
upon normalisation of the data. B. Cells treated with 0-100 nM doxorubicin (plotted as 
log10[doxorubicin]); no statistically difference was seen for both resultant and normalised data. C. Cells 
treated with 0-100 nM gemcitabine (plotted as log10[gemcitabine]); resultant data showed significant 
reduction in OD readout for IKO1a with 50 nM gemcitabine compared to parental cells (p = 1.26´10-5). 
Normalisation of the data revealed an increase in sensitivity of IKO1a cells to 50 and 100 nM (p = 
3.85´10-4 & 1.32´10-3 respectively). Radiation data was normalised to cells that did not receive radiation. 
Doxorubicin and gemcitabine data were normalised to a vehicle control. A * donates statistically 
significant difference in mean as determined by Student’s t-test. D. & E. Viability of cells treated with just 





































































































































































































































































Supplementary Figure 17: Biological repeat of Capan-2 CRISPR-mediated stable Itch knockdown 
cell survival experiments:  
Resultant (left) and normalised (right) SRB cell-survival curves for Capan-2 CRISPR-treated isogenic cell 
lines in combination with additional treatment. A. Cells treated with 0-4 Gy g-radiation; no statistically 
significant decrease in resultant OD readout or increase in cell sensitivity of IKO1a cells.  (p = 1.16´10-6 & 
1.09´10-9 respectively). No statistically significant increase in sensitivity was observed upon normalisation 
of the data. B. Cells treated with 0-100 nM doxorubicin (plotted as log10[doxorubicin]); upon 
normalisation of the data increase in sensitivity of IKO1a cells was found at 10, 50, and 100 nM 
doxorubicin (p = 5.39´10-6, p = 3.00´10-3, and p = 3.67´10-4 respectively)  C. Cells treated with 0-100 nM 
gemcitabine (plotted as log10[gemcitabine]); ; no statistically significant decrease in resultant OD readout 
or increase in cell sensitivity of IKO1a cells resultant data showed significant reduction in OD readout for 
IKO1a. Radiation data was normalised to cells that did not receive radiation. Doxorubicin and gemcitabine 
data were normalised to a vehicle control. A * donates statistically significant difference in mean as 
determined by Student’s t-test. D. & E. Viability of cells treated with just the vehicle control. Number of 

































































Supplementary Figure 18: siRNA-mediated Itch knockdown in PBMCs: 
Image of whole western blot membrane (A.) including technical replicates (Rep 1/Rep 2). Lanes 2 & 3 for 
each block of 5 donate PBMCs transduced with pLentiCRISPRv2 (Scr-scrambled and Itch-CRISPR-Itch 
respectively) and lanes 4 & 5 donate PBMCs transfected with siRNA (-ve-scrambled and ItchSi-Itch 
siRNA respectively). qPCR was performed on additional PBMCs to act as biological replicates and further 
verify transient Itch knockdown (B.). Consistent with qPCR data described in results, Itch mRNA levels 
were reduced by 75-80% in si-Itch treated PBMCs compared to untreated controls. 
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